<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Glia</journal-id>
<journal-id journal-id-type="iso-abbrev">Glia</journal-id>
<journal-id journal-id-type="doi">10.1002/(ISSN)1098-1136</journal-id>
<journal-id journal-id-type="publisher-id">GLIA</journal-id>
<journal-title-group>
<journal-title>Glia</journal-title>
</journal-title-group>
<issn pub-type="ppub">0894-1491</issn>
<issn pub-type="epub">1098-1136</issn>
<publisher>
<publisher-name>John Wiley and Sons Inc.</publisher-name>
<publisher-loc>Hoboken</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28300322</article-id>
<article-id pub-id-type="pmc">5669250</article-id>
<article-id pub-id-type="doi">10.1002/glia.23136</article-id>
<article-id pub-id-type="publisher-id">GLIA23136</article-id>
<article-categories>
<subj-group subj-group-type="overline">
<subject>Review Article</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Review Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Astroglia as a cellular target for neuroprotection and treatment of neuro‐psychiatric disorders</article-title>
<alt-title alt-title-type="left-running-head">LIU et al.</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" id="glia23136-cr-0001">
<name>
<surname>Liu</surname>
<given-names>Beihui</given-names>
</name>
<xref ref-type="aff" rid="glia23136-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="glia23136-cr-0002">
<name>
<surname>Teschemacher</surname>
<given-names>Anja G.</given-names>
</name>
<xref ref-type="aff" rid="glia23136-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes" id="glia23136-cr-0003">
<name>
<surname>Kasparov</surname>
<given-names>Sergey</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1824-1764</contrib-id>
<address>
<email>Sergey.Kasparov@bristol.ac.uk</email>
</address>
<xref ref-type="aff" rid="glia23136-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="glia23136-aff-0002">
<sup>2</sup>
</xref>
</contrib>
</contrib-group>
<aff id="glia23136-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">School of Physiology, Pharmacology and Neuroscience</named-content>
<institution>University of Bristol, University Walk</institution>
<named-content content-type="post-code">BS8 1TD</named-content>
<country country="GB">United Kingdom</country>
</aff>
<aff id="glia23136-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Institute for Chemistry and Biology</named-content>
<institution>Baltic Federal University</institution>
<named-content content-type="city">Kaliningrad</named-content>
<country country="RU">Russian Federation</country>
</aff>
<author-notes>
<corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold> S Kasparov, School of Physiology, Pharmacology and Neuroscience, University of Bristol, University Walk, BS8 1TD, United Kingdom. Email: <email>Sergey.Kasparov@bristol.ac.uk</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>16</day>
<month>3</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<month>8</month>
<year>2017</year>
</pub-date>
<volume>65</volume>
<issue>8</issue>
<issue-id pub-id-type="doi">10.1002/glia.v65.8</issue-id>
<fpage>1205</fpage>
<lpage>1226</lpage>
<history>
<date date-type="received">
<day>15</day>
<month>12</month>
<year>2016</year>
</date>
<date date-type="rev-recd">
<day>15</day>
<month>2</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>17</day>
<month>2</month>
<year>2017</year>
</date>
</history>
<permissions>
<!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2017 Wiley Periodicals, Inc. <copyright-statement>-->
<copyright-statement content-type="article-copyright">© 2017 The Authors GLIA Published by Wiley Periodicals, Inc.</copyright-statement>
<license license-type="creativeCommonsBy">
<license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="file:GLIA-65-1205.pdf" xlink:type="simple"></self-uri>
<abstract>
<title>Abstract</title>
<p>Astrocytes are key homeostatic cells of the central nervous system. They cooperate with neurons at several levels, including ion and water homeostasis, chemical signal transmission, blood flow regulation, immune and oxidative stress defense, supply of metabolites and neurogenesis. Astroglia is also important for viability and maturation of stem‐cell derived neurons. Neurons critically depend on intrinsic protective and supportive properties of astrocytes. Conversely, all forms of pathogenic stimuli which disturb astrocytic functions compromise neuronal functionality and viability. Support of neuroprotective functions of astrocytes is thus an important strategy for enhancing neuronal survival and improving outcomes in disease states. In this review, we first briefly examine how astrocytic dysfunction contributes to major neurological disorders, which are traditionally associated with malfunctioning of processes residing in neurons. Possible molecular entities within astrocytes that could underpin the cause, initiation and/or progression of various disorders are outlined. In the second section, we explore opportunities enhancing neuroprotective function of astroglia. We consider targeting astrocyte‐specific molecular pathways which are involved in neuroprotection or could be expected to have a therapeutic value. Examples of those are oxidative stress defense mechanisms, glutamate uptake, purinergic signaling, water and ion homeostasis, connexin gap junctions, neurotrophic factors and the Nrf2‐ARE pathway. We propose that enhancing the neuroprotective capacity of astrocytes is a viable strategy for improving brain resilience and developing new therapeutic approaches.</p>
</abstract>
<kwd-group kwd-group-type="author-generated">
<kwd id="glia23136-kwd-0001">astrocytes</kwd>
<kwd id="glia23136-kwd-0002">astrocytic dysfunction</kwd>
<kwd id="glia23136-kwd-0003">neurodegenerative disease</kwd>
<kwd id="glia23136-kwd-0004">therapeutic targets</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>MRC
</funding-source>
<award-id>MR/L020661/1
</award-id>
</award-group>
<award-group>
<funding-source>BBSRC
</funding-source>
<award-id>BB/L019396/1
</award-id>
</award-group>
</funding-group>
<counts>
<fig-count count="1"></fig-count>
<table-count count="1"></table-count>
<page-count count="22"></page-count>
<word-count count="21532"></word-count>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>source-schema-version-number</meta-name>
<meta-value>2.0</meta-value>
</custom-meta>
<custom-meta>
<meta-name>component-id</meta-name>
<meta-value>glia23136</meta-value>
</custom-meta>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>August 2017</meta-value>
</custom-meta>
<custom-meta>
<meta-name>details-of-publishers-convertor</meta-name>
<meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.2.1 mode:remove_FC converted:03.11.2017</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes>
<p content-type="self-citation">
<mixed-citation id="glia23136-cit-0001" publication-type="journal">
<string-name>
<surname>Liu</surname>
<given-names>B</given-names>
</string-name>, 
<string-name>
<surname>Teschemacher</surname>
<given-names>AG</given-names>
</string-name>, 
<string-name>
<surname>Kasparov</surname>
<given-names>S</given-names>
</string-name>. <article-title>
<styled-content style="fixed-case">A</styled-content>stroglia as a cellular target for neuroprotection and treatment of neuro‐psychiatric disorders</article-title>. <source/>Glia.
<year>2017</year>;<volume>65</volume>:<fpage>1205</fpage>–<lpage>1226</lpage>. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/glia.23136">https://doi.org/10.1002/glia.23136</ext-link>
<pub-id pub-id-type="pmid">28300322</pub-id></mixed-citation>
</p>
<fn-group>
<fn id="glia23136-note-0001">
<p>
<bold>Funding information</bold> MRC, Grant number: MR/L020661/1; BBSRC, Grant number: BB/L019396/1</p>
</fn>
</fn-group>
</notes>
</front>
<body>
<sec id="glia23136-sec-0001">
<label>1</label>
<title>INTRODUCTION</title>
<p>The central nervous system (CNS) represents a very challenging target for therapeutic interventions. Even though numerus centrally acting drugs are currently in use, these are largely molecules discovered decades ago, sometimes with only minor modifications. It is generally accepted that, for many diseases, effective therapies are lacking and that many of the currently used drugs are only used due to the lack of better ones, in spite of their adverse effects. For decades, the logic for pursuing a potential drug target in the brain was its association with processes localized to neurons, sometimes more and sometimes less specifically aimed at a particular neuronal population. To some extent that reflected the general “neurocentrism” in neuroscience, whereby other components of the brain such as glial and vascular cells were seen as irrelevant. More recently, we have learned of a wide range of mechanisms which astrocytes employ to sustain neuronal networks and sometimes directly affect their operation. One could argue that even though targeting processes which are primarily compartmentalized to astrocytes may not lead to a quick modification of the activity of such networks, in the long term, this approach can be better suited for the chronic human diseases. In this review, we first briefly present evidence that dysregulation of astrocytic functions is a common feature of many CNS diseases and then highlight some of the potentially targetable processes in astrocytes which might be of value for future drug development. For recent reviews on the potential drug targets in microglia see (Moller and Boddeke, <xref ref-type="ref" rid="glia23136-bib-0188">2016</xref>; Noda, <xref ref-type="ref" rid="glia23136-bib-0197">2014</xref>).</p>
</sec>
<sec id="glia23136-sec-0002">
<label>2</label>
<title>ASTROCYTES IN THE DISEASED BRAIN ARE CENTRAL TO NEUROPATHOLOGY</title>
<p>Considering the pivotal role of astrocytes in brain homeostasis and the strong metabolic cooperation between neurons and astrocytes, one can postulate that astrocytic dysfunction may lead to neurological disease. These diseases share common pathogenic processes, such as oxidative stress, excitotoxicity, metabolic failure or inflammation, many of which are counteracted by astrocytes in the healthy brain. Thus, disease progression is associated with escalating harmful stimuli that eventually exhaust the neuroprotective mechanisms of astrocytes. Even worse, sometimes deleterious pathways may be switched on in astrocytes, directly contributing to the pathology. Some excellent reviews were published on this topic in recent years (Parpura et al., <xref ref-type="ref" rid="glia23136-bib-0210">2012</xref>; Pekny et al., <xref ref-type="ref" rid="glia23136-bib-0212">2016</xref>; Sofroniew and Vinters, <xref ref-type="ref" rid="glia23136-bib-0251">2010</xref>; Verkhratsky and Parpura, <xref ref-type="ref" rid="glia23136-bib-0289">2016</xref>).</p>
<sec id="glia23136-sec-0003">
<label>2.1</label>
<title>Alexander disease—a case of “primary” astrocytic disease</title>
<p>A classic example of a “primary” astrocytic disease is Alexander disease (AxD), a human neurological disorder unequivocally caused by a dysfunction of astrocytes due to mutations in the gene encoding glial fibrillary acidic protein (GFAP) (Brenner, Goldman, Quinlan, &amp; Messing, 2009; Messing, Brenner, Feany, Nedergaard, &amp; Goldman, <xref ref-type="ref" rid="glia23136-bib-0178">2012</xref>). A characteristic feature of this fatal disorder is the widespread presence of intracellular protein aggregates in astrocytes, called Rosenthal fibers (RF)—bundles of intermediate filaments surrounding irregular deposits of dense material (Herndon, Rubinstein, Freeman, &amp; Mathieson, <xref ref-type="ref" rid="glia23136-bib-0106">1970</xref>). RF are composed of mutant GFAP in association with other constituents, especially the small stress proteins B‐crystallin and heat shock protein 27 (Iwaki, Kume‐Iwaki, Liem, &amp; Goldman, <xref ref-type="ref" rid="glia23136-bib-0120">1989</xref>). AxD is considered a gain‐of‐function disorder in the sense that the GFAP mutations produce consequences that differ dramatically from those caused by the absence of GFAP (Brenner et al., <xref ref-type="ref" rid="glia23136-bib-0029">2009</xref>; Messing et al., <xref ref-type="ref" rid="glia23136-bib-0178">2012</xref>). This makes gene therapy based on expression of wild type GFAP in AxD patients impossible since it may instead exacerbate disease by increasing the GFAP load. One of the most notable functional changes in Alexander astrocytes is the decreased glutamate transport across the cell membrane. More than 75% reduction of glutamate transporter 1 (GLT1, also known as excitatory amino acid transporter 2, EAAT2, or solute carrier family 1 member 2, SLC1A2) immunoreactivity was observed in mouse models of AxD and astrocytes in hippocampal CA1 region of human patients show variable to complete loss of immunostaining for EAAT2 (Tian et al., <xref ref-type="ref" rid="glia23136-bib-0269">2010b</xref>). EAAT2 is preferentially localized in astrocytes and is the major mediator of glutamate clearance in humans. Reduced glutamate uptake puts neurons at risk of glutamate overload and excitotoxicity, explaining why seizures are common in Alexander disease (Messing et al., <xref ref-type="ref" rid="glia23136-bib-0178">2012</xref>).</p>
</sec>
<sec id="glia23136-sec-0004">
<label>2.2</label>
<title>Other pathologies involving astrocytes</title>
<p>Astrocytic dysfunction has been extensively implicated in the pathogenesis of numerous diseases for which the primary cause has not yet been identified. These include Alzheimer's disease (AD), Amyotrophic lateral sclerosis (ALS), Epilepsy, Huntington's disease (HD), Ischemia/stroke and Parkinson's disease (PD), some of which are listed in (Table <xref ref-type="table-wrap" rid="glia23136-tbl-0001">1</xref>).</p>
<table-wrap id="glia23136-tbl-0001" orientation="portrait" position="float" xml:lang="en">
<label>Table 1</label>
<caption>
<p>Evidence for astrocytic dysfunction in neuro‐psychiatric diseases</p>
</caption>
<table frame="hsides" rules="groups">
<col span="1" style="border-bottom:solid 1px #000000border-right:solid 1px #000000" width="80pt"/>
<col span="1" style="border-bottom:solid 1px #000000border-right:solid 1px #000000" width="80pt"/>
<col span="1" style="border-bottom:solid 1px #000000border-right:solid 1px #000000" width="80pt"/>
<thead valign="bottom">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="bottom">CNS disorder</th>
<th align="left" colspan="1" rowspan="1" valign="bottom">Evidence for the dysfunction of astrocytes</th>
<th align="left" colspan="1" rowspan="1" valign="bottom">Examples</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">AD</td>
<td align="left" colspan="1" rowspan="1" valign="top">
• Intracellular accumulation of Aß in astrocytes<break></break>
• Astroglial degeneration and atrophy<break></break>
• Release of glia‐derived inflammatory molecules<break></break>
• Reactive astrogliosis<break></break>
• Disturbed calcium homeostasis<break></break>
• Upregulated gap junction<break></break>
• Downregulation of EAAT2 which affects glutamate homeostasis and induces excitotoxicity</td>
<td align="left" colspan="1" rowspan="1" valign="top">(Douen et al. <xref ref-type="ref" rid="glia23136-bib-0066">2000</xref>; Filous and Silver <xref ref-type="ref" rid="glia23136-bib-0073">2016</xref>; Jack et al. <xref ref-type="ref" rid="glia23136-bib-0121">2010</xref>; Kuchibhotla et al. <xref ref-type="ref" rid="glia23136-bib-0143">2009</xref>; Meda et al. <xref ref-type="ref" rid="glia23136-bib-0176">2001</xref>; Parpura et al. <xref ref-type="ref" rid="glia23136-bib-0210">2012</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">ALS</td>
<td align="left" colspan="1" rowspan="1" valign="top">
• Decreased expression of EAAT2<break></break>
• Expression of mutant SOD1<break></break>
• Astroglial degeneration and atrophy<break></break>
• Reactive astrogliosis</td>
<td align="left" colspan="1" rowspan="1" valign="top">(Rossi and Volterra <xref ref-type="ref" rid="glia23136-bib-0225">2009</xref>; Turner and Talbot <xref ref-type="ref" rid="glia23136-bib-0275">2008</xref>; Valori et al. <xref ref-type="ref" rid="glia23136-bib-0280">2014</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Epilepsy</td>
<td align="left" colspan="1" rowspan="1" valign="top">
• Reactive astrogliosis<break></break>
• Upregulation of glutamate dehydrogenase and downregulation of glutamine synthetase<break></break>
• Alterations of K<sup>+</sup> buffering, calcium signaling and glutamate and water homeostasis<break></break>
• Deficiency in GABAergic inhibition</td>
<td align="left" colspan="1" rowspan="1" valign="top">(Amiry‐Moghaddam et al. <xref ref-type="ref" rid="glia23136-bib-0009">2003</xref>; Bedner and Steinhauser <xref ref-type="ref" rid="glia23136-bib-0018">2013</xref>; Coulter and Steinhauser <xref ref-type="ref" rid="glia23136-bib-0053">2015</xref>; Robel et al. <xref ref-type="ref" rid="glia23136-bib-0223">2015</xref>; Robel and Sontheimer <xref ref-type="ref" rid="glia23136-bib-0224">2016</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">HD</td>
<td align="left" colspan="1" rowspan="1" valign="top">
• Selective expression of mutant huntingtin<break></break>
• Decreased expression of EAAT2<break></break>
• Downregulation of Kir4.1 channel<break></break>
• Reactive astrogliosis</td>
<td align="left" colspan="1" rowspan="1" valign="top">(Hsiao et al. <xref ref-type="ref" rid="glia23136-bib-0112">2013</xref>; Mangiarini et al. <xref ref-type="ref" rid="glia23136-bib-0162">1996</xref>; Maragakis and Rothstein <xref ref-type="ref" rid="glia23136-bib-0164">2001</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Ischemia/stroke</td>
<td align="left" colspan="1" rowspan="1" valign="top">
• Compromised glutamate, ion and water homeostasis<break></break>
• Reactive astrogliosis</td>
<td align="left" colspan="1" rowspan="1" valign="top">(Liu and Chopp <xref ref-type="ref" rid="glia23136-bib-0156">2015</xref>; Zhao and Rempe <xref ref-type="ref" rid="glia23136-bib-0315">2010</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">PD</td>
<td align="left" colspan="1" rowspan="1" valign="top">
• Selective expression of mutant α‐synuclein, which induces widespread glial activation and neurodegeneration<break></break>
• Excessive production of cytokines and neurotoxic free‐radicals<break></break>
• Reactive astrogliosis</td>
<td align="left" colspan="1" rowspan="1" valign="top">(Adams et al. <xref ref-type="ref" rid="glia23136-bib-0003">2001</xref>; Cabezas et al. <xref ref-type="ref" rid="glia23136-bib-0033">2014</xref>; Spillantini et al. <xref ref-type="ref" rid="glia23136-bib-0252">1997</xref>; Stefanis <xref ref-type="ref" rid="glia23136-bib-0254">2012</xref>; Wang et al. <xref ref-type="ref" rid="glia23136-bib-0296">2015</xref>)</td>
</tr>
</tbody>
</table>
</table-wrap>
<sec id="glia23136-sec-0005">
<label>2.2.1</label>
<title>AD</title>
<p>AD is one of the most common neurodegenerative disorder characterized by progressive memory loss and a range of cognitive deficits (McKhann et al., <xref ref-type="ref" rid="glia23136-bib-0174">1984</xref>). Aggregation and deposition of β‐amyloid (Aβ) and the formation of neurofibrillary tangles are classical hallmarks of AD (Hardy and Selkoe, <xref ref-type="ref" rid="glia23136-bib-0102">2002</xref>). Aβ deposition in the brain seems to precede neurofibrillary tangle formation, neuronal cell death and subsequent functional decline (Jack et al., <xref ref-type="ref" rid="glia23136-bib-0121">2010</xref>). Astrocytes play an important neuroprotective role in AD by internalizing and degrading Aβ peptides, thus helping to avoid formation of the deposits of toxic extracellular Aß (Koistinaho et al., <xref ref-type="ref" rid="glia23136-bib-0139">2004</xref>; Kurt, Davies, &amp; Kidd, <xref ref-type="ref" rid="glia23136-bib-0144">1999</xref>). The precise mechanism by which astrocytes recognize and degrade Aβ is not known, but apolipoprotein E (APOE), which is almost exclusively expressed in astrocytes, has been proposed to be responsible for this function (Koistinaho et al., <xref ref-type="ref" rid="glia23136-bib-0139">2004</xref>). The APOE gene found in humans on chromosome 19 has three loci: APOE‐ε2, APOE‐ε3 and APOE‐ε4. In 1993 it was demonstrated that homozygocity for APOE‐ε4 greatly increases the risk for late onset AD, being almost sufficient to cause it in patients by the age of 80 (Corder et al., <xref ref-type="ref" rid="glia23136-bib-0051">1993</xref>). Shortly afterwards it was reported that the other allele, APOE‐ε2, in contrast, is rather “protective” against AD (Corder et al., <xref ref-type="ref" rid="glia23136-bib-0050">1994</xref>). These two isoforms of APOE have an opposite effect on the phagocytic activity of astrocytes whereby APOE‐ε2 increases their ability to “digest” synapses while APOE‐ε4 reduces it, making synapses more vulnerable to complement‐mediated degeneration (Klionsky et al., <xref ref-type="ref" rid="glia23136-bib-0138">2016</xref>). Literature on the role of APOE in AD is extensive and its detailed revision is outside of the scope of this review.</p>
<p>Current medicines are ineffective and only temporarily alleviate symptoms, or slightly slow down AD progression in some people. Two types of medication are currently approved by the FDA for use against memory loss in AD, acetylcholinesterase inhibitors and memantine. Memantine is classified as an NMDA receptor antagonist, originally developed as anti‐diabetic drug. It is interesting that NMDA receptors on astrocytes and neurons have different subunit compositions and memantine blocks astroglial NMDA receptors with five times lower IC<sub>50</sub> than those on neurons (Palygin, Lalo, &amp; Pankratov, <xref ref-type="ref" rid="glia23136-bib-0206">2011</xref>). Even though therapeutic activity of memantine in AD is subtle, it is still one of the very few drugs clinically approved for moderate‐to‐severe AD.</p>
<p>Recent studies from M. Nedergaard's laboratory opened a very interesting line of thought in this field. It was shown that the extracellular space which is to a large extent, regulated by the subtle changes in the volume of astrocytes has a dramatic effect on the movement of macro‐molecules and their drainage through the so‐called “glymphatic” system (Iliff et al., <xref ref-type="ref" rid="glia23136-bib-0116">2012</xref>; Thrane, Rangroo Thrane, Plog, &amp; Nedergaard, <xref ref-type="ref" rid="glia23136-bib-0267">2015</xref>). During wakefulness this extracellular trafficking pathway for tracer molecules and Aβ shrinks, but during sleep it opens up, facilitating brain clearance of potentially toxic products. Coordinated expansion of the glymphatic clearance pathway seems to be controlled via norepinephrine receptors on astrocytes (Xie et al., 2013). Therefore, AD could be to some extent seen as a result of failure of the “brain drain” pathway.</p>
<p>Reactive astrogliosis is another well‐known feature of AD (Meda, Baron, &amp; Scarlato, <xref ref-type="ref" rid="glia23136-bib-0176">2001</xref>). Astrogliosis tends to be focal in AD such that reactive astrocytes are associated with amyloid plaques and surround them with layers of processes as if forming miniature scars in an attempt to create neuroprotective barriers (Olabarria, Noristani, Verkhratsky, &amp; Rodriguez, <xref ref-type="ref" rid="glia23136-bib-0202">2010</xref>). The intensity of astrogliosis increases with progression of AD, while the levels of astrocyte glutamate transporters decline, exposing neurons to additional excitotoxic damage (Simpson et al., <xref ref-type="ref" rid="glia23136-bib-0249">2010</xref>). The glutamate transporter EAAT2 is downregulated in AD (Tian, Kong, Lai, Ray‐Chaudhury, &amp; Lin, <xref ref-type="ref" rid="glia23136-bib-0268">2010a</xref>). Calcium homeostasis is also affected. Both resting calcium and intracellular calcium waves in astrocytes near plaques are increased, indicating that the astrocyte network contributes to AD pathology (Kuchibhotla, Lattarulo, Hyman, &amp; Bacskai, <xref ref-type="ref" rid="glia23136-bib-0143">2009</xref>). Additionally, gap junctions between astrocytes are altered in AD (Nagy, Li, Hertzberg, &amp; Marotta, <xref ref-type="ref" rid="glia23136-bib-0191">1996</xref>). Increased glutamate and ATP release has been linked to altered gap junction expression, suggesting that blocking hemichannels in neurons could be neuroprotective in AD (Orellana et al., <xref ref-type="ref" rid="glia23136-bib-0203">2011</xref>).</p>
<p>AD is also accompanied by signs of inflammation (Douen et al., <xref ref-type="ref" rid="glia23136-bib-0066">2000</xref>). Increased cerebral levels of Aβ peptides and their subsequent deposition lead to the activation of the surrounding microglia and astrocytes (Li et al., <xref ref-type="ref" rid="glia23136-bib-0154">2011</xref>). Upon activation, both microglia and astrocytes release pro‐ and anti‐inflammatory mediators, thereby establishing a chronic parenchymal inflammation (Orre et al., <xref ref-type="ref" rid="glia23136-bib-0205">2014</xref>). Chronic inflammatory stimulation of astrocytes reduces their capacity to release neurotrophic factors, for example glia‐derived neurotrophic factor, possibly contributing to cognitive decline in AD (Parpura et al., <xref ref-type="ref" rid="glia23136-bib-0210">2012</xref>). At later stages, inflammation becomes directly damaging to the brain and glial cytokines and chemokines lead to destruction of axons, dendrites and synapses (Pekny et al., <xref ref-type="ref" rid="glia23136-bib-0212">2016</xref>).</p>
<p>Accumulation of Aβ increases oxidative stress (Radi, Formichi, Battisti, &amp; Federico, <xref ref-type="ref" rid="glia23136-bib-0219">2014</xref>), possibly due to a decrease in antioxidants and antioxidant enzymes in astrocytes (Canevari, Abramov, &amp; Duchen, <xref ref-type="ref" rid="glia23136-bib-0037">2004</xref>; Zhao and Zhao <xref ref-type="ref" rid="glia23136-bib-0316">2013</xref>), or mitochondrial dysfunction which occur already at the early stages of AD (Gandhi and Abramov <xref ref-type="ref" rid="glia23136-bib-0079">2012</xref>; Kim, Kim, Rhie, &amp; Yoon, <xref ref-type="ref" rid="glia23136-bib-0135">2015</xref>).</p>
<p>To sum up, astrocytes may be involved in the pathogenesis of AD at multiple levels. They might be driving neurodegeneration, but also be elements of defense. Multiple neuroprotective pathways residing in astrocytes have not been fully explored in AD.</p>
</sec>
<sec id="glia23136-sec-0006">
<label>2.2.2</label>
<title>HD</title>
<p>HD is a genetic neurodegenerative disorder characterized by progressive motor, cognitive and psychiatric decline (Ghosh and Tabrizi, <xref ref-type="ref" rid="glia23136-bib-0081">2015</xref>). HD is caused by an expanded chain (more than 36) of glutamines in the N‐terminal region of the huntingtin protein, causing intracellular accumulation and aggregation of mutant huntingtin (mHTT) (Mangiarini et al., <xref ref-type="ref" rid="glia23136-bib-0162">1996</xref>). At the cellular level, neurodegeneration in HD is most evident in striatal medium spiny neurons (MSN) (Vonsattel et al., <xref ref-type="ref" rid="glia23136-bib-0292">1985</xref>). However, the expression of mHTT in neurons alone cannot recapitulate the key features of HD (Gu et al., <xref ref-type="ref" rid="glia23136-bib-0092">2005</xref>). Indeed, mHTT is accumulated in astrocytes, whose function is altered in HD (Shin et al., <xref ref-type="ref" rid="glia23136-bib-0244">2005</xref>). Astrocytic glutamate uptake is defective in the R6/2 HD mouse model, where levels of EAAT2 are reduced, leading to increase in striatal extracellular glutamate and excitotoxicity (Maragakis and Rothstein, <xref ref-type="ref" rid="glia23136-bib-0164">2001</xref>). Recently, astrocytic Kir4.1 was reported to be significantly downregulated in HD mouse models, independently of overt astrogliosis (Ben Haim et al., <xref ref-type="ref" rid="glia23136-bib-0019">2015</xref>). Decreased expression of Kir4.1 K<sup>+</sup> channels leads to elevated striatal extracellular K<sup>+</sup>
<italic>in vivo</italic> which can result in depolarization of neurons. Genetic restoration of Kir4.1 levels in striatal astrocytes returned extracellular K<sup>+</sup> and MSN excitability to normal, along with improvement of some motor functions in R6/2 mice (Tong et al., <xref ref-type="ref" rid="glia23136-bib-0272">2014</xref>). Recent work confirmed that the loss of astrocytic Kir4.1‐ and EAAT2‐mediated homeostatic functions in R6/2 mice compromises glutamate handling and Ca<sup>2+</sup> signaling, contributing to MSNs pathology in the striatum (Jiang, Diaz‐Castro, Looger, &amp; Khakh, <xref ref-type="ref" rid="glia23136-bib-0123">2016</xref>). It follows, that the loss of astrocytic control over glutamate and potassium extracellular levels may contribute to pathology seen in HD and the proteins affected by HD in astrocytes, such as EAAT2 and Kir4.1 channels, might represent therapeutic targets in HD. The difficulty, however, is that in both cases we would need positive modulators which is usually a more difficult task than development of blockers.</p>
<p>Other astrocytic functions which have been implicated in pathogenesis of HD are release of GABA, trophic factors, and inflammatory signaling (Filous and Silver, <xref ref-type="ref" rid="glia23136-bib-0073">2016</xref>). Astrocytes in HD models release less GABA, resulting in impaired tonic extra‐synaptic inhibition (Wojtowicz, Dvorzhak, Semtner, &amp; Grantyn, <xref ref-type="ref" rid="glia23136-bib-0302">2013</xref>). Both human and mouse data consistently show increased activation of the NFkB signaling in astrocytes, leading to enhanced inflammation (Hsiao, Chen, Chen, Tu, &amp; Chern, <xref ref-type="ref" rid="glia23136-bib-0112">2013</xref>). Inhibition of astrocyte‐mediated TNFα signaling enhanced motor function and reduced aggregates of mutant huntingtin in a mouse model of HD, suggesting that targeting of this pathway may be a viable strategy to slow the progression of HD (Hsiao et al., <xref ref-type="ref" rid="glia23136-bib-0112">2013</xref>). Additionally, accumulation of mHTT aggregates in astrocytes reduces secretion of brain derived neurotrophic factor (Wang et al., <xref ref-type="ref" rid="glia23136-bib-0295">2012</xref>). These events induce a reactive state in astrocytes, leading to release of the precursor form of NGF which may promote apoptosis of motor neurons (Domeniconi, Hempstead, &amp; Chao, <xref ref-type="ref" rid="glia23136-bib-0063">2007</xref>).</p>
<p>Thus, poor astrocytic clearance of glutamate, improper control of extracellular K<sup>+</sup>, and reduced release of neurotrophic factors are plausible contributors to the pathogenesis of HD.</p>
</sec>
<sec id="glia23136-sec-0007">
<label>2.2.3</label>
<title>ALS</title>
<p>ALS is an adult‐onset disorder caused by selective degeneration of cortical and spinal motor neurons, leading to progressive paralysis and muscle atrophy (Gordon, <xref ref-type="ref" rid="glia23136-bib-0090">2013</xref>). Both familial and sporadic forms of ALS exist, with ∼20% of familial forms associated with dominant mutations in the gene encoding Cu/Zn‐superoxide dismutase (SOD1). The mutated human hSOD1 has been used for generating experimental models of ALS (Turner and Talbot, <xref ref-type="ref" rid="glia23136-bib-0275">2008</xref>). Analysis of various types of these models revealed the primary role of astroglia in pathology. Astroglial degeneration and atrophy associated with the loss of function precede neuronal death and occur before the emergence of clinical symptoms (Valori, Brambilla, Martorana, &amp; Rossi, <xref ref-type="ref" rid="glia23136-bib-0280">2014</xref>; Verkhratsky, Parpura, Pekna, Pekny &amp; Sofroniew, <xref ref-type="ref" rid="glia23136-bib-0290">2014</xref>). When SOD1 was specifically expressed in astrocytes, it made them highly vulnerable to extracellular glutamate and resulted in secretion of several neurotoxic factors. Silencing of mutant hSOD1 in astrocytes markedly decelerated the progression of experimental ALS (Yamanaka et al., <xref ref-type="ref" rid="glia23136-bib-0308">2008</xref>).</p>
<p>Another critical pathogenic factor in ALS is the deficient glutamate clearance by astroglia. Selective loss or dysfunction of astrocytic glutamate transporters in spinal cord and cerebral cortical areas might account for the glutamate excitotoxicity to neurons. Genetic deletion of astrocytic EAAT2 in mice caused death of motor neurons, thus replicating some features of ALS (Staats and Van Den Bosch, <xref ref-type="ref" rid="glia23136-bib-0253">2009</xref>). In line with this, immunohistochemistry revealed a selective loss of astroglial EAAT2 in the motor cortex and ventral horn of the spinal cord of tissues from patients with sporadic ALS (Rossi and Volterra, <xref ref-type="ref" rid="glia23136-bib-0225">2009</xref>). It has been proposed that the reduced activity of glutamate transporters in familial ALS could be a result of the malfunction of SOD1, leading to long‐lasting oxidation of transporter proteins' sulfhydryl groups (Seifert, Schilling, &amp; Steinhauser, <xref ref-type="ref" rid="glia23136-bib-0236">2006</xref>; Trotti, Rolfs, Danbolt, Brown, &amp; Hediger, <xref ref-type="ref" rid="glia23136-bib-0274">1999</xref>). At the later stages of ALS, reactive astrogliosis as well as the activation of microglial cells become particularly prominent (Turner et al., <xref ref-type="ref" rid="glia23136-bib-0276">2004</xref>; Valori et al., <xref ref-type="ref" rid="glia23136-bib-0280">2014</xref>).</p>
<p>To summarize, at the initial stages of ALS, compromised astroglial glutamate clearance may be the cause of glutamate excitotoxicity. Later, reactive responses of astrocytes and microglia progress in parallel with the loss of motor neurons (Zhu et al., <xref ref-type="ref" rid="glia23136-bib-0113">2015</xref>).</p>
</sec>
<sec id="glia23136-sec-0008">
<label>2.2.4</label>
<title>PD</title>
<p>PD, the second most common age‐associated neurodegenerative disorder, affects ∼1% of the population over 60 years of age. Its main histopathological features are the loss of dopaminergic neurons and the presence of α‐synuclein‐containing aggregates (so‐called Lewy bodies) in the substantia nigra (SN) (Spillantini et al., <xref ref-type="ref" rid="glia23136-bib-0252">1997</xref>). In addition to the commonly known motor symptoms, PD is accompanied by autonomic dysfunction, cognitive, psychiatric, sensory symptoms and sleep disturbances.</p>
<p>Oxidative stress and mitochondrial dysfunction are probably the key events which cause degeneration and death of dopaminergic neurons in the SN (Adams, Chang, &amp; Klaidman, <xref ref-type="ref" rid="glia23136-bib-0003">2001</xref>; Sayre, Smith, &amp; Perry, <xref ref-type="ref" rid="glia23136-bib-0234">2001</xref>). Oxidative stress in PD manifests as low levels of the antioxidant glutathione (GSH) (Bharath, Hsu, Kaur, Rajagopalan, &amp; Andersen, <xref ref-type="ref" rid="glia23136-bib-0024">2002</xref>), increased lipid peroxidation (Dexter et al., <xref ref-type="ref" rid="glia23136-bib-0061">1989</xref>), nucleic acid oxidation (Alam et al., <xref ref-type="ref" rid="glia23136-bib-0004">1997</xref>) and increased iron content in the dopaminergic zones of the brain (Sofic, Paulus, Jellinger, Riederer, &amp; Youdim, <xref ref-type="ref" rid="glia23136-bib-0250">1991</xref>). Astrocytes are important for the antioxidant protection via secretion of various antioxidant molecules (Sidoryk‐Wegrzynowicz, Wegrzynowicz, Lee, Bowman, &amp; Aschner, <xref ref-type="ref" rid="glia23136-bib-0245">2011</xref>). However, in PD, astrocytic protection of neurons is limited, possibly due to a decline in GSH trafficking caused by chronic iNOS induction (Heales, Lam, Duncan, &amp; Land, <xref ref-type="ref" rid="glia23136-bib-0105">2004</xref>). Depletion of GSH may facilitate production of reactive oxygen and reactive nitrogen species, causing alterations in neuronal proteins such as α‐synuclein. Furthermore, the nitration of α‐synuclein by reactive nitrogen species significantly enhances the formation of synuclein fibrils <italic>in vitro</italic>, resembling the situation in PD brains (Chinta and Andersen, <xref ref-type="ref" rid="glia23136-bib-0045">2008</xref>; Paxinou et al., <xref ref-type="ref" rid="glia23136-bib-0211">2001</xref>).</p>
<p>Chronic neuroinflammation is another hallmark of PD pathophysiology. Post‐mortem analyses of human PD patients and experimental animal studies demonstrate activation of glial cells and increases in pro‐inflammatory factors (Wang, Liu, &amp; Zhou, <xref ref-type="ref" rid="glia23136-bib-0296">2015</xref>). Although microglia is the major cell type involved in the inflammatory responses, astrocytes are also involved. A suggested scenario is that α‐synuclein aggregation activates microglia, which then leads to activation of astrocytes by pro‐inflammatory cytokines (Saijo et al., <xref ref-type="ref" rid="glia23136-bib-0233">2009</xref>). Uncontrolled neuroinflammation caused by the synergic activation of microglia and astrocytes ultimately results in production of neurotoxic factors which trigger death of dopaminergic neurons in the SN (Glass, Saijo, Winner, Marchetto, &amp; Gage, <xref ref-type="ref" rid="glia23136-bib-0087">2010</xref>).</p>
</sec>
<sec id="glia23136-sec-0009">
<label>2.2.5</label>
<title>Epilepsy</title>
<p>Epilepsy affects more than 50 million people worldwide (Hesdorffer et al., <xref ref-type="ref" rid="glia23136-bib-0108">2011</xref>). The main clinical manifestation are seizures, sudden, and unpredictable episodes of abnormal electrical brain activity which can lead to convulsions. Seizures are signs of excessive synchronisation of neuronal activity and the search for anti‐epileptic drugs have been largely concentrated on compounds that affect neurons, for example ion channel blockers or agonists of GABA<sub>A</sub> receptors. The efficacy of these drugs, old and newly created, has not improved substantially over the past decades and the drugs merely suppress symptoms without treating the underlying processes. Resistance to treatment is also common. There is, therefore, an urgent need for more efficacious medications. Astrocytes might offer some interesting targets here. Specimens from patients with pharmacoresistant temporal lobe epilepsy and animal epilepsy models revealed alterations in expression, localization and function of astrocytic connexins, K<sup>+</sup> and water channels. In addition, disturbed gliotransmission as well as malfunction of glutamate transporters and of the astrocytic glutamate‐ and adenosine‐converting enzymes—glutamine synthetase and adenosine kinase, respectively—have been documented in epileptic tissues (Coulter and Steinhauser, <xref ref-type="ref" rid="glia23136-bib-0053">2015</xref>).</p>
<p>Downregulation of inward‐rectifying Kir4.1 channels in astrocytes in hippocampus of epileptic patients points to impaired K<sup>+</sup> clearance from the extracellular space and increased seizure susceptibility [reviewed by (Bedner and Steinhauser, <xref ref-type="ref" rid="glia23136-bib-0018">2013</xref>)]. Global knockout of Kir4.1 leads to postnatal lethality (Neusch, Rozengurt, Jacobs, Lester, &amp; Kofuji, <xref ref-type="ref" rid="glia23136-bib-0193">2001</xref>), whereas conditional Kir4.1 knockout in astrocytes alone is able to trigger epilepsy (Chever, Djukic, McCarthy, &amp; Amzica, <xref ref-type="ref" rid="glia23136-bib-0043">2010</xref>; Haj‐Yasein et al., <xref ref-type="ref" rid="glia23136-bib-0095">2011a</xref>). In the same vein, mutations or single nucleotide polymorphisms in the genes encoding Kir4.1 are associated with human epilepsy (Bedner and Steinhauser. 2013). Much of Kir4.1 protein co‐localizes with the water channel AQP4 in the astroglial endfeet (Nielsen et al., <xref ref-type="ref" rid="glia23136-bib-0195">1997</xref>), suggesting that K<sup>+</sup> clearance might depend on concomitant transmembrane flux of water. In line with this idea, reduction in perivascular AQP4 was associated with compromised clearance of extracellular K<sup>+</sup> and impaired K<sup>+</sup> buffering (Amiry‐Moghaddam et al., <xref ref-type="ref" rid="glia23136-bib-0009">2003</xref>). Prolonged seizures occur in AQP4 knockout mice (Binder et al., <xref ref-type="ref" rid="glia23136-bib-0025">2006</xref>).</p>
<p>It is unsurprising that excess of extracellular glutamate characteristic of human epileptic tissue can be linked to recurrent seizures and neuronal death (Glass and Dragunow, <xref ref-type="ref" rid="glia23136-bib-0088">1995</xref>). In mice, knockout of EAAT2 results in spontaneous seizures and hippocampal pathology. Pharmacological inhibition of EAAT2 reduced the threshold for evoking epileptiform activity (Campbell and Hablitz, <xref ref-type="ref" rid="glia23136-bib-0036">2004</xref>; Demarque et al., <xref ref-type="ref" rid="glia23136-bib-0059">2004</xref>). Reduced expression of EAAT2 and glutamate‐aspartate transporters (GLAST, SLC1A3) also occurs in a tuberous sclerosis epilepsy model (Wong et al., <xref ref-type="ref" rid="glia23136-bib-0303">2003</xref>). However, the studies investigating the functional expression of astrocytic glutamate transporters in human epilepsy are inconsistent. Some studies reported a downregulation of EAAT1 and EAAT2 (Proper et al., <xref ref-type="ref" rid="glia23136-bib-0217">2002</xref>), but others reported no significant changes (Eid et al., <xref ref-type="ref" rid="glia23136-bib-0069">2004</xref>). For effective removal of excess extracellular glutamate, the transmitter must be sequestered and metabolized once taken up by astrocytes. Glutamate can be de‐hydrogenated into α‐ketoglutarate by glutamate dehydrogenase. Alternatively, glutamate can be converted into glutamine by glutamine synthase and then returned to neurons. Loss of this astrocyte‐specific enzyme is found in epilepsy (Seifert and Steinhauser, <xref ref-type="ref" rid="glia23136-bib-0237">2013</xref>). A likely consequence is that the shortage of glutamine can affect the pool of GABA which is synthesized from glutamate in the inhibitory neurons, thus weakening inhibition and precipitating seizures (Alvestad et al., <xref ref-type="ref" rid="glia23136-bib-0008">2011</xref>).</p>
<p>A novel and a rather unexpected approach to treatment of epilepsy have been recently proposed by (Sada, Lee, Katsu, Otsuki, &amp; Inoue, <xref ref-type="ref" rid="glia23136-bib-0232">2015</xref>). These authors took their inspiration from the fact that some patients with drug‐resistant epilepsy benefit from a ketogenic diet which limits the intake of carbohydrates. Why this is beneficial is not known but the authors argue that it could be due to the impact on the “lactate shuttle” (Allaman, Belanger, &amp; Magistretti, <xref ref-type="ref" rid="glia23136-bib-0007">2011</xref>; Mosienko, Teschemacher, &amp; Kasparov, <xref ref-type="ref" rid="glia23136-bib-0190">2015</xref>; Pellerin and Magistretti <xref ref-type="ref" rid="glia23136-bib-0214">2003</xref>), whereby astrocytes supply lactate to the actively firing neurons to be used as energy substrate. Reduced supply of carbohydrates theoretically could limit utilization of glucose and therefore production of pyruvate and lactate by astrocytes in the brain. Sada et al. found that neural activity and seizures can be suppressed by lactate dehydrogenase (LDH) inhibition and suggested that LDH could be a target for treatment of epilepsy (see below).</p>
<p>Finally, astrocytic domain organization is disrupted in epilepsy which may, for example, affect K<sup>+</sup> buffering or neurotransmitter clearance (Oberheim et al., <xref ref-type="ref" rid="glia23136-bib-0199">2008</xref>). Interestingly, wide‐spread reactive astrogliosis which develops in a mouse with a conditional deletion of β1‐integrin leads to spontaneous seizures, most likely due to the impaired uptake of glutamate (Robel et al., <xref ref-type="ref" rid="glia23136-bib-0223">2015</xref>). For further information on the role of astrocytes in epilepsy, see (Coulter and Steinhauser <xref ref-type="ref" rid="glia23136-bib-0053">2015</xref>; Robel <xref ref-type="ref" rid="glia23136-bib-0222">2016</xref>) .</p>
</sec>
<sec id="glia23136-sec-0010">
<label>2.2.6</label>
<title>Ischemia/stroke</title>
<p>Stroke is one of the main causes of death worldwide and the leading cause of long‐term neurological disability. The only treatment with proven efficiency is thrombolysis by intravenous administration of recombinant tissue plasminogen activator. The role of astrocytes in stroke recently attracts more and more attention. Indeed, astrocytes are involved in a number of processes which profoundly influence tissue viability during and after ischemia. It is generally acknowledged that astrocytes are substantially more ischemia‐resistant than neurons and survive in conditions of limited blood supply, characteristic for penumbra surrounding the core of the ischemic infarction (Swanson, Farrell, &amp; Stein, <xref ref-type="ref" rid="glia23136-bib-0256">1997</xref>; Vangeison, Carr, Federoff, &amp; Rempe, <xref ref-type="ref" rid="glia23136-bib-0283">2008</xref>). These surviving astrocytes undergo activation and are involved in neuroprotection and post‐ischemic regeneration (Takano, Oberheim, Cotrina, &amp; Nedergaard, <xref ref-type="ref" rid="glia23136-bib-0261">2009</xref>; Zhao and Rempe <xref ref-type="ref" rid="glia23136-bib-0315">2010</xref>). Astroglia contributions to brain resilience could include clearance of glutamate, control over K<sup>+</sup> concentration, supply of lactate to the stressed neurons, secretion of neuroprotective factors, and scavenging reactive oxygen species by releasing GSH and ascorbic acid (Liu and Chopp <xref ref-type="ref" rid="glia23136-bib-0156">2015</xref>; Zhao and Rempe <xref ref-type="ref" rid="glia23136-bib-0315">2010</xref>). Recently, using optogenetic control of H<sup>+</sup> pumps expressed on astrocytes, it was demonstrated that alkalinisation of astrocytes could reduce glutamate release and limit the ischemic brain damage in a cerebellar ischemia model. Therefore, controlling glial pH may be an effective therapeutic strategy (Beppu et al., <xref ref-type="ref" rid="glia23136-bib-0020">2014</xref>). In the absence of astroglia, the vulnerability of neurons to ischemia is greatly increased (Tanaka et al., <xref ref-type="ref" rid="glia23136-bib-0263">1999</xref>). Reactive astrocytes surrounding the ischemic core are the main contributors to the glial scar, along with oligodendrocytes and microglia, establishing a barrier between the damaged and surviving tissue. At the same time, astrocytes are involved in the pathology of stroke by production of neurotoxic substances, release of reactive oxygen species and by being a part of the brain edema mechanism (Liu and Chopp, <xref ref-type="ref" rid="glia23136-bib-0156">2015</xref>; Zhao and Rempe, <xref ref-type="ref" rid="glia23136-bib-0315">2010</xref>). After the stroke, scar formation and expression of proteoglycans might impede neurite outgrowth and inhibit structural and functional recovery (Cregg et al., <xref ref-type="ref" rid="glia23136-bib-0054">2014</xref>; Silver and Miller, <xref ref-type="ref" rid="glia23136-bib-0247">2004</xref>). Glial scars represent powerful barriers for re‐growth of axons, also in the case of mechanical trauma where astrogliosis is seen as a contributor to post‐traumatic epilepsy (Robel, <xref ref-type="ref" rid="glia23136-bib-0222">2016</xref>; Verellen and Cavazos, <xref ref-type="ref" rid="glia23136-bib-0288">2010</xref>). The triggers of glial transformation and activation in stroke or trauma remain elusive.</p>
<p>Thus, astrocytic processes may be either pathogenic in stroke/reperfusion or act as brain defense mechanisms which potentially could be harnessed for therapeutic benefits.</p>
</sec>
</sec>
</sec>
<sec id="glia23136-sec-0011">
<label>3</label>
<title>POTENTIAL THERAPEUTIC TARGETS IN ASTROCYTES</title>
<p>Astrocytes possess a number of potentially targetable and therapeutically plausible biochemical or signaling pathways. In the following section, we summarize some of such candidate pathways and molecules and discuss their therapeutic potential. The key known neuroprotective pathways in astrocytes mentioned in this review are illustrated in Figure <xref ref-type="fig" rid="glia23136-fig-0001">1</xref>.</p>
<fig fig-type="Figure" id="glia23136-fig-0001" orientation="portrait" position="float" xml:lang="en">
<label>Figure 1</label>
<caption>
<p>Major known neuroprotective pathways in astrocytes. Various pathways as discussed in the text demonstrate the multitude of potentially therapeutically exploitable neuroprotective mechanisms in astrocytes. Molecules which have been proposed as their activators or inhibitors are indicated in red (red arrows—putative activators; red T signs—putative inhibitors; red “?”—compounds with unclear mode of action). Metallothioneins (MT) and AQP4 water channels are also labeled with question mark signs since, so far, there is no established pharmacology for these pathways. For further details see the respective sections of the main text</p>
</caption>
<graphic id="nlm-graphic-3" xlink:href="GLIA-65-1205-g001"></graphic>
</fig>
<sec id="glia23136-sec-0012">
<label>3.1</label>
<title>Glutamate transporters, glutamate transmission and excitotoxicity</title>
<p>As mentioned earlier, high concentrations of glutamate are neurotoxic. The most abundant glutamate transporter in the brain is EAAT2 (synonyms: GLT1 and SLC1A2) which is mainly expressed by astrocytes, making them a vital element of the defense against excitotoxicity (Fontana, <xref ref-type="ref" rid="glia23136-bib-0074">2015</xref>; Kim et al., <xref ref-type="ref" rid="glia23136-bib-0136">2011</xref>). Not surprisingly, loss or attenuation of glial glutamate transporters have been implicated in the pathogenesis of many CNS disorders, such as ALS (Rothstein, <xref ref-type="ref" rid="glia23136-bib-0226">2009</xref>), PD (Plaitakis and Shashidharan, <xref ref-type="ref" rid="glia23136-bib-0216">2000</xref>), stroke (Lai, Zhang, &amp; Wang, <xref ref-type="ref" rid="glia23136-bib-0145">2014</xref>), epilepsy (Tanaka et al., <xref ref-type="ref" rid="glia23136-bib-0264">1997</xref>; Wetherington, Serrano, &amp; Dingledine, <xref ref-type="ref" rid="glia23136-bib-0300">2008</xref>), HD (Arzberger, Krampfl, Leimgruber, &amp; Weindl, <xref ref-type="ref" rid="glia23136-bib-0013">1997</xref>), AD (Jacob et al., <xref ref-type="ref" rid="glia23136-bib-0122">2007</xref>; Masliah, Alford, DeTeresa, Mallory, &amp; Hansen, <xref ref-type="ref" rid="glia23136-bib-0170">1996</xref>), and major psychiatric disorders (Choudary et al., <xref ref-type="ref" rid="glia23136-bib-0046">2005</xref>; Lauriat and McInnes, <xref ref-type="ref" rid="glia23136-bib-0146">2007</xref>; Miguel‐Hidalgo et al., <xref ref-type="ref" rid="glia23136-bib-0180">2010</xref>). To the contrary, many animal studies indicate that upregulation of EAAT2 provides significant beneficial effects in models of disease (Harvey et al., <xref ref-type="ref" rid="glia23136-bib-0103">2011</xref>; Kong et al., <xref ref-type="ref" rid="glia23136-bib-0141">2012</xref>; Miller et al., <xref ref-type="ref" rid="glia23136-bib-0181">2012a</xref>; Takahashi et al., <xref ref-type="ref" rid="glia23136-bib-0260">2015b</xref>). Thus, EAAT2 represents a pharmacological target which may modify neuronal function or protect neurons.</p>
<p>The expression or activity of EAAT2 is regulated both transcriptionally and post‐transcriptionally (Grewer, Gameiro, &amp; Rauen, <xref ref-type="ref" rid="glia23136-bib-0091">2014</xref>; Takahashi, Foster, &amp; Lin, <xref ref-type="ref" rid="glia23136-bib-0259">2015a</xref>). Therefore, theoretically, upregulation of EAAT2 could be achieved at transcriptional or translational level. By screening of 1,040 FDA‐approved drugs and nutritionals, Rothstein et al. discovered some molecules which could increase transcription of the EAAT2 gene (Rothstein et al., <xref ref-type="ref" rid="glia23136-bib-0227">2005</xref>). The antibiotic ceftriaxone is one of the best‐studied candidates amongst this group, it has the longest half‐life of available ß‐lactam antibiotics and is believed to penetrate blood brain barrier (Yogev, Shulman, Chadwick, Davis, &amp; Glogowski, <xref ref-type="ref" rid="glia23136-bib-0311">1986</xref>). Ceftriaxone reduces glutamate excitotoxicity in animal models of PD, HD, ischemia, and multiple sclerosis (Cudkowicz et al., <xref ref-type="ref" rid="glia23136-bib-0056">2014</xref>; Hu et al., 2015; Kelsey and Neville, <xref ref-type="ref" rid="glia23136-bib-0133">2014</xref>; Miller et al., <xref ref-type="ref" rid="glia23136-bib-0182">2008</xref>). Ceftriaxone also delays loss of neurons and prolongs survival in mouse models of amyotrophic lateral sclerosis and stroke (Guo et al., <xref ref-type="ref" rid="glia23136-bib-0093">2003</xref>; Thone‐Reineke et al., <xref ref-type="ref" rid="glia23136-bib-0266">2008</xref>). In a clinical trial where ceftriaxone was tested for treatment of ALS patients, it was well tolerated in stages I and II (Berry et al., <xref ref-type="ref" rid="glia23136-bib-0021">2013</xref>). Unfortunately, stage III was discontinued because no increase of the length of survival or prevention of a functional decline was achieved (Cudkowicz et al., <xref ref-type="ref" rid="glia23136-bib-0056">2014</xref>). However, it may still be possible to develop derivatives of ceftriaxone with improved properties. It is also possible that ALS was not the best disease target for it.</p>
<p>Currently, riluzole is the only FDA‐approved drug for the treatment of ALS, although it prolongs the life of ALS patients by only 7 months (Miller, Mitchell, &amp; Moore, <xref ref-type="ref" rid="glia23136-bib-0183">2012b</xref>). A major action of riluzole is the inhibition of glutamate release from presynaptic neurons, but it also enhances astrocytic glutamate uptake by upregulating EAAT2 gene expression (Liu et al., <xref ref-type="ref" rid="glia23136-bib-0155">2011</xref>).</p>
<p>Colton et al. developed a cell‐based enzyme‐linked immunosorbent assay approach to search for translational enhancers and identified 61 compound which increased EAAT2 protein levels (Colton et al., <xref ref-type="ref" rid="glia23136-bib-0049">2010</xref>). These compounds enhanced glutamate transport without changing EAAT2 mRNA level (Colton et al., <xref ref-type="ref" rid="glia23136-bib-0049">2010</xref>). The same group developed thiopyridazine and pyridazine derivatives that increase EAAT2 expression (Xing et al., <xref ref-type="ref" rid="glia23136-bib-0306">2011</xref>). Analog LDN/OSU‐0212320, a pyridazine derivative, protected cultured neurons from glutamate‐mediated excitotoxic injury. It also delayed motor function decline and extended lifespan in an animal model of ALS (Kong et al., <xref ref-type="ref" rid="glia23136-bib-0140">2014</xref>). Further tests of this analog in a range of animal models will potentially reveal other diseases where reduction of excessive extracellular glutamate can provide therapeutic advantage. Wider testing of these compounds in other models and species but mice should verify the therapeutic potential of this strategy.</p>
<p>In addition to EAAT2 transcriptional and translational activators, there are chemicals that directly modulate the function of EAAT2. Parawixin1, purified from the venom of the spider <italic>parawixia bistriata</italic>, enhances directly and selectively EAAT2 function by facilitating conformational transitions involved in substrate translocation (Fontana et al., <xref ref-type="ref" rid="glia23136-bib-0075">2007</xref>). Site‐directed mutagenesis identified a structural region within EAAT2 which is important for the transporter‐enhancing activity in transmembrane domains 2, 5, and 8 (Mortensen, Liberato, Coutinho‐Netto, Dos Santos, &amp; Fontana, <xref ref-type="ref" rid="glia23136-bib-0189">2015</xref>). This unique structural information could be employed in hybrid structure‐based virtual screening of a large library to identify novel allosteric modulators of EAAT2. Another EAAT2 activator is the pyrazoline compound MS‐153 ([R]‐5‐methyl‐1‐nicotinoyl‐2‐pyrazoline) (Shimada et al., <xref ref-type="ref" rid="glia23136-bib-0243">1999</xref>) although recently it has been questioned whether its effects are actually attributable to action on EAAT2 or are a consequence of other effects such as inhibition of Ca<sup>2+</sup> channels.</p>
</sec>
<sec id="glia23136-sec-0013">
<label>3.2</label>
<title>GSH</title>
<p>Decreased brain content of GSH is an indicator of oxidative stress which, in turn, is recognized as a central contributing factor to neurodegenerative diseases (Kim et al., <xref ref-type="ref" rid="glia23136-bib-0135">2015</xref>). Although GSH can cross the blood‐brain barrier, blood is probably not the major source of cerebral GSH (Anderson, Underwood, Bridges, &amp; Meister, <xref ref-type="ref" rid="glia23136-bib-0010">1989</xref>). Instead, the predominant source in the brain is astrocytes, and this allows neurons to maintain a sufficient antioxidant defense. Hence upregulating astrocytic GSH production could be a potential neuroprotective strategy. Zonisamide, a novel anti‐PD agent used in Japan, increased GSH levels in the striatal astrocytes and demonstrated neuroprotective effects against dopaminergic neurodegeneration in PD mice (Asanuma et al., <xref ref-type="ref" rid="glia23136-bib-0014">2010</xref>). However, this drug upregulates expression of a whole range of factors which are also potentially neuroprotective and neurotrophic.</p>
</sec>
<sec id="glia23136-sec-0014">
<label>3.3</label>
<title>Metallothioneins</title>
<p>Metallothioneins (MT) are a family of low molecular weight and cysteine‐rich proteins with antioxidant, anti‐apoptotic, and anti‐inflammatory properties (Bolognin, Cozzi, Zambenedetti, &amp; Zatta, <xref ref-type="ref" rid="glia23136-bib-0026">2014</xref>). MT has been implicated in neurodegenerative diseases including PD, AD, and also brain trauma and ischemia (Hozumi, <xref ref-type="ref" rid="glia23136-bib-0111">2013</xref>). Neuroprotective properties of MT are well documented (Chung, Hidalgo, &amp; West, <xref ref-type="ref" rid="glia23136-bib-0047">2008</xref>; Vasak, <xref ref-type="ref" rid="glia23136-bib-0286">2005</xref>). Deficiency in MT generally worsens the damage caused by neurotoxic factors or trauma (Giralt et al., <xref ref-type="ref" rid="glia23136-bib-0085">2002</xref>). However, in <italic>glioblastoma multiforme</italic> patients, high levels of MT are a negative prognostic factor, probably because MT make tumors more resistant to therapy (Mehrian‐Shai et al., <xref ref-type="ref" rid="glia23136-bib-0177">2015</xref>).</p>
<p>The MT family is comprised of four main members, MT1 to MT4. MT1 and MT2 are primarily expressed in astrocytes and it is thought that astrocyte‐derived MT facilitate neuronal survival and axonal regeneration (Aschner, <xref ref-type="ref" rid="glia23136-bib-0015">1997</xref>; Hidalgo, Aschner, Zatta, &amp; Vasak, <xref ref-type="ref" rid="glia23136-bib-0109">2001</xref>). Exogenous MT1 and MT2 improved neuronal survival and axonal outgrowth in cortical, hippocampal, and dopaminergic cultures (Chung, Vickers, Chuah, &amp; West, <xref ref-type="ref" rid="glia23136-bib-0048">2003</xref>), and astrocytic MT protected dopaminergic neurons in a PD model (Miyazaki et al., <xref ref-type="ref" rid="glia23136-bib-0186">2011</xref>). In contrast, MT1 and MT2 double knockout mice demonstrated impaired axonal regeneration after sciatic nerve crush and MT2A treatment promoted neurite elongation and post‐injury reactive neurite growth (Chung et al., <xref ref-type="ref" rid="glia23136-bib-0048">2003</xref>).</p>
<p>The exact mechanism of MT‐mediated neuroprotection is not known but possibly it involves zinc‐mediated transcriptional activation of genes involved in growth, proliferation, and differentiation (Sharma and Ebadi, <xref ref-type="ref" rid="glia23136-bib-0239">2014</xref>; Sharma, Rais, Sandhu, Nel, &amp; Ebadi, <xref ref-type="ref" rid="glia23136-bib-0240">2013</xref>). MT also regulates copper metabolism and potentially by this route MT1 overexpression can slow disease progression in SOD1 (G93A) mice (model of ALS) (Tokuda, Okawa, Watanabe, &amp; Ono, <xref ref-type="ref" rid="glia23136-bib-0270">2014</xref>). MT also reduce oxidative damage (Bolognin et al., <xref ref-type="ref" rid="glia23136-bib-0026">2014</xref>; Uttara, Singh, Zamboni, &amp; Mahajan, <xref ref-type="ref" rid="glia23136-bib-0278">2009</xref>).</p>
<p>Interestingly, ageing is often accompanied by various late‐life neurodegenerative diseases, while MT show strong anti‐ageing effects (Sharma and Ebadi, <xref ref-type="ref" rid="glia23136-bib-0239">2014</xref>). Dietary supplements combined with genetically increased MT1 have been demonstrated to increase lifespan in mice (Yang et al., <xref ref-type="ref" rid="glia23136-bib-0310">2006</xref>). Interestingly, exercise induces MT, at least in the spinal cord (Hashimoto, Hayashi, Inuzuka, &amp; Hozumi, <xref ref-type="ref" rid="glia23136-bib-0104">2009</xref>). So far, no pharmacological compounds have been reported to specifically induce MT synthesis in astrocytes or non‐selectively in the brain. Nevertheless, given the example of EAAT2 inducers (see above), this does not look like an implausible idea.</p>
</sec>
<sec id="glia23136-sec-0015">
<label>3.4</label>
<title>Aquaporin 4</title>
<p>The AQP4 water channel is exclusively expressed by astrocytes and constitutes an astrocyte‐specific mechanism regulating fluid homeostasis which is fundamental for brain function (Badaut, Lasbennes, Magistretti, &amp; Regli, <xref ref-type="ref" rid="glia23136-bib-0016">2002</xref>; Nielsen et al., <xref ref-type="ref" rid="glia23136-bib-0195">1997</xref>). The enrichment of AQP4 in astroglial endfeet surrounding blood vessels suggests that it regulates not only astrocyte volume, but also the water traffic between vascular and interstitial compartments, as well as the size, shape and diffusion characteristics of the extracellular space (Xiao and Hu, <xref ref-type="ref" rid="glia23136-bib-0305">2014</xref>). AQP4 is co‐localized with Kir4.1, indicating that coordinated action of both channels is required to maintain K<sup>+</sup> homeostasis (Masaki et al., <xref ref-type="ref" rid="glia23136-bib-0169">2010</xref>). Neuronal activity leads to transient increases in the extracellular K<sup>+</sup> concentration and clearance of the excess K<sup>+</sup> from the extracellular space is an important function of astrocytes.</p>
<p>AQP4 knockout mice (both non‐selective and glia‐targeted) have a significantly reduced tendency to develop cerebral edema following water intoxication and stroke, as well as better survival and neurological outcomes (Haj‐Yasein et al., <xref ref-type="ref" rid="glia23136-bib-0096">2011b</xref>; Manley et al., <xref ref-type="ref" rid="glia23136-bib-0163">2000</xref>). Given the role of AQP4 in K<sup>+</sup> and water homeostasis, it seems rational to develop AQP4 modulators as drugs against diseases involving brain edema (King, Yasui, &amp; Agre, <xref ref-type="ref" rid="glia23136-bib-0137">2000</xref>). Unfortunately, limited progress has been made in AQP4‐targeted therapeutics (Verkman, Anderson, &amp; Papadopoulos, <xref ref-type="ref" rid="glia23136-bib-0291">2014</xref>). This is partly due to the lack of robust assays of AQP4 activity. The small size of the functional AQP4 monomer and its very small pore diameter, which prevents the access of conventional small molecules, translates to poor “druggability” (Verkman et al., <xref ref-type="ref" rid="glia23136-bib-0291">2014</xref>). As AQP4 are simple passive pores, they lack sophisticated gating and transport mechanisms suitable for targeting with small molecules. Furthermore, mutations in the extracellular and cytoplasmic domains of AQP4 generally have little effect on water permeability through the channel, which suggests that the binding of an inhibitor has to occur deep in the narrow pore to physically prevent water conduction (Papadopoulos and Verkman, <xref ref-type="ref" rid="glia23136-bib-0208">2013</xref>; Verkman et al., <xref ref-type="ref" rid="glia23136-bib-0291">2014</xref>). Nevertheless, further large‐scale screening of random and computationally biased libraries in search of AQP4 blockers is warranted. Rigorous tests for validation of putative lead compounds also need to be developed.</p>
</sec>
<sec id="glia23136-sec-0016">
<label>3.5</label>
<title>Connexin gap junctions</title>
<p>In contrast to most mature neurons, astrocytes are usually coupled through gap junctions (GJ) to form large intercellular networks (Rouach, Glowinski, &amp; Giaume, <xref ref-type="ref" rid="glia23136-bib-0229">2000</xref>). GJ channels are built of connexin (CX) proteins, of which CX43 and CX30 are the major subtypes in astrocytes (Giaume and McCarthy, <xref ref-type="ref" rid="glia23136-bib-0083">1996</xref>). Individual CX assemble into hexamers to form transmembrane channels, termed connexons, which couple with apposing connexons on neighboring cells. Dense GJ plaques may contain thousands of channels (Unwin and Zampighi, <xref ref-type="ref" rid="glia23136-bib-0277">1980</xref>). GJ couple the cytoplasm of connected cells and permit movement of ions and low molecular weight molecules (about 1–2 kDa (Loewenstein, <xref ref-type="ref" rid="glia23136-bib-0157">1981</xref>).We still do not know to what extent selectivity of the GJ can change under different circumstances.</p>
<p>GJ between astrocytes allow movement of metabolic substrates and support astrocytic spatial K<sup>+</sup> buffering to modulate and potentially synchronize neuronal activity (Gardner‐Medwin, <xref ref-type="ref" rid="glia23136-bib-0080">1983</xref>). GJ are also dense at the endfeet of astrocytes where they provide a perivascular route that facilitates intercellular trafficking between neighboring endfeet (Simard, Arcuino, Takano, Liu, &amp; Nedergaard, <xref ref-type="ref" rid="glia23136-bib-0248">2003</xref>). Connexons exist also on their own as single membrane hemichannels which connect the cell cytoplasm to the extracellular milieu (Giaume, Leybaert, Naus, &amp; Saez, <xref ref-type="ref" rid="glia23136-bib-0082">2013</xref>). It is now known that under certain conditions CX hemichannels can release ATP (Huckstepp et al., <xref ref-type="ref" rid="glia23136-bib-0115">2010</xref>) or lactate (Karagiannis et al., <xref ref-type="ref" rid="glia23136-bib-0132">2016</xref>).</p>
<p>Intercellular communication among astrocytes is lost in CX43/CX30 double knockout mice, demonstrating their pivotal role in astroglial connectivity (Dermietzel et al., <xref ref-type="ref" rid="glia23136-bib-0060">2000</xref>; Giaume and Theis <xref ref-type="ref" rid="glia23136-bib-0084">2010</xref>). CX43/CX30 double knockout leads to impaired potassium clearance and disrupts synaptic transmission and plasticity (Pannasch et al., <xref ref-type="ref" rid="glia23136-bib-0207">2011</xref>; Wallraff et al., <xref ref-type="ref" rid="glia23136-bib-0293">2006</xref>). CX43/CX30 double knockout also causes astrocyte endfeet edema and weakens the blood‐brain barrier (Ezan et al., <xref ref-type="ref" rid="glia23136-bib-0071">2012</xref>). Under pathological conditions, altered CX expression may lead to a failure of glial communication (Rouach et al., <xref ref-type="ref" rid="glia23136-bib-0228">2002</xref>). Changes in CX43 expression have been detected in animal models and human patients with epilepsy, in ischemia and stroke, autism and neurodegenerative diseases (Takeuchi and Suzumura <xref ref-type="ref" rid="glia23136-bib-0262">2014</xref>).</p>
<p>Specific small molecule modulators of CX43/CX30 are not available and, at present, the best‐characterized tools to target specific CX are peptides that mimic a short stretch of amino acids on the extracellular loop motifs of the target connexons. These interfere with GJ formation and inhibit hemichannel activity (Evans and Boitano, <xref ref-type="ref" rid="glia23136-bib-0070">2001</xref>; Leybaert et al., <xref ref-type="ref" rid="glia23136-bib-0153">2003</xref>). Because their initial characterization (Dahl, Nonner, &amp; Werner, <xref ref-type="ref" rid="glia23136-bib-0057">1994</xref>), a series of “Gap” peptides with specificity for certain CX were developed (Abudara et al., <xref ref-type="ref" rid="glia23136-bib-0001">2014</xref>; Chaytor, Evans, &amp; Griffith, <xref ref-type="ref" rid="glia23136-bib-0040">1997</xref>; Evans and Boitano <xref ref-type="ref" rid="glia23136-bib-0070">2001</xref>; Gomes, Srinivas, Van Driessche, Vereecke, &amp; Himpens, <xref ref-type="ref" rid="glia23136-bib-0089">2005</xref>; Leybaert et al., <xref ref-type="ref" rid="glia23136-bib-0153">2003</xref>). A promising new report shows that Gap19, a nonapeptide derived from the cytoplasmic loop of CX43, inhibits astroglial CX43 hemichannels, while not affecting GJ channels (Abudara et al., <xref ref-type="ref" rid="glia23136-bib-0001">2014</xref>). Moreover, Gap19 is specific to CX43 and was demonstrated to cross the blood–brain barrier when coupled to the HIV‐derived TAT internalization sequence (Abudara et al., <xref ref-type="ref" rid="glia23136-bib-0001">2014</xref>). The effect of this peptide in neuroprotection is currently being explored (Freitas‐Andrade and Naus, <xref ref-type="ref" rid="glia23136-bib-0076">2016</xref>).</p>
<p>Because of their importance for astrocytic functions, CX30 and CX43 represent potential drug targets of interest, although further studies are needed in order to understand the precise molecular mechanism regulating their gating properties. However, development of small molecules for such targets clearly requires thinking out of the box.</p>
</sec>
<sec id="glia23136-sec-0017">
<label>3.6</label>
<title>PAR‐1 receptors</title>
<p>Protease‐activated receptors (PAR) are G‐protein‐coupled receptors (GPCR) activated by extracellular serine proteases. The thrombin receptors PAR‐1, −3 and −4 and the tryptase/trypsin receptor PAR‐2 are abundant in CNS (Ramachandran, Noorbakhsh, Defea, &amp; Hollenberg, <xref ref-type="ref" rid="glia23136-bib-0220">2012</xref>). PAR are characterized by the presence of a tethered peptide ligand in their N‐terminal part which, when released by cleavage, acts on the ligand binding site and activates the receptor. The expression of PAR in the brain is differentially regulated in neurodegenerative disorders like PD, AD, multiple sclerosis and stroke (Luo, Wang, &amp; Reiser, <xref ref-type="ref" rid="glia23136-bib-0160">2007</xref>). Activation of PAR can lead to cell death or cell survival, depending on the magnitude and the duration of agonist stimulation.</p>
<p>PAR‐1 is the best characterized receptor of this family which is activated by the cleavage of the extracellular N‐terminal domain by thrombin. This releases a tethered ligand (SFLLRN) that activates the receptor and initiates signaling through <italic>G</italic>
<sub>q/11</sub>, <italic>G</italic>
<sub>i/o</sub>, or <italic>G</italic>
<sub>12/13</sub> G‐proteins (Coughlin <xref ref-type="ref" rid="glia23136-bib-0052">2000</xref>; Traynelis and Trejo, <xref ref-type="ref" rid="glia23136-bib-0273">2007</xref>). In the CNS, PAR‐1 is expressed mainly (and in some areas almost exclusively) by astrocytes although in the hippocampus PAR‐1 is also present in some neurons (Junge et al., <xref ref-type="ref" rid="glia23136-bib-0130">2004</xref>; Niclou, Suidan, Brown‐Luedi, &amp; Monard, <xref ref-type="ref" rid="glia23136-bib-0194">1994</xref>; Wang, Ubl, &amp; Reiser, <xref ref-type="ref" rid="glia23136-bib-0294">2002</xref>). Activation of PAR‐1 leads to increases in astrocytic [Ca<sup>2+</sup>]<sub>i</sub> and astrocytes activated by PAR‐1 agonists can release glutamate which, in turn, may activate NMDA receptors on adjacent neurons (Lee et al., <xref ref-type="ref" rid="glia23136-bib-0147">2007</xref>; Vance, Rogers, &amp; Hermann, <xref ref-type="ref" rid="glia23136-bib-0282">2015</xref>).</p>
<p>Activation of PAR‐1 might produce bimodal effects. Low‐level PAR‐1 activation seems to be protective whereas high levels of PAR‐1 activation compromise cell viability (Acharjee et al., <xref ref-type="ref" rid="glia23136-bib-0002">2011</xref>; Donovan, Pike, Cotman, &amp; Cunningham, <xref ref-type="ref" rid="glia23136-bib-0065">1997</xref>; Vaughan, Pike, Cotman, &amp; Cunningham, <xref ref-type="ref" rid="glia23136-bib-0287">1995</xref>). The neuroprotective effects of thrombin via PAR‐1 activation have been confirmed in several independent studies both <italic>in vitro</italic> and <italic>in vivo</italic>. PAR‐1 activation protected neurons and astrocytes against chemical insults, via regulation of the secretion of cytokine‐induced neutrophil chemoattractants (Wang, Luo, &amp; Reiser, <xref ref-type="ref" rid="glia23136-bib-0298">2007</xref>). PAR‐1 activation by thrombin, further, diminished ceramide‐induced astrocyte death via upregulation of JUN N‐terminal kinase (Wang, Luo, Stricker, &amp; Reiser, <xref ref-type="ref" rid="glia23136-bib-0299">2006</xref>), and rescued astrocytes through the PI3K/Akt signaling pathway from chemically induced apoptosis (Zhu and Reiser, <xref ref-type="ref" rid="glia23136-bib-0318">2014</xref>). <italic>In vivo</italic> PAR‐1 activation was neuroprotective in a 6‐hydroxydopamine model of PD (Cannon et al., <xref ref-type="ref" rid="glia23136-bib-0038">2006</xref>).</p>
<p>In contrast, a number of studies suggest a pathophysiological role for PAR‐1 in various types of brain damage (Gutierrez‐Rodriguez and Herranz, <xref ref-type="ref" rid="glia23136-bib-0094">2015</xref>). In a murine model of stroke, neurotrauma and brain hemorrhage, PAR‐1‐mediated signaling had deleterious effects on neuronal survival and function. PAR‐1 deficiency or its pharmacological inhibition with an antagonist BMS‐200261 reduced infarct volume in the transient occlusion of the middle cerebral artery model (Junge et al., <xref ref-type="ref" rid="glia23136-bib-0131">2003</xref>). PAR‐1 deficiency or the central application of PAR‐1 antagonists also reduced neuronal injury following intrastriatal injection of NMDA in rats (Hamill, Mannaioni, Lyuboslavsky, Sastre, &amp; Traynelis, <xref ref-type="ref" rid="glia23136-bib-0101">2009</xref>). PAR‐1 inhibitors reduced brain damage caused by the neurotoxic effects of blood in intracerebral hemorrhage (Xue, Hollenberg, Demchuk, &amp; Yong, <xref ref-type="ref" rid="glia23136-bib-0307">2009</xref>). PAR‐1 could also be involved in the pathogenesis of chronic neurodegenerative and/or inflammatory conditions. Post‐mortem tissue samples from patients affected by HIV‐associated dementia, a neurodegenerative condition affecting patients with AIDS, show that PAR‐1 expression is enhanced in astrocytes, which in turn could induce expression of inflammatory mediators by these cells (Acharjee et al., <xref ref-type="ref" rid="glia23136-bib-0002">2011</xref>; Boven et al., <xref ref-type="ref" rid="glia23136-bib-0028">2003</xref>). PAR‐1 deficiency, as well as the intraventricular administration of PAR‐1 antagonists, also reduced dopaminergic neuron damage and microgliosis in a MPTP model of PD (Hamill et al., <xref ref-type="ref" rid="glia23136-bib-0100">2007</xref>). Possibly, reports of a potential pathogenic role of PAR‐1 signaling can be linked to facilitation of glutamate release activation of NMDA receptors as mentioned above.</p>
<p>Importantly, there are already small molecule PAR‐1 antagonists such as vorapaxar, also known as Zontivity, marketed as anti‐platelet drug (Bhandari and Mehta, <xref ref-type="ref" rid="glia23136-bib-0023">2014</xref>) and other prototype molecules such as RWJ‐56110 (Andrade‐Gordon et al., <xref ref-type="ref" rid="glia23136-bib-0011">1999</xref>).</p>
<p>To summarize, PAR‐1 modulation may be seen as a fairly astrocyte‐specific intervention within the brain. However, a major concern with the systemic use of PAR‐1 antagonists is their anti‐thrombotic effect. Therefore, a centrally acting drug which modulates astrocytic PAR‐1 would need to be devoid of hematinic side effects, which may be achievable using a pro‐drug strategy.</p>
</sec>
<sec id="glia23136-sec-0018">
<label>3.7</label>
<title>Astrocytic GPR37 and GPR37L1</title>
<p>GPR37 and GRP37L1 are two closely related GPCRs which are almost exclusively expressed in CNS in mammals. GPR37 is alternatively known as the Parkin‐Associated Endothelin‐Like receptor (Pael‐R) (Imai et al., <xref ref-type="ref" rid="glia23136-bib-0117">2001</xref>), while GP37L1 is named for its similarity to GPR37. The interest to GPR37 was boosted by its potential link to PD. Parkin is an E3 ubiquitin‐protein ligase and mutations in this gene are directly linked to autosomal recessive juvenile PD (AR‐JP). Although parkin has many substrates, GPR37 attracted interest because GPR37 is up‐regulated in brains of AR‐JP patients (Takahahshi, <xref ref-type="ref" rid="glia23136-bib-0258">2006</xref>). In addition, GPR37 is present in the core of Lewy bodies, thus suggesting a role of GPR37 aggregates in PD. Also, viral vector‐mediated GPR37 overexpression in substantia nigra results in progressive degeneration of nigral dopaminergic neurons (Dusonchet, Bensadoun, Schneider, &amp; Aebischer, <xref ref-type="ref" rid="glia23136-bib-0068">2009</xref>; Low and Aebischer, <xref ref-type="ref" rid="glia23136-bib-0159">2012</xref>).</p>
<p>Under normal conditions, correctly folded GPR37 is trafficked to the cell surface but it has a high propensity to misfold. Parkin ubiquitinates misfolded GPR37 targeting it for proteasomal degradation. If this process fails, misfolded GPR37 forms aggregates. Mutations in the parkin gene enhanced dopaminergic neuronal cytotoxicity by failing to remove aggregated GPR37 and other substrates. This leads to activation of the unfolded protein response and cell death, a process that can be rescued by re‐expression or overexpression of wild type parkin (Imai et al., <xref ref-type="ref" rid="glia23136-bib-0117">2001</xref>). GPR37L1 does not undergo ubiquitination and thus the phenomenon is limited to GPR37.</p>
<p>Up until relatively recently, the physiological functions of GPR37 and GPR37L1 were assessed mainly through use of knockout mice. The connection between GPR37 and parkin has led to a focus on the dopaminergic system in GPR37 knockout mice which exhibit progressive loss of dopaminergic neurons, various subtle alterations to dopaminergic signaling and significantly reduced locomotor activity (Marazziti et al., <xref ref-type="ref" rid="glia23136-bib-0166">2011</xref>, <xref ref-type="ref" rid="glia23136-bib-0167">2004</xref>, <xref ref-type="ref" rid="glia23136-bib-0168">2007</xref>). In humans, dysregulation of GPR37 has recently been linked to major depressive disorder, bipolar disorder and autism spectrum disorder (Cruceanu et al., <xref ref-type="ref" rid="glia23136-bib-0055">2015</xref>; Fujita‐Jimbo et al., <xref ref-type="ref" rid="glia23136-bib-0077">2012</xref>; Tomita et al., <xref ref-type="ref" rid="glia23136-bib-0271">2013</xref>). In contrast to GPR37, the phenotype of GPR37L1 knockout mice is less well characterized. The most remarkable observation in these animals is that they are hypertensive (Min et al., <xref ref-type="ref" rid="glia23136-bib-0184">2010</xref>) and have cardiac hypertrophy probably due to hypertension (Min et al., <xref ref-type="ref" rid="glia23136-bib-0184">2010</xref>). The link between GPR37L1 and blood pressure control remains elusive. Another study reported abnormal cerebellum development in GPR37L1 knockout mice that was a direct consequence of premature downregulation of granule neuron precursor cell proliferation and concomitant premature development and maturation of Bergmann glia and Purkinje neurons (Marazziti et al., <xref ref-type="ref" rid="glia23136-bib-0165">2013</xref>).</p>
<p>Deorphanisation of GPR37 and GPR37L1 had been a difficult process. Although they were originally identified through searches for homologs of endothelin and bombesin receptors, neither GPR37 nor GPR37L1 bind endothelins or related peptides (Leng, Gu, Simerly, &amp; Spindel, <xref ref-type="ref" rid="glia23136-bib-0152">1999</xref>; Zeng, Su, Kyaw, &amp; Li, <xref ref-type="ref" rid="glia23136-bib-0313">1997</xref>). Eventually, an extracellular peptide, prosaposin, and its active peptide fragments, prosaptides (including the synthetic analog TX14A), were identified as agonists of GPR37 and GPR37L1 (Meyer, Giddens, Schaefer, &amp; Hall, <xref ref-type="ref" rid="glia23136-bib-0179">2013</xref>). Both prosaposin and prosaptides have long been known as powerful and essential neuroprotective and glioprotective factors (O'Brien et al., <xref ref-type="ref" rid="glia23136-bib-0198">1995</xref>; Obrien, Carson, Seo, Hiraiwa, &amp; Kishimoto, <xref ref-type="ref" rid="glia23136-bib-0200">1994</xref>). Mutations in prosaposin in mammals result in severe neurodegeneration (Sikora, Harzer, &amp; Elleder, <xref ref-type="ref" rid="glia23136-bib-0246">2007</xref>; Yoneshige, Suzuki, Suzuki, &amp; Matsuda, <xref ref-type="ref" rid="glia23136-bib-0312">2010</xref>). Prosaposin and prosaptides were shown to couple via Gαi and Gαo proteins which are pertussis toxin‐sensitive (Hiraiwa, Campana, Martin, &amp; O'Brien, <xref ref-type="ref" rid="glia23136-bib-0110">1997</xref>; Yan, Otero, Hiraiwa, &amp; O'Brien, <xref ref-type="ref" rid="glia23136-bib-0309">2000</xref>). The peptides interacted with, at the time, unknown receptors with nanomolar affinity and stimulated ERK phosphorylation (Subramaniam and Unsicker, <xref ref-type="ref" rid="glia23136-bib-0255">2010</xref>). Indeed, recently Meyer and colleagues found that GPR37 and GPR37L1 met all these previously established characteristics (Meyer et al., <xref ref-type="ref" rid="glia23136-bib-0179">2013</xref>).</p>
<p>Within the brain, GPR37 mRNA was detected both in neurons and glia (Zeng et al., <xref ref-type="ref" rid="glia23136-bib-0313">1997</xref>) but it seems that only some neuronal types such as dopaminergic (and probably other catecholaminergic neurons) express it at high level. In contrast to the mixed distribution of GPR37, GPR37L1 is highly expressed in astrocytes, with in situ hybridization revealing greatest density of GPR37L1 within the Bergmann glia of the cerebellum (Valdenaire et al., <xref ref-type="ref" rid="glia23136-bib-0279">1998</xref>). Microarray studies reported more than 100 times higher expression of GPR37L1 in rat and mice astrocytes compared with neurons (Cahoy et al., <xref ref-type="ref" rid="glia23136-bib-0034">2008</xref>; Lovatt et al., <xref ref-type="ref" rid="glia23136-bib-0158">2007</xref>; Zhang et al., <xref ref-type="ref" rid="glia23136-bib-0314">2014</xref>). GPR37L1 is also expressed in oligodendrocytes (Zhang et al., <xref ref-type="ref" rid="glia23136-bib-0314">2014</xref>). These results are consistent with our own, yet unpublished, transcriptomic analysis of rat brainstem astrocytes.</p>
<p>Given that the ligands of these receptors have well established neuroprotective activities and that GPR37 and GPR37L1 are highly expressed in astrocytes, one may speculate that the beneficial effects of prosaposin and its derivatives might be mediated at least partially by astrocytes rather than by a direct action on the neurons. Prosaptide acting on GPR37/GPR37L1 clearly protected cultured astrocytes from oxidative stress (Meyer et al., <xref ref-type="ref" rid="glia23136-bib-0179">2013</xref>). One important direction of current research is to assess how these two receptors regulate astrocytic function and, via this route, modulate activity and survival of neurons. An important question is also whether these effects are specific to only some subtypes of neurons, for example catecholaminergic neurons. Currently, no small molecule ligands for either GPR37 or GPR37L1 are available, and thus the pharmacology of these receptors is unexplored terrain that has the potential to yield clinically useful therapeutic drugs. If any of the <italic>in vivo</italic> protective effects of prosaposin are indeed dependent on astrocytic GPR37and/or GPR37L1, then a screen for small molecule agonists and/or positive allosteric modulators for these receptors would be warranted. Such compounds may have outstanding therapeutic value due to their potential to mimic and/or enhance the glio‐ and neuroprotective actions of secreted prosaposin.</p>
</sec>
<sec id="glia23136-sec-0019">
<label>3.8</label>
<title>Targeting astrocytic adenosine receptor A2a to improve memory in AD</title>
<p>Adenosine is a potent neuromodulator derived from breakdown of ATP and other adenine nucleotides. Adenosine and ATP are released in the brain by diverse cell types (Burnstock, <xref ref-type="ref" rid="glia23136-bib-0032">2007</xref>). A1 and A3 are Gi‐coupled, while A2A and A2B are Gs‐coupled receptors which inhibit and trigger, respectively, cyclic AMP (cAMP)‐mediated signaling. A2A receptors are highly expressed in the brain and have been implicated in diverse neuropathologies, including PD, ischemic brain injury, traumatic brain injury and schizophrenia (Chen et al., <xref ref-type="ref" rid="glia23136-bib-0041">2007</xref>; Matos et al., <xref ref-type="ref" rid="glia23136-bib-0173">2015</xref>). A2A receptors on glial cells and their impact on the neuroinflammatory and neuromodulatory processes are likely to be involved in these diseases. Indeed, the A2A receptor regulates astrocytic functions (Matos, Augusto, Agostinho, Cunha, &amp; Chen, <xref ref-type="ref" rid="glia23136-bib-0171">2013</xref>) and has been implicated in AD (Albasanz, Perez, Barrachina, Ferrer, &amp; Martin, <xref ref-type="ref" rid="glia23136-bib-0005">2008</xref>; Huang and Mucke, <xref ref-type="ref" rid="glia23136-bib-0114">2012</xref>). Astrocytic A2A receptors seem to affect the ability of Aβ peptide to suppress glutamate uptake, which could be one of the mechanisms of excitotoxicity in AD (Matos et al., <xref ref-type="ref" rid="glia23136-bib-0172">2012</xref>). Although microglia also expresses A2A receptors, increased levels of A2A receptor expression in humans with AD are found only in astrocytes. Similar to AD humans, aging mice expressing human amyloid precursor protein also have increased levels of astrocytic A2A receptors (Orr et al., <xref ref-type="ref" rid="glia23136-bib-0204">2015</xref>). Conditional genetic removal of these receptors enhanced memory in these mice, suggesting that inhibiting astrocytic A2A receptors might be considered as a therapeutic strategy for memory enhancement. In line with this speculation, there has been some evidence showing that caffeine, whose main target is A2A receptors, can improve normal memory function or even prevent AD symptoms in older adults (Arendash and Cao, <xref ref-type="ref" rid="glia23136-bib-0012">2010</xref>; Borota et al., <xref ref-type="ref" rid="glia23136-bib-0027">2014</xref>; Carman, Dacks, Lane, Shineman, &amp; Fillit, <xref ref-type="ref" rid="glia23136-bib-0039">2014</xref>). However, the case is not clear, because deletion of astrocytic A2A receptors disrupts glutamate homeostasis, leading to psychomotor and cognitive impairments which resemble schizophrenia (Matos et al., <xref ref-type="ref" rid="glia23136-bib-0173">2015</xref>).</p>
</sec>
<sec id="glia23136-sec-0020">
<label>3.9</label>
<title>Meteorin pathway</title>
<p>Meteorin was first identified as a retinoic‐acid‐responding gene involved in glial differentiation and regulation of axonal extension (Nishino et al., <xref ref-type="ref" rid="glia23136-bib-0196">2004</xref>). It is a fairly long peptide ‐ 291 amino acids in the mouse, including a 21 amino acid signaling peptide. Meteorin is mainly produced and secreted by astroglia and, in addition to the effects on glia and neurons, also acts on endothelial cells (Park et al., <xref ref-type="ref" rid="glia23136-bib-0209">2008</xref>). Lentiviral overexpression of meteorin protected striatal neurons from excitotoxicity caused by quinolinic acid <italic>in vivo</italic> (Jorgensen et al., <xref ref-type="ref" rid="glia23136-bib-0126">2011</xref>) and reversed hypersensitivity in rat models of neuropathic pain (Jorgensen et al., <xref ref-type="ref" rid="glia23136-bib-0127">2012</xref>). Meteorin is upregulated in reactive astrocytes in a photothrombotic ischemia mouse model and functions as a negative feedback effector in reactive gliosis (Lee et al., <xref ref-type="ref" rid="glia23136-bib-0149">2015</xref>). However, the cellular receptor(s) for meteorin are still unknown. It has been reported that meteorin acts through the Jak‐STAT3 pathway to promote glial differentiation in neural stem cells (Lee, Han, Lee, Park, &amp; Kim, <xref ref-type="ref" rid="glia23136-bib-0148">2010</xref>). However, exogenous treatment of astrocytes with meteorin did not activate the same pathway (Lee et al., <xref ref-type="ref" rid="glia23136-bib-0149">2015</xref>). This might be due to the existence of more than one meteorin receptor, with different signaling mechanisms. Nevertheless, once identified, this receptor may become an interesting therapeutic target for neuroprotection.</p>
</sec>
<sec id="glia23136-sec-0021">
<label>3.10</label>
<title>Metabotropic octadecaneuropeptide (ODN) receptor</title>
<p>The CNS is sensitive to oxidative stress due to its high metabolic rate and high levels of unsaturated lipids. ODN is a peptide (QATVGDVNTDRPGLLDLK) generated through the proteolytic cleavage of the 86‐amino acid precursor protein “diazepam‐binding inhibitor” which is expressed by astrocytes (Burgi, Lichtensteiger, Lauber, &amp; Schlumpf, <xref ref-type="ref" rid="glia23136-bib-0031">1999</xref>; Malagon et al., <xref ref-type="ref" rid="glia23136-bib-0161">1993</xref>), although probably not completely exclusively (Alho, Harjuntausta, Schultz, Pelto‐Huikko, &amp; Bovolin, <xref ref-type="ref" rid="glia23136-bib-0006">1991</xref>). ODN is a potent protective agent that prevents oxidative stress‐induced apoptosis and attenuates H<sub>2</sub>O<sub>2</sub>‐evoked inhibition of SOD and catalase activities in astrocytes (Hamdi et al., <xref ref-type="ref" rid="glia23136-bib-0099">2011</xref>). It has been suggested that the anti‐apoptotic activity of ODN is mediated through a putative GPCR coupled to the adenylate cyclase/protein kinase A pathway (Hamdi et al., <xref ref-type="ref" rid="glia23136-bib-0097">2012</xref>). Downstream of protein kinase A, ODN induces ERK phosphorylation which, in turn, activates the expression of the anti‐apoptotic gene Bcl‐2 and blocks the stimulation by H<sub>2</sub>O<sub>2</sub> of the proapoptotic gene Bax. The effect of ODN on the Bax/Bcl‐2 balance could possibly explain its antagonism of the deleterious action of H<sub>2</sub>O<sub>2</sub> on mitochondrial membrane integrity and caspase‐3 activation (Hamdi et al., <xref ref-type="ref" rid="glia23136-bib-0097">2012</xref>, <xref ref-type="ref" rid="glia23136-bib-0098">2015</xref>). This anti‐apoptotic effect of ODN might be important in neurodegenerative diseases and stroke. If a dedicated GPCR for ODN exists, it could be yet another potential candidate for the development of small molecules agonists to be used for the treatment of ischemia and neurodegenerative diseases.</p>
</sec>
<sec id="glia23136-sec-0022">
<label>3.11</label>
<title>Serotonin 1A receptors on astrocytes as a potential route for treatment of PD</title>
<p>The 5‐HT1A receptor, one of 14 subtypes of metabotropic receptors for serotonin, is widely distributed in brain (Barnes and Sharp, <xref ref-type="ref" rid="glia23136-bib-0017">1999</xref>). As a key mediator of serotonergic signaling in the CNS, the 5‐HT1A receptor is involved in numerous effects of central serotonin, ranging from cognition and emotion control to neurite outgrowth and synapse formation (Filip and Bader, <xref ref-type="ref" rid="glia23136-bib-0072">2009</xref>; Ohno, <xref ref-type="ref" rid="glia23136-bib-0201">2011</xref>; Pucadyil, Kalipatnapu, &amp; Chattopadhyay, <xref ref-type="ref" rid="glia23136-bib-0218">2005</xref>).</p>
<p>Quite commonly, effects mediated through 5‐HT1A receptors are claimed to be mediated by neurons. However, since a very long time it has been known that astrocytes also express serotonin receptors and respond to serotonin with increases in [Ca<sup>2+</sup>]<sub>i</sub>. Several studies pointed at the therapeutic potential of astrocytic 5‐HT1A receptors. Stimulation of 5‐HT1A receptors on astrocytes promotes astrocyte proliferation and neuroprotection both <italic>in vitro</italic> and in PD model mice (Miyazaki et al., <xref ref-type="ref" rid="glia23136-bib-0187">2013</xref>). The 8‐OH‐DPAT [(R)‐(+)−8‐hydroxy‐2‐(di‐n‐propylamino)tetralin hydrobromide], a full 5‐HT1A agonist, enhances astrocyte proliferation in mouse striatum. The 8‐OH‐DPAT significantly up‐regulates astrocytic antioxidant pathways by increasing the expression of erythroid 2‐related factor 2 (Nrf2) (Miyazaki et al., <xref ref-type="ref" rid="glia23136-bib-0187">2013</xref>) which activates genes involved in anti‐oxidant defense (see below). Nrf2‐regulated genes are preferentially activated in astrocytes, boosting their detoxification and antioxidant functions (Vargas and Johnson, <xref ref-type="ref" rid="glia23136-bib-0285">2009</xref>). Activation of Nrf2 in astrocytes protects dopaminergic neurons from oxidative stress (Miyazaki et al., <xref ref-type="ref" rid="glia23136-bib-0186">2011</xref>; Wong et al., <xref ref-type="ref" rid="glia23136-bib-0303">2003</xref>). Protein S100ß is expressed in various cell types with the highest level in the cytoplasm of astrocytes (Selinfreund, Barger, Pledger, &amp; Vaneldik, <xref ref-type="ref" rid="glia23136-bib-0238">1991</xref>) which release it into the extracellular space. Extracellular S100β has autocrine effects and promotes astrocytic proliferation (Donato, <xref ref-type="ref" rid="glia23136-bib-0064">2003</xref>). Stimulation of 5‐HT1A receptors on astrocytes leads to secretion of S100β which seems to be protective at nanomolar concentrations although deleterious at micromolar concentrations. It is therefore conceivable that pharmacological modulation of 5‐HT1A receptors on astrocytes could be astro‐ and neuroprotective [for more detail see (Miyazaki and Asanuma, <xref ref-type="ref" rid="glia23136-bib-0185">2016</xref>)].</p>
</sec>
<sec id="glia23136-sec-0023">
<label>3.12</label>
<title>Targeting of astrocytic LDH enzymes to treat epilepsy</title>
<p>In addition to glucose, lactate is a major source of energy in the brain, and a significant amount of lactate is produced through glycolysis by astrocytes (Dienel, <xref ref-type="ref" rid="glia23136-bib-0062">2012</xref>; Gladden, <xref ref-type="ref" rid="glia23136-bib-0086">2004</xref>). LDH catalyzes the interconversion of pyruvate and lactate; some of which is transported from astrocytes to neurons via the so called “lactate shuttle” (Chih and Roberts Jr., <xref ref-type="ref" rid="glia23136-bib-0044">2003</xref>; Pellerin and Magistretti, <xref ref-type="ref" rid="glia23136-bib-0213">1994</xref>). In addition, lactate may have a signaling role in the brain (Tang et al., <xref ref-type="ref" rid="glia23136-bib-0265">2014</xref>), see also our recent review (Mosienko et al., <xref ref-type="ref" rid="glia23136-bib-0190">2015</xref>).</p>
<p>In epilepsy where activity of hyperexcitable neurons is uncontrollably synchronized, abundant energy for these activities has to be supplied (Bertram, Zhang, Mangan, Fountain, &amp; Rempe, <xref ref-type="ref" rid="glia23136-bib-0022">1998</xref>). Expectedly, high rates of glucose metabolism and elevated activity of LDH have been shown in human epilepsy and in animal models (Dufour, Koning, &amp; Nehlig, <xref ref-type="ref" rid="glia23136-bib-0067">2003</xref>). A recent study suggested that the effectiveness of a ketogenic diet against epilepsy is linked to bypassing glycolysis in astrocytes (Sada et al., <xref ref-type="ref" rid="glia23136-bib-0232">2015</xref>). It was found that that inhibition of LDH hyperpolarised neurons, reducing their excitability, and that this could be reversed by pyruvate, which supports the notion of it being a metabolic, rather than receptor mediated action. It turned out that stiripentol, which is sometimes used to treat epilepsy, is an LDH inhibitor. Moreover, an analog of stiripentol was found which proved to be effective <italic>in vivo</italic> in a rodent epilepsy model, thus potentially setting up a new class of anti‐epileptic therapies (Sada et al., <xref ref-type="ref" rid="glia23136-bib-0232">2015</xref>). Other findings also implicate lactate in epilepsy, for example, altered level and cellular distribution of monocarboxylate transporters (Perez et al., <xref ref-type="ref" rid="glia23136-bib-0215">2012</xref>).</p>
<p>In contrast, some studies suggested that lactate can be neuroprotective (Jourdain et al., <xref ref-type="ref" rid="glia23136-bib-0129">2016</xref>; Lee et al., <xref ref-type="ref" rid="glia23136-bib-0151">2012</xref>).Therefore, reduction of lactate production by LDH inhibitors is a double‐edged sword strategy since compromising neuroprotection is undesirable. This issue requires further exploration using new models and, perhaps, other species but mice.</p>
</sec>
<sec id="glia23136-sec-0024">
<label>3.13</label>
<title>Nrf2‐ARE pathway</title>
<p>Maintaining redox homeostasis in the brain is essential for survival. One critical pathway through which the cell regulates its antioxidant defense is the Nrf2‐antioxidant response element (ARE) (Johnson and Johnson, <xref ref-type="ref" rid="glia23136-bib-0125">2015</xref>) which is a cis‐acting regulatory element controlling expression of phase II detoxifying and antioxidant genes (Rushmore, Morton, &amp; Pickett, <xref ref-type="ref" rid="glia23136-bib-0230">1991</xref>; Rushmore and Pickett, <xref ref-type="ref" rid="glia23136-bib-0231">1990</xref>). Nrf2 is a cytoplasmic protein sequestered by actin‐bound protein Keap1 (Kelch ECH associating protein) (Itoh et al., <xref ref-type="ref" rid="glia23136-bib-0118">1999</xref>; Zipper and Mulcahy, <xref ref-type="ref" rid="glia23136-bib-0319">2002</xref>). Under normal unstressed conditions, Nrf2 is anchored to Keap1 and rapidly degraded (Itoh et al., <xref ref-type="ref" rid="glia23136-bib-0119">2003</xref>; McMahon, Itoh, Yamamoto, &amp; Hayes, <xref ref-type="ref" rid="glia23136-bib-0175">2003</xref>). This process seems to be much more powerful in neurons than in astrocytes (Jimenez‐Blasco, Santofimia‐Castano, Gonzalez, Almeida, &amp; Bolanos, <xref ref-type="ref" rid="glia23136-bib-0124">2015</xref>). Oxidative stress or exposure to electrophilic agents that react with Keap1 slow down Nrf2 degradation and lead to its nuclear accumulation. Nrf2 binding to the ARE drives expression of several detoxifying and antioxidant genes including SOD, GCL, GSH synthase, GSH peroxidase, GSH reductase and γ‐glutamine cysteine synthase, boosting anti‐oxidant defence (Kensler, Wakabayash, &amp; Biswal, <xref ref-type="ref" rid="glia23136-bib-0134">2007</xref>; Sykiotis and Bohmann, <xref ref-type="ref" rid="glia23136-bib-0257">2010</xref>). Hence, the Nrf2‐ARE pathway is considered a high‐value therapeutic target (de Vries et al., <xref ref-type="ref" rid="glia23136-bib-0058">2008</xref>; Johnson and Johnson, <xref ref-type="ref" rid="glia23136-bib-0125">2015</xref>; van Muiswinkel and Kuiperij, <xref ref-type="ref" rid="glia23136-bib-0281">2005</xref>). It is preferentially activated in astrocytes while neurons largely depend on astrocytes for the antioxidant defense (Kraft, Johnson, &amp; Johnson, <xref ref-type="ref" rid="glia23136-bib-0142">2004</xref>; Lee, Calkins, Chan, Kan, &amp; Johnson, <xref ref-type="ref" rid="glia23136-bib-0150">2003</xref>; Shih et al., <xref ref-type="ref" rid="glia23136-bib-0242">2003</xref>). Therefore, unsurprisingly, many studies report that activation of the Nrf2 pathway in astrocytes is neuroprotective (Calkins, Vargas, Johnson, &amp; Johnson, <xref ref-type="ref" rid="glia23136-bib-0035">2010</xref>; Chen et al., <xref ref-type="ref" rid="glia23136-bib-0042">2009</xref>; Gan, Vargas, Johnson, &amp; Johnson, <xref ref-type="ref" rid="glia23136-bib-0078">2012</xref>; Vargas, Johnson, Sirkis, Messing, &amp; Johnson, <xref ref-type="ref" rid="glia23136-bib-0284">2008</xref>). For example, astrocyte‐specific overexpression of Nrf2 protects dopaminergic neurons in MPTP‐injected Nrf2‐deficient parkinsonic mice (Chen et al., <xref ref-type="ref" rid="glia23136-bib-0042">2009</xref>). For further information see (Buendia et al., <xref ref-type="ref" rid="glia23136-bib-0030">2016</xref>; Joshi and Johnson, <xref ref-type="ref" rid="glia23136-bib-0128">2012</xref>).</p>
<p>Numerous cell‐based and <italic>in silico</italic> screens have identified Nrf2‐activating compounds (Schaap, Hancock, Wilderspin, &amp; Wells, <xref ref-type="ref" rid="glia23136-bib-0235">2013</xref>; Wang et al., <xref ref-type="ref" rid="glia23136-bib-0297">2013</xref>; Williamson et al., <xref ref-type="ref" rid="glia23136-bib-0301">2012</xref>; Wu, McDonald, Liu, Chaguturu, &amp; Klaassen, <xref ref-type="ref" rid="glia23136-bib-0304">2012</xref>), including triterpenoid 2‐cyano‐3,12‐dioxooleana‐1,9(11)‐dien‐28‐oate‐methylamide (CDDO‐MA), puerarin, sulforaphane, CDDO‐ethyl amide and others. Nrf2 activators demonstrated activity in <italic>in vitro</italic> and <italic>in vivo</italic> in different neurodegenerative mouse models, protecting neurons, decreasing the accumulation of aberrant proteins and increasing life span (Buendia et al., <xref ref-type="ref" rid="glia23136-bib-0030">2016</xref>; Joshi and Johnson <xref ref-type="ref" rid="glia23136-bib-0128">2012</xref>). The existing data are strongest for PD, ALS, and multiple sclerosis models, but the therapeutic potential of this pathway in AD and HD is under investigation. In conclusion, the Nrf2–ARE pathway is definitely a promising target in neurodegenerative diseases with several classes of small molecules already demonstrated to act as its inducers.</p>
</sec>
</sec>
<sec id="glia23136-sec-0025">
<label>4</label>
<title>CONCLUDING REMARKS</title>
<p>The mechanisms and pathologies mentioned in this review by no means exhaust the list of known astroglial neuroprotective or therapeutic mechanisms. For example, astrocytes could be an important target for antidepressants which block re‐uptake of noradrenaline (Hertz, Chen, Gibbs, Zang, &amp; Peng, <xref ref-type="ref" rid="glia23136-bib-0107">2004</xref>) and there is evidence that statins can reduce release of APOE from astrocytes (Naidu, Xu, Catalano, &amp; Cordell, <xref ref-type="ref" rid="glia23136-bib-0192">2002</xref>). Only about 30 years ago, the very thought that a centrally acting drug may target an astrocytic receptor seemed implausible. For instance, monoamine oxidase B (MAO‐B) which is a target for the antidepressant deprenil and is localized almost exclusively in astrocytes (Riederer et al., <xref ref-type="ref" rid="glia23136-bib-0221">1987</xref>), has recently attracted attention because it can be used as an activator for pro‐drugs that, after the reaction with MAO‐B, become cytotoxic for glioma cells, which typically upregulate MAO‐B (Sharpe and Baskin, <xref ref-type="ref" rid="glia23136-bib-0241">2016</xref>). Irrespective of glioma treatment, MAO‐B potentially could be used for local activation of other astroglia‐targeted molecules.</p>
<p>To sum up, the neurocentric view of brain function and disease has been challenged by extensive data supporting the physiopathological and therapeutic potential of astroglia. A solid body of evidence now indicates that harnessing the natural capacity of astrocytes to protect neurons is a promising clinical strategy. Modulation and protection of astrocytes could in some cases become a more effective therapeutic approach than the attempts to directly modify neuronal function or to directly protect neurons from various insults or degeneration.</p>
</sec>
</body>
<back>
<ack id="glia23136-sec-0026">
<title>ACKNOWLEDGMENT</title>
<p>The authors are supported by MRC grant MR/L020661/1 and BBSRC grant BB/L019396/1.</p>
</ack>
<ref-list content-type="cited-references">
<title>REFERENCES</title>
<ref id="glia23136-bib-0001">
<mixed-citation id="glia23136-cit-0002" publication-type="journal">
<string-name>
<surname>Abudara</surname>, <given-names>V.</given-names>
</string-name>, 
<string-name>
<surname>Bechberger</surname>, <given-names>J.</given-names>
</string-name>, 
<string-name>
<surname>Freitas‐Andrade</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>De Bock</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Wang</surname>, <given-names>N.</given-names>
</string-name>, 
<string-name>
<surname>Bultynck</surname>, <given-names>G.</given-names>
</string-name>, … 
<string-name>
<surname>Giaume</surname>
<given-names>C.</given-names>
</string-name> (<year>2014</year>). <article-title>The connexin43 mimetic peptide Gap19 inhibits hemichannels without altering gap junctional communication in astrocytes</article-title>. <source/>Frontiers in Cellular Neuroscience
<volume>8</volume>, <fpage>306</fpage>.
<pub-id pub-id-type="pmid">25374505</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0002">
<mixed-citation id="glia23136-cit-0003" publication-type="journal">
<string-name>
<surname>Acharjee</surname>, <given-names>S.</given-names>
</string-name>, 
<string-name>
<surname>Zhu</surname>, <given-names>Y.</given-names>
</string-name>, 
<string-name>
<surname>Maingat</surname>, <given-names>F.</given-names>
</string-name>, 
<string-name>
<surname>Pardo</surname>, <given-names>C.</given-names>
</string-name>, 
<string-name>
<surname>Ballanyi</surname>, <given-names>K.</given-names>
</string-name>, 
<string-name>
<surname>Hollenberg</surname>, <given-names>M. D.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Power</surname>, <given-names>C.</given-names>
</string-name> (<year>2011</year>). <article-title>Proteinase‐activated receptor‐1 mediates dorsal root ganglion neuronal degeneration in HIV/AIDS</article-title>. <source/>Brain
<volume>134</volume>, <fpage>3209</fpage>–<lpage>3221</lpage>.
<pub-id pub-id-type="pmid">22021895</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0003">
<mixed-citation id="glia23136-cit-0004" publication-type="journal">
<string-name>
<surname>Adams</surname>, <given-names>J. D.</given-names>
</string-name>, 
<string-name>
<surname>Chang</surname>, <given-names>M. L.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Klaidman</surname>, <given-names>L.</given-names>
</string-name> (<year>2001</year>). <article-title>Parkinson's disease—Redox mechanisms</article-title>. <source/>Current Medicinal Chemistry, <volume>8</volume>, <fpage>809</fpage>–<lpage>814</lpage>.
<pub-id pub-id-type="pmid">11375751</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0004">
<mixed-citation id="glia23136-cit-0005" publication-type="journal">
<string-name>
<surname>Alam</surname>, <given-names>Z. I.</given-names>
</string-name>, 
<string-name>
<surname>Jenner</surname>, <given-names>A.</given-names>
</string-name>, 
<string-name>
<surname>Daniel</surname>, <given-names>S. E.</given-names>
</string-name>, 
<string-name>
<surname>Lees</surname>, <given-names>A. J.</given-names>
</string-name>, 
<string-name>
<surname>Cairns</surname>, <given-names>N.</given-names>
</string-name>, 
<string-name>
<surname>Marsden</surname>, <given-names>C. D.</given-names>
</string-name>, … 
<string-name>
<surname>Halliwell</surname>, <given-names>B.</given-names>
</string-name> (<year>1997</year>). <article-title>Oxidative DNA damage in the parkinsonian brain: An apparent selective increase in 8‐hydroxyguanine levels in substantia nigra</article-title>. <source/>Journal of Neurochemistry, <volume>69</volume>, <fpage>1196</fpage>–<lpage>1203</lpage>.
<pub-id pub-id-type="pmid">9282943</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0005">
<mixed-citation id="glia23136-cit-0006" publication-type="journal">
<string-name>
<surname>Albasanz</surname>, <given-names>J. L.</given-names>
</string-name>, 
<string-name>
<surname>Perez</surname>, <given-names>S.</given-names>
</string-name>, 
<string-name>
<surname>Barrachina</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Ferrer</surname>, <given-names>I.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Martin</surname>, <given-names>M.</given-names>
</string-name> (<year>2008</year>). <article-title>Up‐regulation of adenosine receptors in the frontal cortex in Alzheimer's disease</article-title>. <source/>Brain Pathology, <volume>18</volume>, <fpage>211</fpage>–<lpage>219</lpage>.
<pub-id pub-id-type="pmid">18241242</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0006">
<mixed-citation id="glia23136-cit-0007" publication-type="journal">
<string-name>
<surname>Alho</surname>, <given-names>H.</given-names>
</string-name>, 
<string-name>
<surname>Harjuntausta</surname>, <given-names>T.</given-names>
</string-name>, 
<string-name>
<surname>Schultz</surname>, <given-names>R.</given-names>
</string-name>, 
<string-name>
<surname>Pelto‐Huikko</surname>, <given-names>M.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Bovolin</surname>, <given-names>P.</given-names>
</string-name> (<year>1991</year>). <article-title>Immunohistochemistry of diazepam binding inhibitor (DBI) in the central nervous system and peripheral organs: Its possible role as an endogenous regulator of different types of benzodiazepine receptors</article-title>. <source/>Neuropharmacology, <volume>30</volume>, <fpage>1381</fpage>–<lpage>1386</lpage>.
<pub-id pub-id-type="pmid">1664066</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0007">
<mixed-citation id="glia23136-cit-0008" publication-type="journal">
<string-name>
<surname>Allaman</surname>, <given-names>I.</given-names>
</string-name>, 
<string-name>
<surname>Belanger</surname>, <given-names>M.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Magistretti</surname>, <given-names>P. J.</given-names>
</string-name> (<year>2011</year>). <article-title>Astrocyte‐neuron metabolic relationships: For better and for worse</article-title>. <source/>Trends in Neuroscience, <volume>34</volume>, <fpage>76</fpage>–<lpage>87</lpage>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0008">
<mixed-citation id="glia23136-cit-0009" publication-type="journal">
<string-name>
<surname>Alvestad</surname>, <given-names>S.</given-names>
</string-name>, 
<string-name>
<surname>Hammer</surname>, <given-names>J.</given-names>
</string-name>, 
<string-name>
<surname>Qu</surname>, <given-names>H.</given-names>
</string-name>, 
<string-name>
<surname>Haberg</surname>, <given-names>A.</given-names>
</string-name>, 
<string-name>
<surname>Ottersen</surname>, <given-names>O. P.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Sonnewald</surname>, <given-names>U.</given-names>
</string-name> (<year>2011</year>). <article-title>Reduced astrocytic contribution to the turnover of glutamate, glutamine, and GABA characterizes the latent phase in the kainate model of temporal lobe epilepsy</article-title>. <source/>Journal of Cerebral Blood Flow Metabolism, <volume>31</volume>, <fpage>1675</fpage>–<lpage>1686</lpage>.
<pub-id pub-id-type="pmid">21522161</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0009">
<mixed-citation id="glia23136-cit-0010" publication-type="journal">
<string-name>
<surname>Amiry‐Moghaddam</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Williamson</surname>, <given-names>A.</given-names>
</string-name>, 
<string-name>
<surname>Palomba</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Eid</surname>, <given-names>T.</given-names>
</string-name>, 
<string-name>
<surname>de Lanerolle</surname>, <given-names>N. C.</given-names>
</string-name>, 
<string-name>
<surname>Nagelhus</surname>, <given-names>E. A.</given-names>
</string-name>, … 
<string-name>
<surname>Ottersen</surname>, <given-names>O. P.</given-names>
</string-name> (<year>2003</year>). <article-title>Delayed K+ clearance associated with aquaporin‐4 mislocalization: Phenotypic defects in brains of alpha‐syntrophin‐null mice</article-title>. <source/>Proceedings of the National Academy of Science of United States of America, <volume>100</volume>, <fpage>13615</fpage>–<lpage>13620</lpage>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0010">
<mixed-citation id="glia23136-cit-0011" publication-type="journal">
<string-name>
<surname>Anderson</surname>, <given-names>M. E.</given-names>
</string-name>, 
<string-name>
<surname>Underwood</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Bridges</surname>, <given-names>R. J.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Meister</surname>, <given-names>A.</given-names>
</string-name> (<year>1989</year>). <article-title>Glutathione metabolism at the blood‐cerebrospinal fluid barrier</article-title>. <source/>FASEB Journal, <volume>3</volume>, <fpage>2527</fpage>–<lpage>2531</lpage>.
<pub-id pub-id-type="pmid">2572501</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0011">
<mixed-citation id="glia23136-cit-0012" publication-type="journal">
<string-name>
<surname>Andrade‐Gordon</surname>, <given-names>P.</given-names>
</string-name>, 
<string-name>
<surname>Maryanoff</surname>, <given-names>B. E.</given-names>
</string-name>, 
<string-name>
<surname>Derian</surname>, <given-names>C. K.</given-names>
</string-name>, 
<string-name>
<surname>Zhang</surname>, <given-names>H. C.</given-names>
</string-name>, 
<string-name>
<surname>Addo</surname>, <given-names>M. F.</given-names>
</string-name>, 
<string-name>
<surname>Darrow</surname>, <given-names>A. L.</given-names>
</string-name>, … 
<string-name>
<surname>White</surname>, <given-names>K.B.</given-names>
</string-name> (<year>1999</year>). <article-title>Design, synthesis, and biological characterization of a peptide‐mimetic antagonist for a tethered‐ligand receptor</article-title>. <source/>Proceedings of the National Academy of Science of United States of America, <volume>96</volume>, <fpage>12257</fpage>–<lpage>12262</lpage>. 
</mixed-citation>
</ref>
<ref id="glia23136-bib-0012">
<mixed-citation id="glia23136-cit-0013" publication-type="journal">
<string-name>
<surname>Arendash</surname>, <given-names>G. W.</given-names>
</string-name> &amp; 
<string-name>
<surname>Cao</surname>, <given-names>C.</given-names>
</string-name> (<year>2010</year>). <article-title>Caffeine and coffee as therapeutics against Alzheimer's disease</article-title>. <source/>Journal of Alzheimers Disease, <volume>20 (Suppl 1)</volume>, <fpage>S117</fpage>–S<lpage>126</lpage>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0013">
<mixed-citation id="glia23136-cit-0014" publication-type="journal">
<string-name>
<surname>Arzberger</surname>, <given-names>T.</given-names>
</string-name>, 
<string-name>
<surname>Krampfl</surname>, <given-names>K.</given-names>
</string-name>, 
<string-name>
<surname>Leimgruber</surname>, <given-names>S.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Weindl</surname>, <given-names>A.</given-names>
</string-name> (<year>1997</year>). <article-title>Changes of NMDA receptor subunit (NR1, NR2B) and glutamate transporter (GLT1) mRNA expression in Huntington's disease—An in situ hybridization study</article-title>. <source/>Journal of Neuropathology &amp; Experimental Neurology, <volume>56</volume>, <fpage>440</fpage>–<lpage>454</lpage>.
<pub-id pub-id-type="pmid">9100675</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0014">
<mixed-citation id="glia23136-cit-0015" publication-type="journal">
<string-name>
<surname>Asanuma</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Miyazaki</surname>, <given-names>I.</given-names>
</string-name>, 
<string-name>
<surname>Diaz‐Corrales</surname>, <given-names>F. J.</given-names>
</string-name>, 
<string-name>
<surname>Kimoto</surname>, <given-names>N.</given-names>
</string-name>, 
<string-name>
<surname>Kikkawa</surname>, <given-names>Y.</given-names>
</string-name>, 
<string-name>
<surname>Takeshima</surname>, <given-names>M.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Murata</surname>, <given-names>M.</given-names>
</string-name> (<year>2010</year>). <article-title>Neuroprotective effects of zonisamide target astrocyte</article-title>. <source/>Annals of Neurology, <volume>67</volume>, <fpage>239</fpage>–<lpage>249</lpage>.
<pub-id pub-id-type="pmid">20225289</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0015">
<mixed-citation id="glia23136-cit-0016" publication-type="journal">
<string-name>
<surname>Aschner</surname>, <given-names>M.</given-names>
</string-name> (<year>1997</year>). <article-title>Astrocyte metallothioneins (MTs) and their neuroprotective role</article-title>. <source/>Annals of New York Academy of Science, <volume>825</volume>, <fpage>334</fpage>–<lpage>347</lpage>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0016">
<mixed-citation id="glia23136-cit-0017" publication-type="journal">
<string-name>
<surname>Badaut</surname>, <given-names>J.</given-names>
</string-name>, 
<string-name>
<surname>Lasbennes</surname>, <given-names>F.</given-names>
</string-name>, 
<string-name>
<surname>Magistretti</surname>, <given-names>P. J.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Regli</surname>, <given-names>L.</given-names>
</string-name> (<year>2002</year>). <article-title>Aquaporins in brain: Distribution, physiology, and pathophysiology</article-title>. <source/>Journal of Cerebral Blood Flow Metabolism, <volume>22</volume>, <fpage>367</fpage>–<lpage>378</lpage>.
<pub-id pub-id-type="pmid">11919508</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0017">
<mixed-citation id="glia23136-cit-0018" publication-type="journal">
<string-name>
<surname>Barnes</surname>, <given-names>N. M.</given-names>
</string-name> &amp; 
<string-name>
<surname>Sharp</surname>, <given-names>T.</given-names>
</string-name> (<year>1999</year>). <article-title>A review of central 5‐HT receptors and their function</article-title>. <source/>Neuropharmacology, <volume>38</volume>, <fpage>1083</fpage>–<lpage>1152</lpage>.
<pub-id pub-id-type="pmid">10462127</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0018">
<mixed-citation id="glia23136-cit-0019" publication-type="journal">
<string-name>
<surname>Bedner</surname>, <given-names>P.</given-names>
</string-name> &amp; 
<string-name>
<surname>Steinhauser</surname>, <given-names>C.</given-names>
</string-name> (<year>2013</year>). <article-title>Altered Kir and gap junction channels in temporal lobe epilepsy</article-title>. <source/>Neurochemistry International, <volume>63</volume>, <fpage>682</fpage>–<lpage>687</lpage>.
<pub-id pub-id-type="pmid">23357483</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0019">
<mixed-citation id="glia23136-cit-0020" publication-type="journal">
<string-name>
<surname>Ben Haim</surname>, <given-names>L.</given-names>
</string-name>, 
<string-name>
<surname>Ceyzeriat</surname>, <given-names>K.</given-names>
</string-name>, 
<string-name>
<surname>Carrillo‐de Sauvage</surname>, <given-names>M. A.</given-names>
</string-name>, 
<string-name>
<surname>Aubry</surname>, <given-names>F.</given-names>
</string-name>, 
<string-name>
<surname>Auregan</surname>, <given-names>G.</given-names>
</string-name>, 
<string-name>
<surname>Guillermier</surname>, <given-names>M.</given-names>
</string-name>, … 
<string-name>
<surname>Escartin</surname>, <given-names>C.</given-names>
</string-name> (<year>2015</year>). <article-title>The JAK/STAT3 pathway is a common inducer of astrocyte reactivity in Alzheimer's and Huntington's diseases</article-title>. <source/>Journal of Neuroscience, <volume>35</volume>, <fpage>2817</fpage>–<lpage>2829</lpage>.
<pub-id pub-id-type="pmid">25673868</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0020">
<mixed-citation id="glia23136-cit-0021" publication-type="journal">
<string-name>
<surname>Beppu</surname>, <given-names>K.</given-names>
</string-name>, 
<string-name>
<surname>Sasaki</surname>, <given-names>T.</given-names>
</string-name>, 
<string-name>
<surname>Tanaka</surname>, <given-names>K. F.</given-names>
</string-name>, 
<string-name>
<surname>Yamanaka</surname>, <given-names>A.</given-names>
</string-name>, 
<string-name>
<surname>Fukazawa</surname>, <given-names>Y.</given-names>
</string-name>, 
<string-name>
<surname>Shigemoto</surname>, <given-names>R.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Matsui</surname>, <given-names>K.</given-names>
</string-name> (<year>2014</year>). <article-title>Optogenetic countering of glial acidosis suppresses glial glutamate release and ischemic brain damage</article-title>. <source/>Neuron, <volume>81</volume>, <fpage>314</fpage>–<lpage>320</lpage>.
<pub-id pub-id-type="pmid">24462096</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0021">
<mixed-citation id="glia23136-cit-0022" publication-type="journal">
<string-name>
<surname>Berry</surname>, <given-names>J. D.</given-names>
</string-name>, 
<string-name>
<surname>Shefner</surname>, <given-names>J. M.</given-names>
</string-name>, 
<string-name>
<surname>Conwit</surname>, <given-names>R.</given-names>
</string-name>, 
<string-name>
<surname>Schoenfeld</surname>, <given-names>D.</given-names>
</string-name>, 
<string-name>
<surname>Keroack</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Felsenstein</surname>, <given-names>D.</given-names>
</string-name>, … 
<string-name>
<surname>Cudkowicz</surname>, <given-names>M. E.</given-names>
</string-name>
<year>2013</year>
<article-title>Design and initial results of a multi‐phase randomized trial of ceftriaxone in amyotrophic lateral sclerosis</article-title>. <source/>PLoS One, <volume>8</volume>, <fpage>e61177</fpage>.
<pub-id pub-id-type="pmid">23613806</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0022">
<mixed-citation id="glia23136-cit-0023" publication-type="journal">
<string-name>
<surname>Bertram</surname>, <given-names>E. H.</given-names>
</string-name>, 
<string-name>
<surname>Zhang</surname>, <given-names>D. X.</given-names>
</string-name>, 
<string-name>
<surname>Mangan</surname>, <given-names>P.</given-names>
</string-name>, 
<string-name>
<surname>Fountain</surname>, <given-names>N.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Rempe</surname>, <given-names>D.</given-names>
</string-name> (<year>1998</year>). <article-title>Functional anatomy of limbic epilepsy: A proposal for central synchronization of a diffusely hyperexcitable network</article-title>. <source/>Epilepsy Research, <volume>32</volume>, <fpage>194</fpage>–<lpage>205</lpage>.
<pub-id pub-id-type="pmid">9761320</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0023">
<mixed-citation id="glia23136-cit-0024" publication-type="journal">
<string-name>
<surname>Bhandari</surname>, <given-names>B.</given-names>
</string-name> &amp; 
<string-name>
<surname>Mehta</surname>, <given-names>B.</given-names>
</string-name> (<year>2014</year>). <article-title>Vorapaxar, a protease‐activated receptor‐1 antagonist, a double‐edged sword!</article-title>. <source/>Recent Advances in Cardiovascular Drug Discovery, <volume>9</volume>, <fpage>73</fpage>–<lpage>77</lpage>.
<pub-id pub-id-type="pmid">26104312</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0024">
<mixed-citation id="glia23136-cit-0025" publication-type="journal">
<string-name>
<surname>Bharath</surname>, <given-names>S.</given-names>
</string-name>, 
<string-name>
<surname>Hsu</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Kaur</surname>, <given-names>D.</given-names>
</string-name>, 
<string-name>
<surname>Rajagopalan</surname>, <given-names>S.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Andersen</surname>, <given-names>J. K.</given-names>
</string-name> (<year>2002</year>). <article-title>Glutathione, iron and Parkinson's disease</article-title>. <source/>Biochemical Pharmacology, <volume>64</volume>, <fpage>1037</fpage>–<lpage>1048</lpage>.
<pub-id pub-id-type="pmid">12213603</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0025">
<mixed-citation id="glia23136-cit-0026" publication-type="journal">
<string-name>
<surname>Binder</surname>, <given-names>D. K.</given-names>
</string-name>, 
<string-name>
<surname>Yao</surname>, <given-names>X.</given-names>
</string-name>, 
<string-name>
<surname>Zador</surname>, <given-names>Z.</given-names>
</string-name>, 
<string-name>
<surname>Sick</surname>, <given-names>T. J.</given-names>
</string-name>, 
<string-name>
<surname>Verkman</surname>, <given-names>A. S.</given-names>
</string-name>, 
<string-name>
<surname>Manley</surname>, <given-names>G. T.</given-names>
</string-name> (<year>2006</year>). <article-title>Increased seizure duration and slowed potassium kinetics in mice lacking aquaporin‐4 water channels</article-title>. <source/>Glia, <volume>53</volume>, <fpage>631</fpage>–<lpage>636</lpage>.
<pub-id pub-id-type="pmid">16470808</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0026">
<mixed-citation id="glia23136-cit-0027" publication-type="journal">
<string-name>
<surname>Bolognin</surname>, <given-names>S.</given-names>
</string-name>, 
<string-name>
<surname>Cozzi</surname>, <given-names>B.</given-names>
</string-name>, 
<string-name>
<surname>Zambenedetti</surname>, <given-names>P.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Zatta</surname>, <given-names>P.</given-names>
</string-name> (<year>2014</year>). <article-title>Metallothioneins and the central nervous system: From a deregulation in neurodegenerative diseases to the development of new therapeutic approaches</article-title>. <source/>Journal of Alzheimers Disease, <volume>41</volume>, <fpage>29</fpage>–<lpage>42</lpage>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0027">
<mixed-citation id="glia23136-cit-0028" publication-type="journal">
<string-name>
<surname>Borota</surname>, <given-names>D.</given-names>
</string-name>, 
<string-name>
<surname>Murray</surname>, <given-names>E.</given-names>
</string-name>, 
<string-name>
<surname>Keceli</surname>, <given-names>G.</given-names>
</string-name>, 
<string-name>
<surname>Chang</surname>, <given-names>A.</given-names>
</string-name>, 
<string-name>
<surname>Watabe</surname>, <given-names>J. M.</given-names>
</string-name>, 
<string-name>
<surname>Ly</surname>, <given-names>M.</given-names>
</string-name>, … 
<string-name>
<surname>Yassa</surname>, <given-names>M. A.</given-names>
</string-name> (<year>2014</year>). <article-title>Post‐study caffeine administration enhances memory consolidation in humans</article-title>. <source/>Nature Neuroscience, <volume>17</volume>, <fpage>201</fpage>–<lpage>203</lpage>.
<pub-id pub-id-type="pmid">24413697</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0028">
<mixed-citation id="glia23136-cit-0029" publication-type="journal">
<string-name>
<surname>Boven</surname>, <given-names>L. A.</given-names>
</string-name>, 
<string-name>
<surname>Vergnolle</surname>, <given-names>N.</given-names>
</string-name>, 
<string-name>
<surname>Henry</surname>, <given-names>S. D.</given-names>
</string-name>, 
<string-name>
<surname>Silva</surname>, <given-names>C.</given-names>
</string-name>, 
<string-name>
<surname>Imai</surname>, <given-names>Y.</given-names>
</string-name>, 
<string-name>
<surname>Holden</surname>, <given-names>J.</given-names>
</string-name>, … 
<string-name>
<surname>Power</surname>, <given-names>C.</given-names>
</string-name> (<year>2003</year>). <article-title>Up‐regulation of proteinase‐activated receptor 1 expression in astrocytes during HIV encephalitis</article-title>. <source/>Journal of Immunology, <volume>170</volume>, <fpage>2638</fpage>–<lpage>2646</lpage>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0029">
<mixed-citation id="glia23136-cit-0030" publication-type="book">
<string-name>
<surname>Brenner</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Goldman</surname>, <given-names>J. E.</given-names>
</string-name>, 
<string-name>
<surname>Quinlan</surname>, <given-names>R. A.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Messing</surname>, <given-names>A.</given-names>
</string-name> (<year>2009</year>). <chapter-title>Alexander disease: A genetic disorder of astrocytes</chapter-title> In <person-group person-group-type="editor"><name><surname>Parpura</surname><given-names>V. H. P.</given-names></name></person-group>, (Ed.), <source/>Astrocytes in (patho)physiology of the nervous system (pp <fpage>591</fpage>–<lpage>648</lpage>). <publisher-loc>New York</publisher-loc>: <publisher-name>Springer</publisher-name>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0030">
<mixed-citation id="glia23136-cit-0031" publication-type="journal">
<string-name>
<surname>Buendia</surname>, <given-names>I.</given-names>
</string-name>, 
<string-name>
<surname>Michalska</surname>, <given-names>P.</given-names>
</string-name>, 
<string-name>
<surname>Navarro</surname>, <given-names>E.</given-names>
</string-name>, 
<string-name>
<surname>Gameiro</surname>, <given-names>I.</given-names>
</string-name>, 
<string-name>
<surname>Egea</surname>, <given-names>J.</given-names>
</string-name>, &amp; 
<string-name>
<surname>León</surname>
<given-names>R.</given-names>
</string-name> (<year>2016</year>). <article-title>Nrf2–ARE pathway: An emerging target against oxidative stress and neuroinflammation in neurodegenerative diseases</article-title>. <source/>Pharmacology &amp; Therapeutics, <volume>157</volume>, <fpage>84</fpage>–<lpage>104</lpage>.
<pub-id pub-id-type="pmid">26617217</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0031">
<mixed-citation id="glia23136-cit-0032" publication-type="journal">
<string-name>
<surname>Burgi</surname>, <given-names>B.</given-names>
</string-name>, 
<string-name>
<surname>Lichtensteiger</surname>, <given-names>W.</given-names>
</string-name>, 
<string-name>
<surname>Lauber</surname>, <given-names>M. E.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Schlumpf</surname>, <given-names>M.</given-names>
</string-name> (<year>1999</year>). <article-title>Ontogeny of diazepam binding inhibitor/acyl‐CoA binding protein mRNA and peripheral benzodiazepine receptor mRNA expression in the rat</article-title>. <source/>Journal of Neuroendocrinology, <volume>11</volume>, <fpage>85</fpage>–<lpage>100</lpage>.
<pub-id pub-id-type="pmid">10048463</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0032">
<mixed-citation id="glia23136-cit-0033" publication-type="journal">
<string-name>
<surname>Burnstock</surname>, <given-names>G.</given-names>
</string-name> (<year>2007</year>). <article-title>Physiology and pathophysiology of purinergic neurotransmission</article-title>. <source/>Physiological Reviews, <volume>87</volume>, <fpage>659</fpage>–<lpage>797</lpage>.
<pub-id pub-id-type="pmid">17429044</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0033">
<mixed-citation id="glia23136-cit-0034" publication-type="journal">
<string-name>
<surname>Cabezas</surname>, <given-names>R.</given-names>
</string-name>, 
<string-name>
<surname>Avila</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Gonzalez</surname>, <given-names>J.</given-names>
</string-name>, 
<string-name>
<surname>El‐Bacha</surname>, <given-names>R. S.</given-names>
</string-name>, 
<string-name>
<surname>Baez</surname>, <given-names>E.</given-names>
</string-name>, 
<string-name>
<surname>Garcia‐Segura</surname>, <given-names>L. M.</given-names>
</string-name>, … 
<string-name>
<surname>Barreto</surname>, <given-names>G. E.</given-names>
</string-name> (<year>2014</year>). <article-title>Astrocytic modulation of blood brain barrier: Perspectives on Parkinson's disease</article-title>. <source/>Frontiers in Cellular Neuroscience, <volume>8</volume>, <fpage>211</fpage>.
<pub-id pub-id-type="pmid">25136294</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0034">
<mixed-citation id="glia23136-cit-0035" publication-type="journal">
<string-name>
<surname>Cahoy</surname>, <given-names>J. D.</given-names>
</string-name>, 
<string-name>
<surname>Emery</surname>, <given-names>B.</given-names>
</string-name>, 
<string-name>
<surname>Kaushal</surname>, <given-names>A.</given-names>
</string-name>, 
<string-name>
<surname>Foo</surname>, <given-names>L. C.</given-names>
</string-name>, 
<string-name>
<surname>Zamanian</surname>, <given-names>J. L.</given-names>
</string-name>, 
<string-name>
<surname>Christopherson</surname>, <given-names>K. S.</given-names>
</string-name>, … 
<string-name>
<surname>Barres</surname>, <given-names>B. A.</given-names>
</string-name> (<year>2008</year>). <article-title>A transcriptome database for astrocytes, neurons, and oligodendrocytes: A new resource for understanding brain development and function</article-title>. <source/>Journal of Neuroscience, <volume>28</volume>, <fpage>264</fpage>–<lpage>278</lpage>.
<pub-id pub-id-type="pmid">18171944</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0035">
<mixed-citation id="glia23136-cit-0036" publication-type="journal">
<string-name>
<surname>Calkins</surname>, <given-names>M. J.</given-names>
</string-name>, 
<string-name>
<surname>Vargas</surname>, <given-names>M. R.</given-names>
</string-name>, 
<string-name>
<surname>Johnson</surname>, <given-names>D. A.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Johnson</surname>, <given-names>J. A.</given-names>
</string-name> (<year>2010</year>). <article-title>Astrocyte‐specific overexpression of Nrf2 protects striatal neurons from mitochondrial complex II Inhibition</article-title>. <source/>Toxicological Science, <volume>115</volume>, <fpage>557</fpage>–<lpage>568</lpage>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0036">
<mixed-citation id="glia23136-cit-0037" publication-type="journal">
<string-name>
<surname>Campbell</surname>, <given-names>S. L.</given-names>
</string-name> &amp; 
<string-name>
<surname>Hablitz</surname>, <given-names>J. J.</given-names>
</string-name> (<year>2004</year>). <article-title>Glutamate transporters regulate excitability in local networks in rat neocortex</article-title>. <source/>Neuroscience, <volume>127</volume>, <fpage>625</fpage>–<lpage>635</lpage>.
<pub-id pub-id-type="pmid">15283962</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0037">
<mixed-citation id="glia23136-cit-0038" publication-type="journal">
<string-name>
<surname>Canevari</surname>, <given-names>L.</given-names>
</string-name>, 
<string-name>
<surname>Abramov</surname>, <given-names>A. Y.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Duchen</surname>, <given-names>M. R.</given-names>
</string-name> (<year>2004</year>). <article-title>Toxicity of amyloid beta peptide: Tales of calcium, mitochondria, and oxidative stress</article-title>. <source/>Neurochemistry Research, <volume>29</volume>, <fpage>637</fpage>–<lpage>650</lpage>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0038">
<mixed-citation id="glia23136-cit-0039" publication-type="journal">
<string-name>
<surname>Cannon</surname>, <given-names>J. R.</given-names>
</string-name>, 
<string-name>
<surname>Keep</surname>, <given-names>R. F.</given-names>
</string-name>, 
<string-name>
<surname>Schallert</surname>, <given-names>T.</given-names>
</string-name>, 
<string-name>
<surname>Hua</surname>, <given-names>Y.</given-names>
</string-name>, 
<string-name>
<surname>Richardson</surname>, <given-names>R. J.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Xi</surname>, <given-names>G.</given-names>
</string-name> (<year>2006</year>). <article-title>Protease‐activated receptor‐1 mediates protection elicited by thrombin preconditioning in a rat 6‐hydroxydopamine model of Parkinson's disease</article-title>. <source/>Brain Research, <volume>1116</volume>, <fpage>177</fpage>–<lpage>186</lpage>.
<pub-id pub-id-type="pmid">16934779</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0039">
<mixed-citation id="glia23136-cit-0040" publication-type="journal">
<string-name>
<surname>Carman</surname>, <given-names>A. J.</given-names>
</string-name>, 
<string-name>
<surname>Dacks</surname>, <given-names>P. A.</given-names>
</string-name>, 
<string-name>
<surname>Lane</surname>, <given-names>R. F.</given-names>
</string-name>, 
<string-name>
<surname>Shineman</surname>, <given-names>D. W.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Fillit</surname>, <given-names>H. M.</given-names>
</string-name> (<year>2014</year>). <article-title>Current evidence for the use of coffee and caffeine to prevent age‐related cognitive decline and Alzheimer's disease</article-title>. <italic>The</italic>
<source/>Journal of Nutrition, Health &amp; Aging, <volume>18</volume>, <fpage>383</fpage>–<lpage>392</lpage>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0040">
<mixed-citation id="glia23136-cit-0041" publication-type="journal">
<string-name>
<surname>Chaytor</surname>, <given-names>A. T.</given-names>
</string-name>, 
<string-name>
<surname>Evans</surname>, <given-names>W. H.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Griffith</surname>, <given-names>T. M.</given-names>
</string-name> (<year>1997</year>). <article-title>Peptides homologous to extracellular loop motifs of connexin 43 reversibly abolish rhythmic contractile activity in rabbit arteries</article-title>. <source/>Journal of Physiology, <volume>503 (Part 1)</volume>, <fpage>99</fpage>–<lpage>110</lpage>.
<pub-id pub-id-type="pmid">9288678</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0041">
<mixed-citation id="glia23136-cit-0042" publication-type="journal">
<string-name>
<surname>Chen</surname>, <given-names>J. F.</given-names>
</string-name>, 
<string-name>
<surname>Sonsalla</surname>, <given-names>P. K.</given-names>
</string-name>, 
<string-name>
<surname>Pedata</surname>, <given-names>F.</given-names>
</string-name>, 
<string-name>
<surname>Melani</surname>, <given-names>A.</given-names>
</string-name>, 
<string-name>
<surname>Domenici</surname>, <given-names>M. R.</given-names>
</string-name>, 
<string-name>
<surname>Popoli</surname>, <given-names>P.</given-names>
</string-name>, … 
<string-name>
<surname>de Mendonca</surname>
<given-names>A.</given-names>
</string-name> (<year>2007</year>). <article-title>Adenosine A2A receptors and brain injury: broad spectrum of neuroprotection, multifaceted actions and “fine tuning” modulation</article-title>. <source/>Progress in Neurobiology, <volume>83</volume>, <fpage>310</fpage>–<lpage>331</lpage>.
<pub-id pub-id-type="pmid">18023959</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0042">
<mixed-citation id="glia23136-cit-0043" publication-type="journal">
<string-name>
<surname>Chen</surname>, <given-names>P. C.</given-names>
</string-name>, 
<string-name>
<surname>Vargas</surname>, <given-names>M. R.</given-names>
</string-name>, 
<string-name>
<surname>Pani</surname>, <given-names>A. K.</given-names>
</string-name>, 
<string-name>
<surname>Smeyne</surname>, <given-names>R. J.</given-names>
</string-name>, 
<string-name>
<surname>Johnson</surname>, <given-names>D. A.</given-names>
</string-name>, 
<string-name>
<surname>Kan</surname>, <given-names>Y. W.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Johnson</surname>, <given-names>J. A.</given-names>
</string-name> (<year>2009</year>). <article-title>Nrf2‐mediated neuroprotection in the MPTP mouse model of Parkinson's disease: Critical role for the astrocyte</article-title>. <source/>Proceedings of the National Academy of Science of United States of America, <volume>106</volume>, <fpage>2933</fpage>–<lpage>2938</lpage>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0043">
<mixed-citation id="glia23136-cit-0044" publication-type="journal">
<string-name>
<surname>Chever</surname>, <given-names>O.</given-names>
</string-name>, 
<string-name>
<surname>Djukic</surname>, <given-names>B.</given-names>
</string-name>, 
<string-name>
<surname>McCarthy</surname>, <given-names>K. D.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Amzica</surname>, <given-names>F.</given-names>
</string-name> (<year>2010</year>). <article-title>Implication of Kir4.1 channel in excess potassium clearance: An in vivo study on anesthetized glial‐conditional Kir4.1 knock‐out mice</article-title>. <source/>Journal of Neuroscience, <volume>30</volume>, <fpage>15769</fpage>–<lpage>15777</lpage>.
<pub-id pub-id-type="pmid">21106816</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0044">
<mixed-citation id="glia23136-cit-0045" publication-type="journal">
<string-name>
<surname>Chih</surname>, <given-names>C. P.</given-names>
</string-name> &amp; 
<string-name>
<surname>Roberts</surname>, <given-names>E. L.</given-names>, <suffix>Jr.</suffix>
</string-name> (<year>2003</year>). <article-title>Energy substrates for neurons during neural activity: A critical review of the astrocyte‐neuron lactate shuttle hypothesis</article-title>. <source/>Journal of Cerebral Blood Flow Metabolism, <volume>23</volume>, <fpage>1263</fpage>–<lpage>1281</lpage>.
<pub-id pub-id-type="pmid">14600433</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0045">
<mixed-citation id="glia23136-cit-0046" publication-type="journal">
<string-name>
<surname>Chinta</surname>, <given-names>S. J.</given-names>
</string-name> &amp; 
<string-name>
<surname>Andersen</surname>, <given-names>J. K.</given-names>
</string-name> (<year>2008</year>). <article-title>Redox imbalance in Parkinson's disease</article-title>. <source/>Biochimica et Biophysica Acta—General Subjects, <volume>1780</volume>, <fpage>1362</fpage>–<lpage>1367</lpage>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0046">
<mixed-citation id="glia23136-cit-0047" publication-type="journal">
<string-name>
<surname>Choudary</surname>, <given-names>P. V.</given-names>
</string-name>, 
<string-name>
<surname>Molnar</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Evans</surname>, <given-names>S. J.</given-names>
</string-name>, 
<string-name>
<surname>Tomita</surname>, <given-names>H.</given-names>
</string-name>, 
<string-name>
<surname>Li</surname>, <given-names>J. Z.</given-names>
</string-name>, 
<string-name>
<surname>Vawter</surname>, <given-names>M. P.</given-names>
</string-name>, 
<string-name>
<surname>Myers</surname>, <given-names>R. M.</given-names>
</string-name>, 
<string-name>
<surname>Bunney</surname>, <given-names>W. E.</given-names>, <suffix>Jr.</suffix>
</string-name>, 
<string-name>
<surname>Akil</surname>, <given-names>H.</given-names>
</string-name>, 
<string-name>
<surname>Watson</surname>, <given-names>S. J.</given-names>
</string-name>, et al. (<year>2005</year>). <article-title>Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression</article-title>. <source/>Proceedings of the National Academy of Science of United States of America, <volume>102</volume>, <fpage>15653</fpage>–<lpage>15658</lpage>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0047">
<mixed-citation id="glia23136-cit-0048" publication-type="journal">
<string-name>
<surname>Chung</surname>, <given-names>R. S.</given-names>
</string-name>, 
<string-name>
<surname>Hidalgo</surname>, <given-names>J.</given-names>
</string-name>, &amp; 
<string-name>
<surname>West</surname>, <given-names>A. K.</given-names>
</string-name> (<year>2008</year>). <article-title>New insight into the molecular pathways of metallothionein‐mediated neuroprotection and regeneration</article-title>. <source/>Journal of Neurochemistry, <volume>104</volume>, <fpage>14</fpage>–<lpage>20</lpage>.
<pub-id pub-id-type="pmid">17986229</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0048">
<mixed-citation id="glia23136-cit-0049" publication-type="journal">
<string-name>
<surname>Chung</surname>, <given-names>R. S.</given-names>
</string-name>, 
<string-name>
<surname>Vickers</surname>, <given-names>J. C.</given-names>
</string-name>, 
<string-name>
<surname>Chuah</surname>, <given-names>M. I.</given-names>
</string-name>, &amp; 
<string-name>
<surname>West</surname>, <given-names>A. K.</given-names>
</string-name> (<year>2003</year>). <article-title>Metallothionein‐IIA promotes initial neurite elongation and postinjury reactive neurite growth and facilitates healing after focal cortical brain injury</article-title>. <source/>J Neurosci
<volume>23</volume>:<fpage>3336</fpage>–<lpage>3342</lpage>.
<pub-id pub-id-type="pmid">12716941</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0049">
<mixed-citation id="glia23136-cit-0050" publication-type="journal">
<string-name>
<surname>Colton</surname>, <given-names>C. K.</given-names>
</string-name>, 
<string-name>
<surname>Kong</surname>, <given-names>Q. M.</given-names>
</string-name>, 
<string-name>
<surname>Lai</surname>, <given-names>L. C.</given-names>
</string-name>, 
<string-name>
<surname>Zhu</surname>, <given-names>M. X.</given-names>
</string-name>, 
<string-name>
<surname>Seyb</surname>, <given-names>K. I.</given-names>
</string-name>, 
<string-name>
<surname>Cuny</surname>, <given-names>G. D.</given-names>
</string-name>, … 
<string-name>
<surname>Lin</surname>, <given-names>C. L. G.</given-names>
</string-name> (<year>2010</year>). <article-title>Identification of translational activators of glial glutamate transporter EAAT2 through cell‐based high‐throughput screening: An approach to prevent excitotoxicity</article-title>. <source/>Journal of Biomolecular Screening, <volume>15</volume>, <fpage>653</fpage>–<lpage>662</lpage>.
<pub-id pub-id-type="pmid">20508255</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0050">
<mixed-citation id="glia23136-cit-0051" publication-type="journal">
<string-name>
<surname>Corder</surname>, <given-names>E. H.</given-names>
</string-name>, 
<string-name>
<surname>Saunders</surname>, <given-names>A. M.</given-names>
</string-name>, 
<string-name>
<surname>Risch</surname>, <given-names>N. J.</given-names>
</string-name>, 
<string-name>
<surname>Strittmatter</surname>, <given-names>W. J.</given-names>
</string-name>, 
<string-name>
<surname>Schmechel</surname>, <given-names>D. E.</given-names>
</string-name>, 
<string-name>
<surname>Gaskell</surname>, <given-names>P. C.</given-names>, <suffix>Jr.</suffix>
</string-name>, 
<string-name>
<surname>Rimmler</surname>, <given-names>J. B.</given-names>
</string-name>, 
<string-name>
<surname>Locke</surname>, <given-names>P. A.</given-names>
</string-name>, 
<string-name>
<surname>Conneally</surname>, <given-names>P. M.</given-names>
</string-name>, 
<string-name>
<surname>Schmader</surname>, <given-names>K. E.</given-names>
</string-name>, et al. (<year>1994</year>). <article-title>Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease</article-title>. <source/>Nature Genetics, <volume>7</volume>, <fpage>180</fpage>–<lpage>184</lpage>.
<pub-id pub-id-type="pmid">7920638</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0051">
<mixed-citation id="glia23136-cit-0052" publication-type="journal">
<string-name>
<surname>Corder</surname>, <given-names>E. H.</given-names>
</string-name>, 
<string-name>
<surname>Saunders</surname>, <given-names>A. M.</given-names>
</string-name>, 
<string-name>
<surname>Strittmatter</surname>, <given-names>W. J.</given-names>
</string-name>, 
<string-name>
<surname>Schmechel</surname>, <given-names>D. E.</given-names>
</string-name>, 
<string-name>
<surname>Gaskell</surname>, <given-names>P. C.</given-names>
</string-name>, 
<string-name>
<surname>Small</surname>, <given-names>G. W.</given-names>
</string-name>, … 
<string-name>
<surname>Pericak‐Vance</surname>, <given-names>M. A.</given-names>
</string-name> (<year>1993</year>). <article-title>Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families</article-title>. <source/>Science, <volume>261</volume>, <fpage>921</fpage>–<lpage>923</lpage>.
<pub-id pub-id-type="pmid">8346443</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0052">
<mixed-citation id="glia23136-cit-0053" publication-type="journal">
<string-name>
<surname>Coughlin</surname>, <given-names>S. R.</given-names>
</string-name> (<year>2000</year>). <article-title>Thrombin signalling and protease‐activated receptors</article-title>. <source/>Nature, (<volume>407)</volume>, <fpage>258</fpage>–<lpage>264</lpage>.
<pub-id pub-id-type="pmid">11001069</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0053">
<mixed-citation id="glia23136-cit-0054" publication-type="journal">
<string-name>
<surname>Coulter</surname>, <given-names>D. A.</given-names>
</string-name> &amp; 
<string-name>
<surname>Steinhauser</surname>, <given-names>C.</given-names>
</string-name> (<year>2015</year>). <article-title>Role of astrocytes in epilepsy</article-title>. <source/>Cold Spring Harbor Perspectives in Medicine, <volume>5</volume>, <fpage>a022434</fpage>.
<pub-id pub-id-type="pmid">25732035</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0054">
<mixed-citation id="glia23136-cit-0055" publication-type="journal">
<string-name>
<surname>Cregg</surname>, <given-names>J. M.</given-names>
</string-name>, 
<string-name>
<surname>DePaul</surname>, <given-names>M. A.</given-names>
</string-name>, 
<string-name>
<surname>Filous</surname>, <given-names>A. R.</given-names>
</string-name>, 
<string-name>
<surname>Lang</surname>, <given-names>B. T.</given-names>
</string-name>, 
<string-name>
<surname>Tran</surname>, <given-names>A.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Silver</surname>, <given-names>J.</given-names>
</string-name> (<year>2014</year>). <article-title>Functional regeneration beyond the glial scar</article-title>. <source/>Experimental Neurology, <volume>253</volume>, <fpage>197</fpage>–<lpage>207</lpage>.
<pub-id pub-id-type="pmid">24424280</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0055">
<mixed-citation id="glia23136-cit-0056" publication-type="journal">
<string-name>
<surname>Cruceanu</surname>, <given-names>C.</given-names>
</string-name>, 
<string-name>
<surname>Tan</surname>, <given-names>P. P. C.</given-names>
</string-name>, 
<string-name>
<surname>Rogic</surname>, <given-names>S.</given-names>
</string-name>, 
<string-name>
<surname>Lopez</surname>, <given-names>J. P.</given-names>
</string-name>, 
<string-name>
<surname>Torres‐Platas</surname>, <given-names>S. G.</given-names>
</string-name>, 
<string-name>
<surname>Gigek</surname>, <given-names>C. O.</given-names>
</string-name>, … 
<string-name>
<surname>Turecki</surname>, <given-names>G.</given-names>
</string-name> (<year>2015</year>). <article-title>Transcriptome sequencing of the anterior cingulate in bipolar disorder: Dysregulation of G protein‐coupled receptors</article-title>. <source/>American Journal of Psychiatry, <volume>172</volume>, <fpage>1131</fpage>–<lpage>1140</lpage>.
<pub-id pub-id-type="pmid">26238605</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0056">
<mixed-citation id="glia23136-cit-0057" publication-type="journal">
<string-name>
<surname>Cudkowicz</surname>, <given-names>M. E.</given-names>
</string-name>, 
<string-name>
<surname>Titus</surname>, <given-names>S.</given-names>
</string-name>, 
<string-name>
<surname>Kearney</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Yu</surname>, <given-names>H.</given-names>
</string-name>, 
<string-name>
<surname>Sherman</surname>, <given-names>A.</given-names>
</string-name>, 
<string-name>
<surname>Schoenfeld</surname>, <given-names>D.</given-names>
</string-name>, 
<string-name>
<surname>Hayden</surname>, <given-names>D.</given-names>
</string-name>, 
<string-name>
<surname>Shui</surname>, <given-names>A.</given-names>
</string-name>, 
<string-name>
<surname>Brooks</surname>, <given-names>B.</given-names>
</string-name>, 
<string-name>
<surname>Conwit</surname>, <given-names>R.</given-names>
</string-name>, et al. (<year>2014</year>). <article-title>Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: A multi‐stage, randomised, double‐blind, placebo‐controlled trial</article-title>. <source/>Lancet Neurology, <volume>13</volume>, <fpage>1083</fpage>–<lpage>1091</lpage>.
<pub-id pub-id-type="pmid">25297012</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0057">
<mixed-citation id="glia23136-cit-0058" publication-type="journal">
<string-name>
<surname>Dahl</surname>, <given-names>G.</given-names>
</string-name>, 
<string-name>
<surname>Nonner</surname>, <given-names>W.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Werner</surname>, <given-names>R.</given-names>
</string-name> (<year>1994</year>). <article-title>Attempts to define functional domains of gap junction proteins with synthetic peptides</article-title>. <source/>Biophysics Journal, <volume>67</volume>, <fpage>1816</fpage>–<lpage>1822</lpage>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0058">
<mixed-citation id="glia23136-cit-0059" publication-type="journal">
<string-name>
<surname>de Vries</surname>, <given-names>H. E.</given-names>
</string-name>, 
<string-name>
<surname>Witte</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Hondius</surname>, <given-names>D.</given-names>
</string-name>, 
<string-name>
<surname>Rozermuller</surname>, <given-names>A. J. M.</given-names>
</string-name>, 
<string-name>
<surname>Drukarch</surname>, <given-names>B.</given-names>
</string-name>, 
<string-name>
<surname>Hoozemans</surname>, <given-names>J.</given-names>
</string-name>, &amp; 
<string-name>
<surname>van Horssen</surname>, <given-names>J.</given-names>
</string-name> (<year>2008</year>). <article-title>Nrf2‐induced antioxidant protection: A promising target to counteract ROS‐mediated damage in neurodegenerative disease?</article-title>
<source/>Free Radical Biology &amp; Medicine, <volume>45</volume>, <fpage>1375</fpage>–<lpage>1383</lpage>.
<pub-id pub-id-type="pmid">18824091</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0059">
<mixed-citation id="glia23136-cit-0060" publication-type="journal">
<string-name>
<surname>Demarque</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Villeneuve</surname>, <given-names>N.</given-names>
</string-name>, 
<string-name>
<surname>Manent</surname>, <given-names>J. B.</given-names>
</string-name>, 
<string-name>
<surname>Becq</surname>, <given-names>H.</given-names>
</string-name>, 
<string-name>
<surname>Represa</surname>, <given-names>A.</given-names>
</string-name>, 
<string-name>
<surname>Ben‐Ari</surname>, <given-names>Y.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Aniksztejn</surname>, <given-names>L.</given-names>
</string-name> (<year>2004</year>). <article-title>Glutamate transporters prevent the generation of seizures in the developing rat neocortex</article-title>. <source/>Journal of Neuroscience, <volume>24</volume>, <fpage>3289</fpage>–<lpage>3294</lpage>.
<pub-id pub-id-type="pmid">15056708</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0060">
<mixed-citation id="glia23136-cit-0061" publication-type="journal">
<string-name>
<surname>Dermietzel</surname>, <given-names>R.</given-names>
</string-name>, 
<string-name>
<surname>Gao</surname>, <given-names>Y.</given-names>
</string-name>, 
<string-name>
<surname>Scemes</surname>, <given-names>E.</given-names>
</string-name>, 
<string-name>
<surname>Vieria</surname>, <given-names>D.</given-names>
</string-name>, 
<string-name>
<surname>Urban</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Kremer</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Bennett</surname>, <given-names>M. V. L.</given-names>
</string-name>, 
<string-name>
<surname>Spray</surname>, <given-names>D. C.</given-names>
</string-name> (<year>2000</year>). <article-title>Connexin43 null mice reveal that astrocytes express multiple connexins</article-title>. <source/>Brain Research Reviews, <volume>32</volume>, <fpage>45</fpage>–<lpage>56</lpage>.
<pub-id pub-id-type="pmid">10751656</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0061">
<mixed-citation id="glia23136-cit-0062" publication-type="journal">
<string-name>
<surname>Dexter</surname>, <given-names>D. T.</given-names>
</string-name>, 
<string-name>
<surname>Carter</surname>, <given-names>C. J.</given-names>
</string-name>, 
<string-name>
<surname>Wells</surname>, <given-names>F. R.</given-names>
</string-name>, 
<string-name>
<surname>Javoy‐Agid</surname>, <given-names>F.</given-names>
</string-name>, 
<string-name>
<surname>Agid</surname>, <given-names>Y.</given-names>
</string-name>, 
<string-name>
<surname>Lees</surname>, <given-names>A.</given-names>
</string-name>, … 
<string-name>
<surname>Marsden</surname>, <given-names>C. D.</given-names>
</string-name> (<year>1989</year>). <article-title>Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease</article-title>. <source/>Journal of Neurochemistry, <volume>52</volume>, <fpage>381</fpage>–<lpage>389</lpage>.
<pub-id pub-id-type="pmid">2911023</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0062">
<mixed-citation id="glia23136-cit-0063" publication-type="journal">
<string-name>
<surname>Dienel</surname>, <given-names>G. A.</given-names>
</string-name> (<year>2012</year>). <article-title>Brain lactate metabolism: The discoveries and the controversies</article-title>. <source/>Journal of Cerebral Blood Flow Metabolism, <volume>32</volume>, <fpage>1107</fpage>–<lpage>1138</lpage>.
<pub-id pub-id-type="pmid">22186669</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0063">
<mixed-citation id="glia23136-cit-0064" publication-type="journal">
<string-name>
<surname>Domeniconi</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Hempstead</surname>, <given-names>B. L.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Chao</surname>, <given-names>M. V.</given-names>
</string-name> (<year>2007</year>). <article-title>Pro‐NGF secreted by astrocytes promotes motor neuron cell death</article-title>. <source/>Molecular &amp; Cellular Neuroscience, <volume>34</volume>, <fpage>271</fpage>–<lpage>279</lpage>.
<pub-id pub-id-type="pmid">17188890</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0064">
<mixed-citation id="glia23136-cit-0065" publication-type="journal">
<string-name>
<surname>Donato</surname>, <given-names>R.</given-names>
</string-name> (<year>2003</year>). <article-title>Intracellular and extracellular roles of s100 proteins</article-title>. <source/>Microscopy Research &amp; Technique, <volume>60</volume>, <fpage>540</fpage>–<lpage>551</lpage>.
<pub-id pub-id-type="pmid">12645002</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0065">
<mixed-citation id="glia23136-cit-0066" publication-type="journal">
<string-name>
<surname>Donovan</surname>, <given-names>F. M.</given-names>
</string-name>, 
<string-name>
<surname>Pike</surname>, <given-names>C. J.</given-names>
</string-name>, 
<string-name>
<surname>Cotman</surname>, <given-names>C. W.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Cunningham</surname>, <given-names>D. D.</given-names>
</string-name> (<year>1997</year>). <article-title>Thrombin induces apoptosis in cultured neurons and astrocytes via a pathway requiring tyrosine kinase and RhoA activities</article-title>. <source/>Journal of Neuroscience, <volume>17</volume>, <fpage>5316</fpage>–<lpage>5326</lpage>.
<pub-id pub-id-type="pmid">9204916</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0066">
<mixed-citation id="glia23136-cit-0067" publication-type="journal">
<string-name>
<surname>Douen</surname>, <given-names>A. G.</given-names>
</string-name>, 
<string-name>
<surname>Akiyama</surname>, <given-names>K.</given-names>
</string-name>, 
<string-name>
<surname>Hogan</surname>, <given-names>M. J.</given-names>
</string-name>, 
<string-name>
<surname>Wang</surname>, <given-names>F.</given-names>
</string-name>, 
<string-name>
<surname>Dong</surname>, <given-names>L.</given-names>
</string-name>, 
<string-name>
<surname>Chow</surname>, <given-names>A. K.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Hakim</surname>, <given-names>A.</given-names>
</string-name> (<year>2000</year>). <article-title>Preconditioning with cortical spreading depression decreases intraischemic cerebral glutamate levels and down‐regulates excitatory amino acid transporters EAAT1 and EAAT2 from rat cerebal cortex plasma membranes</article-title>. <source/>Journal of Neurochemistry, <volume>75</volume>, <fpage>812</fpage>–<lpage>818</lpage>.
<pub-id pub-id-type="pmid">10899959</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0067">
<mixed-citation id="glia23136-cit-0068" publication-type="journal">
<string-name>
<surname>Dufour</surname>, <given-names>F.</given-names>
</string-name>, 
<string-name>
<surname>Koning</surname>, <given-names>E.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Nehlig</surname>, <given-names>A.</given-names>
</string-name> (<year>2003</year>). <article-title>Basal levels of metabolic activity are elevated in genetic absence epilepsy rats from Strasbourg (GAERS): Measurement of regional activity of cytochrome oxidase and lactate dehydrogenase by histochemistry</article-title>. <source/>Experimental Neurology, <volume>182</volume>, <fpage>346</fpage>–<lpage>352</lpage>.
<pub-id pub-id-type="pmid">12895445</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0068">
<mixed-citation id="glia23136-cit-0069" publication-type="journal">
<string-name>
<surname>Dusonchet</surname>, <given-names>J.</given-names>
</string-name>, 
<string-name>
<surname>Bensadoun</surname>, <given-names>J. C.</given-names>
</string-name>, 
<string-name>
<surname>Schneider</surname>, <given-names>B. L.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Aebischer</surname>, <given-names>P.</given-names>
</string-name> (<year>2009</year>). <article-title>Targeted overexpression of the parkin substrate Pael‐R in the nigrostriatal system of adult rats to model Parkinson's disease</article-title>. <source/>Neurobiology of Disease, <volume>35</volume>, <fpage>32</fpage>–<lpage>41</lpage>.
<pub-id pub-id-type="pmid">19348945</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0069">
<mixed-citation id="glia23136-cit-0070" publication-type="journal">
<string-name>
<surname>Eid</surname>, <given-names>T.</given-names>
</string-name>, 
<string-name>
<surname>Thomas</surname>, <given-names>M. J.</given-names>
</string-name>, 
<string-name>
<surname>Spencer</surname>, <given-names>D. D.</given-names>
</string-name>, 
<string-name>
<surname>Runden‐Pran</surname>, <given-names>E.</given-names>
</string-name>, 
<string-name>
<surname>Lai</surname>, <given-names>J. C.</given-names>
</string-name>, 
<string-name>
<surname>Malthankar</surname>, <given-names>G. V.</given-names>
</string-name>, … 
<string-name>
<surname>de Lanerolle</surname>
<given-names>NC.</given-names>
</string-name> (<year>2004</year>). <article-title>Loss of glutamine synthetase in the human epileptogenic hippocampus: Possible mechanism for raised extracellular glutamate in mesial temporal lobe epilepsy</article-title>. <source/>Lancet, <volume>363</volume>, <fpage>28</fpage>–<lpage>37</lpage>.
<pub-id pub-id-type="pmid">14723991</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0070">
<mixed-citation id="glia23136-cit-0071" publication-type="journal">
<string-name>
<surname>Evans</surname>, <given-names>W. H.</given-names>
</string-name> &amp; 
<string-name>
<surname>Boitano</surname>, <given-names>S.</given-names>
</string-name> (<year>2001</year>). <article-title>Connexin mimetic peptides: Specific inhibitors of gap‐junctional intercellular communication</article-title>. <source/>Biochemical Society Transactions, <volume>29</volume>, <fpage>606</fpage>–<lpage>612</lpage>.
<pub-id pub-id-type="pmid">11498037</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0071">
<mixed-citation id="glia23136-cit-0072" publication-type="journal">
<string-name>
<surname>Ezan</surname>, <given-names>P.</given-names>
</string-name>, 
<string-name>
<surname>Andre</surname>, <given-names>P.</given-names>
</string-name>, 
<string-name>
<surname>Cisternino</surname>, <given-names>S.</given-names>
</string-name>, 
<string-name>
<surname>Saubamea</surname>, <given-names>B.</given-names>
</string-name>, 
<string-name>
<surname>Boulay</surname>, <given-names>A. C.</given-names>
</string-name>, 
<string-name>
<surname>Doutremer</surname>, <given-names>S.</given-names>
</string-name>, … 
<string-name>
<surname>Cohen‐Salmon</surname>
<given-names>M.</given-names>
</string-name> (<year>2012</year>). <article-title>Deletion of astroglial connexins weakens the blood‐brain barrier</article-title>. <source/>Journal of Cerebral Blood Flow Metabolism, <volume>32</volume>, <fpage>1457</fpage>–<lpage>1467</lpage>.
<pub-id pub-id-type="pmid">22472609</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0072">
<mixed-citation id="glia23136-cit-0073" publication-type="journal">
<string-name>
<surname>Filip</surname>, <given-names>M.</given-names>
</string-name> &amp; 
<string-name>
<surname>Bader</surname>, <given-names>M.</given-names>
</string-name> (<year>2009</year>). <article-title>Overview on 5‐HT receptors and their role in physiology and pathology of the central nervous system</article-title>. <source/>Pharmacology Reports, <volume>61</volume>, <fpage>761</fpage>–<lpage>777</lpage>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0073">
<mixed-citation id="glia23136-cit-0074" publication-type="journal">
<string-name>
<surname>Filous</surname>, <given-names>A. R.</given-names>
</string-name> &amp; 
<string-name>
<surname>Silver</surname>, <given-names>J.</given-names>
</string-name> (<year>2016</year>). <article-title>Targeting astrocytes in CNS injury and disease: A translational research approach</article-title>. <source/>Progress in Neurobiology, <volume>144</volume>, <fpage>173</fpage>–<lpage>187</lpage>.
<pub-id pub-id-type="pmid">27026202</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0074">
<mixed-citation id="glia23136-cit-0075" publication-type="journal">
<string-name>
<surname>Fontana</surname>, <given-names>A. C.</given-names>
</string-name> (<year>2015</year>). <article-title>Current approaches to enhance glutamate transporter function and expression</article-title>. <source/>Journal of Neurochemistry, <volume>134</volume>, <fpage>982</fpage>–<lpage>1007</lpage>.
<pub-id pub-id-type="pmid">26096891</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0075">
<mixed-citation id="glia23136-cit-0076" publication-type="journal">
<string-name>
<surname>Fontana</surname>, <given-names>A. C.</given-names>
</string-name>, 
<string-name>
<surname>de Oliveira Beleboni</surname>, <given-names>R.</given-names>
</string-name>, 
<string-name>
<surname>Wojewodzic</surname>, <given-names>M. W.</given-names>
</string-name>, 
<string-name>
<surname>Ferreira Dos Santos</surname>, <given-names>W.</given-names>
</string-name>, 
<string-name>
<surname>Coutinho‐Netto</surname>, <given-names>J.</given-names>
</string-name>, 
<string-name>
<surname>Grutle</surname>, <given-names>N. J.</given-names>
</string-name>, … 
<string-name>
<surname>Amara</surname>, <given-names>S. G.</given-names>
</string-name> (<year>2007</year>). <article-title>Enhancing glutamate transport: Mechanism of action of Parawixin1, a neuroprotective compound from Parawixia bistriata spider venom</article-title>. <source/>Molecular Pharmacology, <volume>72</volume>, <fpage>1228</fpage>–<lpage>1237</lpage>.
<pub-id pub-id-type="pmid">17646426</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0076">
<mixed-citation id="glia23136-cit-0077" publication-type="journal">
<string-name>
<surname>Freitas‐Andrade</surname>, <given-names>M.</given-names>
</string-name> &amp; 
<string-name>
<surname>Naus</surname>, <given-names>C. C.</given-names>
</string-name> (<year>2016</year>). <article-title>Astrocytes in neuroprotection and neurodegeneration: The role of connexin43 and pannexin1</article-title>. <source/>Neuroscience, <volume>323</volume>, <fpage>207</fpage>–<lpage>221</lpage>.
<pub-id pub-id-type="pmid">25913636</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0077">
<mixed-citation id="glia23136-cit-0078" publication-type="journal">
<string-name>
<surname>Fujita‐Jimbo</surname>, <given-names>E.</given-names>
</string-name>, 
<string-name>
<surname>Yu</surname>, <given-names>Z. L.</given-names>
</string-name>, 
<string-name>
<surname>Li</surname>, <given-names>H.</given-names>
</string-name>, 
<string-name>
<surname>Yamagata</surname>, <given-names>T.</given-names>
</string-name>, 
<string-name>
<surname>Mori</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Momoi</surname>, <given-names>T.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Momoi</surname>, <given-names>M. Y.</given-names>
</string-name> (<year>2012</year>). <article-title>Mutation in Parkinson disease‐associated, G‐protein‐coupled receptor 37 (GPR37/PaelR) is related to autism spectrum disorder</article-title>. <source/>PLoS One, <volume>7</volume>, <fpage>e51155</fpage>.
<pub-id pub-id-type="pmid">23251443</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0078">
<mixed-citation id="glia23136-cit-0079" publication-type="journal">
<string-name>
<surname>Gan</surname>, <given-names>L.</given-names>
</string-name>, 
<string-name>
<surname>Vargas</surname>, <given-names>M. R.</given-names>
</string-name>, 
<string-name>
<surname>Johnson</surname>, <given-names>D. A.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Johnson</surname>, <given-names>J. A.</given-names>
</string-name> (<year>2012</year>). <article-title>Astrocyte‐specific overexpression of Nrf2 delays motor pathology and synuclein aggregation throughout the CNS in the alpha‐synuclein mutant (A53T) mouse model</article-title>. <source/>Journal of Neuroscience, <volume>32</volume>, <fpage>17775</fpage>–<lpage>17787</lpage>.
<pub-id pub-id-type="pmid">23223297</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0079">
<mixed-citation id="glia23136-cit-0080" publication-type="journal">
<string-name>
<surname>Gandhi</surname>, <given-names>S.</given-names>
</string-name> &amp; 
<string-name>
<surname>Abramov</surname>, <given-names>A. Y.</given-names>
</string-name> (<year>2012</year>). <article-title>Mechanism of oxidative stress in neurodegeneration</article-title>. <source/>Oxidative Medicine and Cellular Longevity, <volume>2012</volume>, <fpage>428010</fpage>.
<pub-id pub-id-type="pmid">22685618</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0080">
<mixed-citation id="glia23136-cit-0081" publication-type="journal">
<string-name>
<surname>Gardner‐Medwin</surname>, <given-names>A. R.</given-names>
</string-name> (<year>1983</year>). <article-title>Analysis of potassium dynamics in mammalian brain tissue</article-title>. <source/>Journal of Physiology, <volume>335</volume>, <fpage>393</fpage>–<lpage>426</lpage>.
<pub-id pub-id-type="pmid">6875885</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0081">
<mixed-citation id="glia23136-cit-0082" publication-type="journal">
<string-name>
<surname>Ghosh</surname>, <given-names>R.</given-names>
</string-name> &amp; 
<string-name>
<surname>Tabrizi</surname>, <given-names>S. J.</given-names>
</string-name> (<year>2015</year>). <article-title>Clinical aspects of Huntington's disease</article-title>. <source/>Current Topics in Behavioral Neuroscience, <volume>22</volume>,<fpage>3</fpage>–<lpage>31</lpage>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0082">
<mixed-citation id="glia23136-cit-0083" publication-type="journal">
<string-name>
<surname>Giaume</surname>, <given-names>C.</given-names>
</string-name>, 
<string-name>
<surname>Leybaert</surname>, <given-names>L.</given-names>
</string-name>, 
<string-name>
<surname>Naus</surname>, <given-names>C. C.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Saez</surname>, <given-names>J. C.</given-names>
</string-name> (<year>2013</year>). <article-title>Connexin and pannexin hemichannels in brain glial cells: Properties, pharmacology, and roles</article-title>. <source/>Frontiers in Pharmacology, <volume>4</volume>, <fpage>88</fpage>.
<pub-id pub-id-type="pmid">23882216</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0083">
<mixed-citation id="glia23136-cit-0084" publication-type="journal">
<string-name>
<surname>Giaume</surname>, <given-names>C.</given-names>
</string-name> &amp; 
<string-name>
<surname>McCarthy</surname>, <given-names>K. D.</given-names>
</string-name> (<year>1996</year>). <article-title>Control of gap‐junctional communication in astrocytic networks</article-title>. <source/>Trends in Neuroscience, <volume>19</volume>, <fpage>319</fpage>–<lpage>325</lpage>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0084">
<mixed-citation id="glia23136-cit-0085" publication-type="journal">
<string-name>
<surname>Giaume</surname>, <given-names>C.</given-names>
</string-name> &amp; 
<string-name>
<surname>Theis</surname>, <given-names>M.</given-names>
</string-name> (<year>2010</year>). <article-title>Pharmacological and genetic approaches to study connexin‐mediated channels in glial cells of the central nervous system</article-title>. <source/>Brain Research Reviews, <volume>63</volume>, <fpage>160</fpage>–<lpage>176</lpage>.
<pub-id pub-id-type="pmid">19963007</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0085">
<mixed-citation id="glia23136-cit-0086" publication-type="journal">
<string-name>
<surname>Giralt</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Penkowa</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Hernandez</surname>, <given-names>J.</given-names>
</string-name>, 
<string-name>
<surname>Molinero</surname>, <given-names>A.</given-names>
</string-name>, 
<string-name>
<surname>Carrasco</surname>, <given-names>J.</given-names>
</string-name>, 
<string-name>
<surname>Lago</surname>, <given-names>N.</given-names>
</string-name>, … 
<string-name>
<surname>Hidalgo</surname>, <given-names>J.</given-names>
</string-name> (<year>2002</year>). <article-title>Metallothionein‐1 + 2 deficiency increases brain pathology in transgenic mice with astrocyte‐targeted expression of interleukin 6</article-title>. <source/>Neurobiology of Diseases, <volume>9</volume>, <fpage>319</fpage>–<lpage>338</lpage>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0086">
<mixed-citation id="glia23136-cit-0087" publication-type="journal">
<string-name>
<surname>Gladden</surname>, <given-names>L. B.</given-names>
</string-name> (<year>2004</year>). <article-title>Lactate metabolism: A new paradigm for the third millennium</article-title>. <source/>Journal of Physiology, <volume>558</volume>, <fpage>5</fpage>–<lpage>30</lpage>.
<pub-id pub-id-type="pmid">15131240</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0087">
<mixed-citation id="glia23136-cit-0088" publication-type="journal">
<string-name>
<surname>Glass</surname>, <given-names>C. K.</given-names>
</string-name>, 
<string-name>
<surname>Saijo</surname>, <given-names>K.</given-names>
</string-name>, 
<string-name>
<surname>Winner</surname>, <given-names>B.</given-names>
</string-name>, 
<string-name>
<surname>Marchetto</surname>, <given-names>M. C.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Gage</surname>, <given-names>F. H.</given-names>
</string-name> (<year>2010</year>). <article-title>Mechanisms underlying inflammation in neurodegeneration</article-title>. <source/>Cell, <volume>140</volume>, <fpage>918</fpage>–<lpage>934</lpage>.
<pub-id pub-id-type="pmid">20303880</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0088">
<mixed-citation id="glia23136-cit-0089" publication-type="journal">
<string-name>
<surname>Glass</surname>, <given-names>M.</given-names>
</string-name> &amp; 
<string-name>
<surname>Dragunow</surname>, <given-names>M.</given-names>
</string-name> (<year>1995</year>). <article-title>Neurochemical and morphological changes associated with human epilepsy</article-title>. <source/>Brain Research Brain Research Reviews, <volume>21</volume>, <fpage>29</fpage>–<lpage>41</lpage>.
<pub-id pub-id-type="pmid">8547953</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0089">
<mixed-citation id="glia23136-cit-0090" publication-type="journal">
<string-name>
<surname>Gomes</surname>, <given-names>P.</given-names>
</string-name>, 
<string-name>
<surname>Srinivas</surname>, <given-names>S. P.</given-names>
</string-name>, 
<string-name>
<surname>Van Driessche</surname>, <given-names>W.</given-names>
</string-name>, 
<string-name>
<surname>Vereecke</surname>, <given-names>J.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Himpens</surname>, <given-names>B.</given-names>
</string-name> (<year>2005</year>). <article-title>ATP release through connexin hemichannels in corneal endothelial cells</article-title>. <source/>Investigative Ophthalmology &amp; Visual Science, <volume>46</volume>, <fpage>1208</fpage>–<lpage>1218</lpage>.
<pub-id pub-id-type="pmid">15790881</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0090">
<mixed-citation id="glia23136-cit-0091" publication-type="journal">
<string-name>
<surname>Gordon</surname>, <given-names>P. H.</given-names>
</string-name> (<year>2013</year>). <article-title>Amyotrophic lateral sclerosis: An update for 2013 clinical features, pathophysiology, management and therapeutic trials</article-title>. <source/>Aging &amp; Disease, <volume>4</volume>, <fpage>295</fpage>–<lpage>310</lpage>.
<pub-id pub-id-type="pmid">24124634</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0091">
<mixed-citation id="glia23136-cit-0092" publication-type="journal">
<string-name>
<surname>Grewer</surname>, <given-names>C.</given-names>
</string-name>, 
<string-name>
<surname>Gameiro</surname>, <given-names>A.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Rauen</surname>, <given-names>T.</given-names>
</string-name> (<year>2014</year>). <article-title>SLC1 glutamate transporters</article-title>. <source/>Pflugers Archives, <volume>466</volume>, <fpage>3</fpage>–<lpage>24</lpage>.
<pub-id pub-id-type="pmid">24240778</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0092">
<mixed-citation id="glia23136-cit-0093" publication-type="journal">
<string-name>
<surname>Gu</surname>, <given-names>X.</given-names>
</string-name>, 
<string-name>
<surname>Li</surname>, <given-names>C.</given-names>
</string-name>, 
<string-name>
<surname>Wei</surname>, <given-names>W.</given-names>
</string-name>, 
<string-name>
<surname>Lo</surname>, <given-names>V.</given-names>
</string-name>, 
<string-name>
<surname>Gong</surname>, <given-names>S.</given-names>
</string-name>, 
<string-name>
<surname>Li</surname>, <given-names>S. H.</given-names>
</string-name>, 
<string-name>
<surname>Iwasato</surname>, <given-names>T.</given-names>
</string-name>, 
<string-name>
<surname>Itohara</surname>, <given-names>S.</given-names>
</string-name>, 
<string-name>
<surname>Li</surname>, <given-names>X. J.</given-names>
</string-name>, 
<string-name>
<surname>Mody</surname>, <given-names>I.</given-names>
</string-name>, et al. (<year>2005</year>). <article-title>Pathological cell‐cell interactions elicited by a neuropathogenic form of mutant Huntingtin contribute to cortical pathogenesis in HD mice</article-title>. <source/>Neuron, <volume>46</volume>, <fpage>433</fpage>–<lpage>444</lpage>.
<pub-id pub-id-type="pmid">15882643</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0093">
<mixed-citation id="glia23136-cit-0094" publication-type="journal">
<string-name>
<surname>Guo</surname>, <given-names>H.</given-names>
</string-name>, 
<string-name>
<surname>Lai</surname>, <given-names>L.</given-names>
</string-name>, 
<string-name>
<surname>Butchbach</surname>, <given-names>M. E.</given-names>
</string-name>, 
<string-name>
<surname>Stockinger</surname>, <given-names>M. P.</given-names>
</string-name>, 
<string-name>
<surname>Shan</surname>, <given-names>X.</given-names>
</string-name>, 
<string-name>
<surname>Bishop</surname>, <given-names>G. A.</given-names>
</string-name>, 
<string-name>
<surname>Lin</surname>, <given-names>C. L.</given-names>
</string-name> (<year>2003</year>). <article-title>Increased expression of the glial glutamate transporter EAAT2 modulates excitotoxicity and delays the onset but not the outcome of ALS in mice</article-title>. <source/>Human Molecular Genetics, <volume>12</volume>, <fpage>2519</fpage>–<lpage>2532</lpage>.
<pub-id pub-id-type="pmid">12915461</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0094">
<mixed-citation id="glia23136-cit-0095" publication-type="journal">
<string-name>
<surname>Gutierrez‐Rodriguez</surname>, <given-names>M.</given-names>
</string-name> &amp; 
<string-name>
<surname>Herranz</surname>, <given-names>R.</given-names>
</string-name> (<year>2015</year>). <article-title>From multiple PAR1 receptor/protein interactions to their multiple therapeutic implications</article-title>. <source/>Current Topics in Medicinal Chemistry, <volume>15</volume>, <fpage>2080</fpage>–<lpage>2114</lpage>.
<pub-id pub-id-type="pmid">25986685</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0095">
<mixed-citation id="glia23136-cit-0096" publication-type="journal">
<string-name>
<surname>Haj‐Yasein</surname>, <given-names>N. N.</given-names>
</string-name>, 
<string-name>
<surname>Jensen</surname>, <given-names>V.</given-names>
</string-name>, 
<string-name>
<surname>Vindedal</surname>, <given-names>G. F.</given-names>
</string-name>, 
<string-name>
<surname>Gundersen</surname>, <given-names>G. A.</given-names>
</string-name>, 
<string-name>
<surname>Klungland</surname>, <given-names>A.</given-names>
</string-name>, 
<string-name>
<surname>Ottersen</surname>, <given-names>O. P.</given-names>
</string-name>, … 
<string-name>
<surname>Nagelhus</surname>
<given-names>EA.</given-names>
</string-name> (<year>2011a</year>). <article-title>Evidence that compromised K+ spatial buffering contributes to the epileptogenic effect of mutations in the human Kir4.1 gene (KCNJ10)</article-title>. <source/>Glia, <volume>59</volume>, <fpage>1635</fpage>–<lpage>1642</lpage>.
<pub-id pub-id-type="pmid">21748805</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0096">
<mixed-citation id="glia23136-cit-0097" publication-type="journal">
<string-name>
<surname>Haj‐Yasein</surname>, <given-names>N. N.</given-names>
</string-name>, 
<string-name>
<surname>Vindedal</surname>, <given-names>G. F.</given-names>
</string-name>, 
<string-name>
<surname>Eilert‐Olsen</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Gundersen</surname>, <given-names>G. A.</given-names>
</string-name>, 
<string-name>
<surname>Skare</surname>, <given-names>O.</given-names>
</string-name>, 
<string-name>
<surname>Laake</surname>, <given-names>P.</given-names>
</string-name>, 
<string-name>
<surname>Klungland</surname>, <given-names>A.</given-names>
</string-name>, 
<string-name>
<surname>Thoren</surname>, <given-names>A. E.</given-names>
</string-name>, 
<string-name>
<surname>Burkhardt</surname>, <given-names>J. M.</given-names>
</string-name>, 
<string-name>
<surname>Ottersen</surname>, <given-names>O. P.</given-names>
</string-name>, et al. (<year>2011b</year>). <article-title>Glial‐conditional deletion of aquaporin‐4 (Aqp4) reduces blood‐brain water uptake and confers barrier function on perivascular astrocyte endfeet</article-title>. <source/>Proceedings of the National Academy of Science of United States of America, <volume>108</volume>, <fpage>17815</fpage>–<lpage>17820</lpage>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0097">
<mixed-citation id="glia23136-cit-0098" publication-type="journal">
<string-name>
<surname>Hamdi</surname>, <given-names>Y.</given-names>
</string-name>, 
<string-name>
<surname>Kaddour</surname>, <given-names>H.</given-names>
</string-name>, 
<string-name>
<surname>Vaudry</surname>, <given-names>D.</given-names>
</string-name>, 
<string-name>
<surname>Bahdoudi</surname>, <given-names>S.</given-names>
</string-name>, 
<string-name>
<surname>Douiri</surname>, <given-names>S.</given-names>
</string-name>, 
<string-name>
<surname>Leprince</surname>, <given-names>J.</given-names>
</string-name>, 
<string-name>
<surname>Castel</surname>, <given-names>H.</given-names>
</string-name>, 
<string-name>
<surname>Vaudry</surname>, <given-names>H.</given-names>
</string-name>, 
<string-name>
<surname>Tonon</surname>, <given-names>M. C.</given-names>
</string-name>, 
<string-name>
<surname>Amri</surname>, <given-names>M.</given-names>
</string-name>, et al. <year>2012</year>
<article-title>The octadecaneuropeptide ODN protects astrocytes against hydrogen peroxide‐induced apoptosis via a PKA/MAPK‐dependent mechanism</article-title>. <source/>Plos One, <volume>7</volume>, <fpage>e42498</fpage>.
<pub-id pub-id-type="pmid">22927932</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0098">
<mixed-citation id="glia23136-cit-0099" publication-type="journal">
<string-name>
<surname>Hamdi</surname>, <given-names>Y.</given-names>
</string-name>, 
<string-name>
<surname>Kaddour</surname>, <given-names>H.</given-names>
</string-name>, 
<string-name>
<surname>Vaudry</surname>, <given-names>D.</given-names>
</string-name>, 
<string-name>
<surname>Leprince</surname>, <given-names>J.</given-names>
</string-name>, 
<string-name>
<surname>Zarrouk</surname>, <given-names>A.</given-names>
</string-name>, 
<string-name>
<surname>Hammami</surname>, <given-names>M.</given-names>
</string-name>, … 
<string-name>
<surname>Masmoudi‐Kouki</surname>
<given-names>O.</given-names>
</string-name>
<year>2015</year>
<article-title>Octadecaneuropeptide ODN prevents hydrogen peroxide‐induced oxidative damage of biomolecules in cultured rat astrocytes</article-title>. <source/>Peptides, <volume>71</volume>, <fpage>56</fpage>–<lpage>65</lpage>.
<pub-id pub-id-type="pmid">26143507</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0099">
<mixed-citation id="glia23136-cit-0100" publication-type="journal">
<string-name>
<surname>Hamdi</surname>, <given-names>Y.</given-names>
</string-name>, 
<string-name>
<surname>Masmoudi‐Kouki</surname>, <given-names>O.</given-names>
</string-name>, 
<string-name>
<surname>Kaddour</surname>, <given-names>H.</given-names>
</string-name>, 
<string-name>
<surname>Belhadj</surname>, <given-names>F.</given-names>
</string-name>, 
<string-name>
<surname>Gandolfo</surname>, <given-names>P.</given-names>
</string-name>, 
<string-name>
<surname>Vaudry</surname>, <given-names>D.</given-names>
</string-name>, 
<string-name>
<surname>Mokni</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Leprince</surname>, <given-names>J.</given-names>
</string-name>, 
<string-name>
<surname>Hachem</surname>, <given-names>R.</given-names>
</string-name>, 
<string-name>
<surname>Vaudry</surname>, <given-names>H.</given-names>
</string-name>, et al. (<year>2011</year>). <article-title>Protective effect of the octadecaneuropeptide on hydrogen peroxide‐induced oxidative stress and cell death in cultured rat astrocytes</article-title>. <source/>Journal of Neurochemistry, <volume>118</volume>, <fpage>416</fpage>–<lpage>428</lpage>.
<pub-id pub-id-type="pmid">21599667</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0100">
<mixed-citation id="glia23136-cit-0101" publication-type="journal">
<string-name>
<surname>Hamill</surname>, <given-names>C. E.</given-names>
</string-name>, 
<string-name>
<surname>Caudle</surname>, <given-names>W. M.</given-names>
</string-name>, 
<string-name>
<surname>Richardson</surname>, <given-names>J. R.</given-names>
</string-name>, 
<string-name>
<surname>Yuan</surname>, <given-names>H.</given-names>
</string-name>, 
<string-name>
<surname>Pennell</surname>, <given-names>K. D.</given-names>
</string-name>, 
<string-name>
<surname>Greene</surname>, <given-names>J. G.</given-names>
</string-name>, … 
<string-name>
<surname>Traynelis</surname>, <given-names>S. F.</given-names>
</string-name> (<year>2007</year>). <article-title>Exacerbation of dopaminergic terminal damage in a mouse model of Parkinson's disease by the G‐protein‐coupled receptor protease‐activated receptor 1</article-title>. <source/>Molecular Pharmacology, <volume>72</volume>, <fpage>653</fpage>–<lpage>664</lpage>.
<pub-id pub-id-type="pmid">17596374</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0101">
<mixed-citation id="glia23136-cit-0102" publication-type="journal">
<string-name>
<surname>Hamill</surname>, <given-names>C. E.</given-names>
</string-name>, 
<string-name>
<surname>Mannaioni</surname>, <given-names>G.</given-names>
</string-name>, 
<string-name>
<surname>Lyuboslavsky</surname>, <given-names>P.</given-names>
</string-name>, 
<string-name>
<surname>Sastre</surname>, <given-names>A. A.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Traynelis</surname>, <given-names>S. F.</given-names>
</string-name> (<year>2009</year>). <article-title>Protease‐activated receptor 1‐dependent neuronal damage involves NMDA receptor function</article-title>. <source/>Experimental Neurology, <volume>217</volume>, <fpage>136</fpage>–<lpage>146</lpage>.
<pub-id pub-id-type="pmid">19416668</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0102">
<mixed-citation id="glia23136-cit-0103" publication-type="journal">
<string-name>
<surname>Hardy</surname>, <given-names>J.</given-names>
</string-name> &amp; 
<string-name>
<surname>Selkoe</surname>, <given-names>D. J.</given-names>
</string-name> (<year>2002</year>). <article-title>The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics</article-title>. <source/>Science, <volume>297</volume>, <fpage>353</fpage>–<lpage>356</lpage>.
<pub-id pub-id-type="pmid">12130773</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0103">
<mixed-citation id="glia23136-cit-0104" publication-type="journal">
<string-name>
<surname>Harvey</surname>, <given-names>B. K.</given-names>
</string-name>, 
<string-name>
<surname>Airavaara</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Hinzman</surname>, <given-names>J.</given-names>
</string-name>, 
<string-name>
<surname>Wires</surname>, <given-names>E. M.</given-names>
</string-name>, 
<string-name>
<surname>Chiocco</surname>, <given-names>M. J.</given-names>
</string-name>, 
<string-name>
<surname>Howard</surname>, <given-names>D. B.</given-names>
</string-name>, … 
<string-name>
<surname>Wang</surname>, <given-names>Y.</given-names>
</string-name> (<year>2011</year>). <article-title>Targeted over‐expression of glutamate transporter 1 (GLT‐1) reduces ischemic brain injury in a rat model of stroke</article-title>. <source/>PLoS One, <volume>6</volume>, <fpage>e22135</fpage>.
<pub-id pub-id-type="pmid">21853027</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0104">
<mixed-citation id="glia23136-cit-0105" publication-type="journal">
<string-name>
<surname>Hashimoto</surname>, <given-names>K.</given-names>
</string-name>, 
<string-name>
<surname>Hayashi</surname>, <given-names>Y.</given-names>
</string-name>, 
<string-name>
<surname>Inuzuka</surname>, <given-names>T.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Hozumi</surname>, <given-names>I.</given-names>
</string-name> (<year>2009</year>). <article-title>Exercise induces metallothioneins in mouse spinal cord</article-title>. <source/>Neuroscience, <volume>163</volume>, <fpage>244</fpage>–<lpage>251</lpage>.
<pub-id pub-id-type="pmid">19490933</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0105">
<mixed-citation id="glia23136-cit-0106" publication-type="journal">
<string-name>
<surname>Heales</surname>, <given-names>S. J.</given-names>
</string-name>, 
<string-name>
<surname>Lam</surname>, <given-names>A. A.</given-names>
</string-name>, 
<string-name>
<surname>Duncan</surname>, <given-names>A. J.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Land</surname>, <given-names>J. M.</given-names>
</string-name> (<year>2004</year>). <article-title>Neurodegeneration or neuroprotection: the pivotal role of astrocytes</article-title>. <source/>Neurochemical Research, <volume>29</volume>, <fpage>513</fpage>–<lpage>519</lpage>.
<pub-id pub-id-type="pmid">15038599</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0106">
<mixed-citation id="glia23136-cit-0107" publication-type="journal">
<string-name>
<surname>Herndon</surname>, <given-names>R. M.</given-names>
</string-name>, 
<string-name>
<surname>Rubinstein</surname>, <given-names>L. J.</given-names>
</string-name>, 
<string-name>
<surname>Freeman</surname>, <given-names>J. M.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Mathieson</surname>, <given-names>G.</given-names>
</string-name> (<year>1970</year>). <article-title>Light and electron microscopic observations on Rosenthal fibers in Alexander's disease and in multiple sclerosis</article-title>. <source/>Journal of Neuropathology &amp; Experimental Neurology, <volume>29</volume>, <fpage>524</fpage>–<lpage>551</lpage>.
<pub-id pub-id-type="pmid">5471920</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0107">
<mixed-citation id="glia23136-cit-0108" publication-type="journal">
<string-name>
<surname>Hertz</surname>, <given-names>L.</given-names>
</string-name>, 
<string-name>
<surname>Chen</surname>, <given-names>Y.</given-names>
</string-name>, 
<string-name>
<surname>Gibbs</surname>, <given-names>M. E.</given-names>
</string-name>, 
<string-name>
<surname>Zang</surname>, <given-names>P.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Peng</surname>, <given-names>L.</given-names>
</string-name> (<year>2004</year>). <article-title>Astrocytic adrenoceptors: A major drug target in neurological and psychiatric disorders?</article-title>
<source/>Current Drug Targets—CNS &amp; Neurological Disorders, <volume>3</volume>, <fpage>239</fpage>–<lpage>267</lpage>.
<pub-id pub-id-type="pmid">15180484</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0108">
<mixed-citation id="glia23136-cit-0109" publication-type="journal">
<string-name>
<surname>Hesdorffer</surname>, <given-names>D. C.</given-names>
</string-name>, 
<string-name>
<surname>Logroscino</surname>, <given-names>G.</given-names>
</string-name>, 
<string-name>
<surname>Benn</surname>, <given-names>E. K.</given-names>
</string-name>, 
<string-name>
<surname>Katri</surname>, <given-names>N.</given-names>
</string-name>, 
<string-name>
<surname>Cascino</surname>, <given-names>G.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Hauser</surname>, <given-names>W. A.</given-names>
</string-name> (<year>2011</year>). <article-title>Estimating risk for developing epilepsy: A population‐based study in Rochester, Minnesota</article-title>. <source/>Neurology, <volume>76</volume>, <fpage>23</fpage>–<lpage>27</lpage>.
<pub-id pub-id-type="pmid">21205691</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0109">
<mixed-citation id="glia23136-cit-0110" publication-type="journal">
<string-name>
<surname>Hidalgo</surname>, <given-names>J.</given-names>
</string-name>, 
<string-name>
<surname>Aschner</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Zatta</surname>, <given-names>P.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Vasak</surname>, <given-names>M.</given-names>
</string-name> (<year>2001</year>). <article-title>Roles of the metallothionein family of proteins in the central nervous system</article-title>. <source/>Brain Research Bulletin, <volume>55</volume>, <fpage>133</fpage>–<lpage>145</lpage>.
<pub-id pub-id-type="pmid">11470309</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0110">
<mixed-citation id="glia23136-cit-0111" publication-type="journal">
<string-name>
<surname>Hiraiwa</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Campana</surname>, <given-names>W. M.</given-names>
</string-name>, 
<string-name>
<surname>Martin</surname>, <given-names>B. M.</given-names>
</string-name>, &amp; 
<string-name>
<surname>O'Brien</surname>, <given-names>J. S.</given-names>
</string-name> (<year>1997</year>). <article-title>Prosaposin receptor: Evidence for a G‐protein‐associated receptor</article-title>. <source/>Biochemical &amp; Biophysical Research Communications, <volume>240</volume>, <fpage>415</fpage>–<lpage>418</lpage>.
<pub-id pub-id-type="pmid">9388493</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0111">
<mixed-citation id="glia23136-cit-0112" publication-type="journal">
<string-name>
<surname>Hozumi</surname>, <given-names>I.</given-names>
</string-name> (<year>2013</year>). <article-title>Roles and therapeutic potential of metallothioneins in neurodegenerative diseases</article-title>. <source/>Current Pharmaceutical Biotechnology, <volume>14</volume>, <fpage>408</fpage>–<lpage>413</lpage>.
<pub-id pub-id-type="pmid">23590138</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0112">
<mixed-citation id="glia23136-cit-0113" publication-type="journal">
<string-name>
<surname>Hsiao</surname>, <given-names>H. Y.</given-names>
</string-name>, 
<string-name>
<surname>Chen</surname>, <given-names>Y. C.</given-names>
</string-name>, 
<string-name>
<surname>Chen</surname>, <given-names>H. M.</given-names>
</string-name>, 
<string-name>
<surname>Tu</surname>, <given-names>P. H.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Chern</surname>, <given-names>Y.</given-names>
</string-name> (<year>2013</year>). <article-title>A critical role of astrocyte‐mediated nuclear factor‐kappaB‐dependent inflammation in Huntington's disease</article-title>. <source/>Human Molecular Genetics, <volume>22</volume>, <fpage>1826</fpage>–<lpage>1842</lpage>.
<pub-id pub-id-type="pmid">23372043</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0113">
<mixed-citation id="glia23136-cit-0114" publication-type="journal">
<string-name>
<surname>Hu</surname>, <given-names>Y. Y.</given-names>
</string-name>, 
<string-name>
<surname>Xu</surname>, <given-names>J.</given-names>
</string-name>, 
<string-name>
<surname>Zhang</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Wang</surname>, <given-names>D.</given-names>
</string-name>, 
<string-name>
<surname>Li</surname>, <given-names>L.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Li</surname>, <given-names>W. B.</given-names>
</string-name> (<year>2015</year>). <article-title>Ceftriaxone modulates uptake activity of glial glutamate transporter‐1 against global brain ischemia in rats</article-title>. <source/>Journal of Neurochemistry, <volume>132</volume>, <fpage>194</fpage>–<lpage>205</lpage>.
<pub-id pub-id-type="pmid">25270764</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0114">
<mixed-citation id="glia23136-cit-0115" publication-type="journal">
<string-name>
<surname>Huang</surname>, <given-names>Y. D.</given-names>
</string-name> &amp; 
<string-name>
<surname>Mucke</surname>, <given-names>L.</given-names>
</string-name> (<year>2012</year>). <article-title>Alzheimer mechanisms and therapeutic strategies</article-title>. <source/>Cell, <volume>148</volume>, <fpage>1204</fpage>–<lpage>1222</lpage>.
<pub-id pub-id-type="pmid">22424230</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0115">
<mixed-citation id="glia23136-cit-0116" publication-type="journal">
<string-name>
<surname>Huckstepp</surname>, <given-names>R. T. R.</given-names>
</string-name>, 
<string-name>
<surname>Bihi</surname>, <given-names>R. I.</given-names>
</string-name>, 
<string-name>
<surname>Eason</surname>, <given-names>R.</given-names>
</string-name>, 
<string-name>
<surname>Spyer</surname>, <given-names>K. M.</given-names>
</string-name>, 
<string-name>
<surname>Dicke</surname>, <given-names>N.</given-names>
</string-name>, 
<string-name>
<surname>Willecke</surname>, <given-names>K.</given-names>
</string-name>, … 
<string-name>
<surname>Dale</surname>, <given-names>N.</given-names>
</string-name> (<year>2010</year>). <article-title>Connexin hemichannel‐mediated CO<sub>2</sub>‐dependent release of ATP in the medulla oblongata contributes to central respiratory chemosensitivity</article-title>. <source/>Journal of Physiology—London, <volume>588</volume>, <fpage>3901</fpage>–<lpage>3920</lpage>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0116">
<mixed-citation id="glia23136-cit-0117" publication-type="journal">
<string-name>
<surname>Iliff</surname>, <given-names>J. J.</given-names>
</string-name>, 
<string-name>
<surname>Wang</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Liao</surname>, <given-names>Y.</given-names>
</string-name>, 
<string-name>
<surname>Plogg</surname>, <given-names>B. A.</given-names>
</string-name>, 
<string-name>
<surname>Peng</surname>, <given-names>W.</given-names>
</string-name>, 
<string-name>
<surname>Gundersen</surname>, <given-names>G. A.</given-names>
</string-name>, 
<string-name>
<surname>Benveniste</surname>, <given-names>H.</given-names>
</string-name>, 
<string-name>
<surname>Vates</surname>, <given-names>G. E.</given-names>
</string-name>, 
<string-name>
<surname>Deane</surname>, <given-names>R.</given-names>
</string-name>, 
<string-name>
<surname>Goldman</surname>, <given-names>S. A.</given-names>
</string-name>, et al. (<year>2012</year>). <article-title>A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta</article-title>. <source/>Science Translational Medicine, <volume>4</volume>, <fpage>147ra111</fpage>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0117">
<mixed-citation id="glia23136-cit-0118" publication-type="journal">
<string-name>
<surname>Imai</surname>, <given-names>Y.</given-names>
</string-name>, 
<string-name>
<surname>Soda</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Inoue</surname>, <given-names>H.</given-names>
</string-name>, 
<string-name>
<surname>Hattori</surname>, <given-names>N.</given-names>
</string-name>, 
<string-name>
<surname>Mizuno</surname>, <given-names>Y.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Takahashi</surname>, <given-names>R.</given-names>
</string-name> (<year>2001</year>). <article-title>An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin</article-title>. <source/>Cell, <volume>105</volume>, <fpage>891</fpage>–<lpage>902</lpage>.
<pub-id pub-id-type="pmid">11439185</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0118">
<mixed-citation id="glia23136-cit-0119" publication-type="journal">
<string-name>
<surname>Itoh</surname>, <given-names>K.</given-names>
</string-name>, 
<string-name>
<surname>Wakabayashi</surname>, <given-names>N.</given-names>
</string-name>, 
<string-name>
<surname>Katoh</surname>, <given-names>Y.</given-names>
</string-name>, 
<string-name>
<surname>Ishii</surname>, <given-names>T.</given-names>
</string-name>, 
<string-name>
<surname>Igarashi</surname>, <given-names>K.</given-names>
</string-name>, 
<string-name>
<surname>Engel</surname>, <given-names>J. D.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Yamamoto</surname>, <given-names>M.</given-names>
</string-name> (<year>1999</year>). <article-title>Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino‐terminal Neh2 domain</article-title>. <source/>Genes &amp; Developement, <volume>13</volume>, <fpage>76</fpage>–<lpage>86</lpage>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0119">
<mixed-citation id="glia23136-cit-0120" publication-type="journal">
<string-name>
<surname>Itoh</surname>, <given-names>K.</given-names>
</string-name>, 
<string-name>
<surname>Wakabayashi</surname>, <given-names>N.</given-names>
</string-name>, 
<string-name>
<surname>Katoh</surname>, <given-names>Y.</given-names>
</string-name>, 
<string-name>
<surname>Ishii</surname>, <given-names>T.</given-names>
</string-name>, 
<string-name>
<surname>O'Connor</surname>, <given-names>T.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Yamamoto</surname>, <given-names>M.</given-names>
</string-name> (<year>2003</year>). <article-title>Keap1 regulates both cytoplasmic‐nuclear shuttling and degradation of Nrf2 in response to electrophiles</article-title>. <source/>Genes Cells, <volume>8</volume>, <fpage>379</fpage>–<lpage>391</lpage>.
<pub-id pub-id-type="pmid">12653965</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0120">
<mixed-citation id="glia23136-cit-0121" publication-type="journal">
<string-name>
<surname>Iwaki</surname>, <given-names>T.</given-names>
</string-name>, 
<string-name>
<surname>Kume‐Iwaki</surname>, <given-names>A.</given-names>
</string-name>, 
<string-name>
<surname>Liem</surname>, <given-names>R. K.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Goldman</surname>, <given-names>J. E.</given-names>
</string-name> (<year>1989</year>). <article-title>Alpha B‐crystallin is expressed in non‐lenticular tissues and accumulates in Alexander's disease brain</article-title>. <source/>Cell, <volume>57</volume>, <fpage>71</fpage>–<lpage>78</lpage>.
<pub-id pub-id-type="pmid">2539261</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0121">
<mixed-citation id="glia23136-cit-0122" publication-type="journal">
<string-name>
<surname>Jack</surname>, <given-names>C. R.</given-names>, <suffix>Jr.</suffix>
</string-name>, 
<string-name>
<surname>Knopman</surname>, <given-names>D. S.</given-names>
</string-name>, 
<string-name>
<surname>Jagust</surname>, <given-names>W. J.</given-names>
</string-name>, 
<string-name>
<surname>Shaw</surname>, <given-names>L. M.</given-names>
</string-name>, 
<string-name>
<surname>Aisen</surname>, <given-names>P. S.</given-names>
</string-name>, 
<string-name>
<surname>Weiner</surname>, <given-names>M. W.</given-names>
</string-name>, … 
<string-name>
<surname>Trojanowski</surname>, <given-names>J. Q.</given-names>
</string-name> (<year>2010</year>). <article-title>Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade</article-title>. <source/>Lancet Neurology, <volume>9</volume>, <fpage>119</fpage>–<lpage>128</lpage>.
<pub-id pub-id-type="pmid">20083042</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0122">
<mixed-citation id="glia23136-cit-0123" publication-type="journal">
<string-name>
<surname>Jacob</surname>, <given-names>C. P.</given-names>
</string-name>, 
<string-name>
<surname>Koutsilieri</surname>, <given-names>E.</given-names>
</string-name>, 
<string-name>
<surname>Bartl</surname>, <given-names>J.</given-names>
</string-name>, 
<string-name>
<surname>Neuen‐Jacob</surname>, <given-names>E.</given-names>
</string-name>, 
<string-name>
<surname>Arzberger</surname>, <given-names>T.</given-names>
</string-name>, 
<string-name>
<surname>Zander</surname>, <given-names>N.</given-names>
</string-name>, … 
<string-name>
<surname>Grunblatt</surname>, <given-names>E.</given-names>
</string-name> (<year>2007</year>). <article-title>Alterations in expression of glutamatergic transporters and receptors in sporadic Alzheimer's disease</article-title>. <source/>Journal of Alzheimers Disease, <volume>11</volume>, <fpage>97</fpage>–<lpage>116</lpage>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0123">
<mixed-citation id="glia23136-cit-0124" publication-type="journal">
<string-name>
<surname>Jiang</surname>, <given-names>R.</given-names>
</string-name>, 
<string-name>
<surname>Diaz‐Castro</surname>, <given-names>B.</given-names>
</string-name>, 
<string-name>
<surname>Looger</surname>, <given-names>L. L.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Khakh</surname>, <given-names>B. S.</given-names>
</string-name> (<year>2016</year>). <article-title>Dysfunctional calcium and glutamate signaling in striatal astrocytes from Huntington's disease model mice</article-title>. <source/>Journal of Neuroscience, <volume>36</volume>, <fpage>3453</fpage>–<lpage>3470</lpage>.
<pub-id pub-id-type="pmid">27013675</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0124">
<mixed-citation id="glia23136-cit-0125" publication-type="journal">
<string-name>
<surname>Jimenez‐Blasco</surname>, <given-names>D.</given-names>
</string-name>, 
<string-name>
<surname>Santofimia‐Castano</surname>, <given-names>P.</given-names>
</string-name>, 
<string-name>
<surname>Gonzalez</surname>, <given-names>A.</given-names>
</string-name>, 
<string-name>
<surname>Almeida</surname>, <given-names>A.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Bolanos</surname>, <given-names>J. P.</given-names>
</string-name> (<year>2015</year>). <article-title>Astrocyte NMDA receptors' activity sustains neuronal survival through a Cdk5‐Nrf2 pathway</article-title>. <source/>Cell Death &amp; Differentiation, <volume>22</volume>, <fpage>1877</fpage>–<lpage>1889</lpage>.
<pub-id pub-id-type="pmid">25909891</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0125">
<mixed-citation id="glia23136-cit-0126" publication-type="journal">
<string-name>
<surname>Johnson</surname>, <given-names>D. A. &amp;</given-names>
</string-name>
<string-name>
<surname>Johnson</surname>, <given-names>J. A.</given-names>
</string-name> (<year>2015</year>). <article-title>Nrf2‐a therapeutic target for the treatment of neurodegenerative diseases</article-title>. <source/>Free Radical Biology &amp; Medicine, <volume>88</volume>, <fpage>253</fpage>–<lpage>267</lpage>.
<pub-id pub-id-type="pmid">26281945</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0126">
<mixed-citation id="glia23136-cit-0127" publication-type="journal">
<string-name>
<surname>Jorgensen</surname>, <given-names>J. R.</given-names>
</string-name>, 
<string-name>
<surname>Emerich</surname>, <given-names>D. F.</given-names>
</string-name>, 
<string-name>
<surname>Thanos</surname>, <given-names>C.</given-names>
</string-name>, 
<string-name>
<surname>Thompson</surname>, <given-names>L. H.</given-names>
</string-name>, 
<string-name>
<surname>Torp</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Bintz</surname>, <given-names>B.</given-names>
</string-name>, … 
<string-name>
<surname>Wahlberg</surname>, <given-names>L. U.</given-names>
</string-name> (<year>2011</year>). <article-title>Lentiviral delivery of meteorin protects striatal neurons against excitotoxicity and reverses motor deficits in the quinolinic acid rat model</article-title>. <source/>Neurobiology of Disease, <volume>41</volume>, <fpage>160</fpage>–<lpage>168</lpage>.
<pub-id pub-id-type="pmid">20840868</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0127">
<mixed-citation id="glia23136-cit-0128" publication-type="journal">
<string-name>
<surname>Jorgensen</surname>, <given-names>J. R.</given-names>
</string-name>, 
<string-name>
<surname>Xu</surname>, <given-names>X. J.</given-names>
</string-name>, 
<string-name>
<surname>Arnold</surname>, <given-names>H. M.</given-names>
</string-name>, 
<string-name>
<surname>Munro</surname>, <given-names>G.</given-names>
</string-name>, 
<string-name>
<surname>Hao</surname>, <given-names>J. X.</given-names>
</string-name>, 
<string-name>
<surname>Pepinsky</surname>, <given-names>B.</given-names>
</string-name>, 
<string-name>
<surname>Huang</surname>, <given-names>C.</given-names>
</string-name>, 
<string-name>
<surname>Gong</surname>, <given-names>B. J.</given-names>
</string-name>, 
<string-name>
<surname>Wiesenfeld‐Hallin</surname>, <given-names>Z.</given-names>
</string-name>, 
<string-name>
<surname>Wahlberg</surname>, <given-names>L. U.</given-names>
</string-name>, et al. (<year>2012</year>). <article-title>Meteorin reverses hypersensitivity in rat models of neuropathic pain</article-title>. <source/>Experimental Neurology, <volume>237</volume>, <fpage>260</fpage>–<lpage>266</lpage>.
<pub-id pub-id-type="pmid">22766205</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0128">
<mixed-citation id="glia23136-cit-0129" publication-type="journal">
<string-name>
<surname>Joshi</surname>, <given-names>G.</given-names>
</string-name> &amp; 
<string-name>
<surname>Johnson</surname>, <given-names>J. A.</given-names>
</string-name> (<year>2012</year>). <article-title>The Nrf2‐ARE pathway: A valuable therapeutic target for the treatment of neurodegenerative diseases</article-title>. <source/>Recent Patents on CNS Drug Discovery, <volume>7</volume>, <fpage>218</fpage>–<lpage>229</lpage>.
<pub-id pub-id-type="pmid">22742419</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0129">
<mixed-citation id="glia23136-cit-0130" publication-type="journal">
<string-name>
<surname>Jourdain</surname>, <given-names>P.</given-names>
</string-name>, 
<string-name>
<surname>Allaman</surname>, <given-names>I.</given-names>
</string-name>, 
<string-name>
<surname>Rothenfusser</surname>, <given-names>K.</given-names>
</string-name>, 
<string-name>
<surname>Fiumelli</surname>, <given-names>H.</given-names>
</string-name>, 
<string-name>
<surname>Marquet</surname>, <given-names>P.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Magistretti</surname>, <given-names>P. J.</given-names>
</string-name> (<year>2016</year>). <article-title>l‐Lactate protects neurons against excitotoxicity: Implication of an ATP‐mediated signaling cascade</article-title>. <source/>Scientific Reports, <volume>6</volume>, <fpage>21250</fpage>.
<pub-id pub-id-type="pmid">26893204</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0130">
<mixed-citation id="glia23136-cit-0131" publication-type="journal">
<string-name>
<surname>Junge</surname>, <given-names>C. E.</given-names>
</string-name>, 
<string-name>
<surname>Lee</surname>, <given-names>C. J.</given-names>
</string-name>, 
<string-name>
<surname>Hubbard</surname>, <given-names>K. B.</given-names>
</string-name>, 
<string-name>
<surname>Zhang</surname>, <given-names>Z.</given-names>
</string-name>, 
<string-name>
<surname>Olson</surname>, <given-names>J. J.</given-names>
</string-name>, 
<string-name>
<surname>Hepler</surname>, <given-names>J. R.</given-names>
</string-name>, … 
<string-name>
<surname>Traynelis</surname>
<given-names>SF.</given-names>
</string-name> (<year>2004</year>). <article-title>Protease‐activated receptor‐1 in human brain: Localization and functional expression in astrocytes</article-title>. <source/>Experimental Neurology, <volume>188</volume>, <fpage>94</fpage>–<lpage>103</lpage>.
<pub-id pub-id-type="pmid">15191806</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0131">
<mixed-citation id="glia23136-cit-0132" publication-type="journal">
<string-name>
<surname>Junge</surname>, <given-names>C. E.</given-names>
</string-name>, 
<string-name>
<surname>Sugawara</surname>, <given-names>T.</given-names>
</string-name>, 
<string-name>
<surname>Mannaioni</surname>, <given-names>G.</given-names>
</string-name>, 
<string-name>
<surname>Alagarsamy</surname>, <given-names>S.</given-names>
</string-name>, 
<string-name>
<surname>Conn</surname>, <given-names>P. J.</given-names>
</string-name>, 
<string-name>
<surname>Brat</surname>, <given-names>D. J.</given-names>
</string-name>, … 
<string-name>
<surname>Traynelis</surname>, <given-names>S. F.</given-names>
</string-name> (<year>2003</year>). <article-title>The contribution of protease‐activated receptor 1 to neuronal damage caused by transient focal cerebral ischemia</article-title>. <source/>Proceedings of the National Academy of Sciences of United States of America, <volume>100</volume>, <fpage>13019</fpage>–<lpage>13024</lpage>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0132">
<mixed-citation id="glia23136-cit-0133" publication-type="journal">
<string-name>
<surname>Karagiannis</surname>, <given-names>A.</given-names>
</string-name>, 
<string-name>
<surname>Sylantyev</surname>, <given-names>S.</given-names>
</string-name>, 
<string-name>
<surname>Hadjihambi</surname>, <given-names>A.</given-names>
</string-name>, 
<string-name>
<surname>Hosford</surname>, <given-names>P. S.</given-names>
</string-name>, 
<string-name>
<surname>Kasparov</surname>, <given-names>S.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Gourine</surname>, <given-names>A. V.</given-names>
</string-name> (<year>2016</year>). <article-title>Hemichannel‐mediated release of lactate</article-title>. <source/>Journal of Cerebral Blood Flow Metabolism, <volume>36</volume>, <fpage>1202</fpage>–<lpage>1211</lpage>.
<pub-id pub-id-type="pmid">26661210</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0133">
<mixed-citation id="glia23136-cit-0134" publication-type="journal">
<string-name>
<surname>Kelsey</surname>, <given-names>J. E.</given-names>
</string-name> &amp; 
<string-name>
<surname>Neville</surname>, <given-names>C.</given-names>
</string-name> (<year>2014</year>). <article-title>The effects of the beta‐lactam antibiotic, ceftriaxone, on forepaw stepping and L‐DOPA‐induced dyskinesia in a rodent model of Parkinson's disease</article-title>. <source/>Psychopharmacology (Berl), <volume>231</volume>, <fpage>2405</fpage>–<lpage>2415</lpage>.
<pub-id pub-id-type="pmid">24402134</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0134">
<mixed-citation id="glia23136-cit-0135" publication-type="journal">
<string-name>
<surname>Kensler</surname>, <given-names>T. W.</given-names>
</string-name>, 
<string-name>
<surname>Wakabayash</surname>, <given-names>N.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Biswal</surname>, <given-names>S.</given-names>
</string-name> (<year>2007</year>). <article-title>Cell survival responses to environmental stresses via the Keap1‐Nrf2‐ARE pathway</article-title>. <source/>Annual Reviews in Pharmacology &amp; Toxicology, <volume>47</volume>, <fpage>89</fpage>–<lpage>116</lpage>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0135">
<mixed-citation id="glia23136-cit-0136" publication-type="journal">
<string-name>
<surname>Kim</surname>, <given-names>G. H.</given-names>
</string-name>, 
<string-name>
<surname>Kim</surname>, <given-names>J. E.</given-names>
</string-name>, 
<string-name>
<surname>Rhie</surname>, <given-names>S. J.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Yoon</surname>, <given-names>S.</given-names>
</string-name> (<year>2015</year>). <article-title>The role of oxidative stress in neurodegenerative diseases</article-title>. <source/>Experimental Neurobiology, <volume>24</volume>, <fpage>325</fpage>–<lpage>340</lpage>.
<pub-id pub-id-type="pmid">26713080</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0136">
<mixed-citation id="glia23136-cit-0137" publication-type="journal">
<string-name>
<surname>Kim</surname>, <given-names>K.</given-names>
</string-name>, 
<string-name>
<surname>Lee</surname>, <given-names>S. G.</given-names>
</string-name>, 
<string-name>
<surname>Kegelman</surname>, <given-names>T. P.</given-names>
</string-name>, 
<string-name>
<surname>Su</surname>, <given-names>Z. Z.</given-names>
</string-name>, 
<string-name>
<surname>Das</surname>, <given-names>S. K.</given-names>
</string-name>, 
<string-name>
<surname>Dash</surname>, <given-names>R.</given-names>
</string-name>, 
<string-name>
<surname>Dasgupta</surname>, <given-names>S.</given-names>
</string-name>, 
<string-name>
<surname>Barral</surname>, <given-names>P. M.</given-names>
</string-name>, 
<string-name>
<surname>Hedvat</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Diaz</surname>, <given-names>P.</given-names>
</string-name>, et al. (<year>2011</year>). <article-title>Role of excitatory amino acid transporter‐2 (EAAT2) and glutamate in neurodegeneration: opportunities for developing novel therapeutics</article-title>. <source/>Journal of Cell Physiology, <volume>226</volume>, <fpage>2484</fpage>–<lpage>2493</lpage>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0137">
<mixed-citation id="glia23136-cit-0138" publication-type="journal">
<string-name>
<surname>King</surname>, <given-names>L. S.</given-names>
</string-name>, 
<string-name>
<surname>Yasui</surname>, <given-names>M.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Agre</surname>, <given-names>P.</given-names>
</string-name> (<year>2000</year>). <article-title>Aquaporins in health and disease</article-title>. <source/>Molecular Medicine Today, <volume>6</volume>, <fpage>60</fpage>–<lpage>65</lpage>.
<pub-id pub-id-type="pmid">10652478</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0138">
<mixed-citation id="glia23136-cit-0139" publication-type="journal">
<string-name>
<surname>Klionsky</surname>, <given-names>D. J.</given-names>
</string-name>, 
<string-name>
<surname>Abdelmohsen</surname>, <given-names>K.</given-names>
</string-name>, 
<string-name>
<surname>Abe</surname>, <given-names>A.</given-names>
</string-name>, 
<string-name>
<surname>Abedin</surname>, <given-names>M. J.</given-names>
</string-name>, 
<string-name>
<surname>Abeliovich</surname>, <given-names>H.</given-names>
</string-name>, 
<string-name>
<surname>Acevedo Arozena</surname>, <given-names>A.</given-names>
</string-name>, 
<string-name>
<surname>Adachi</surname>, <given-names>H.</given-names>
</string-name>, 
<string-name>
<surname>Adams</surname>, <given-names>C. M.</given-names>
</string-name>, 
<string-name>
<surname>Adams</surname>, <given-names>P. D.</given-names>
</string-name>, 
<string-name>
<surname>Adeli</surname>, <given-names>K.</given-names>
</string-name>, et al. (<year>2016</year>). <article-title>Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)</article-title>. <source/>Autophagy, <volume>12</volume>, <fpage>1</fpage>–<lpage>222</lpage>.
<pub-id pub-id-type="pmid">26799652</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0139">
<mixed-citation id="glia23136-cit-0140" publication-type="journal">
<string-name>
<surname>Koistinaho</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Lin</surname>, <given-names>S.</given-names>
</string-name>, 
<string-name>
<surname>Wu</surname>, <given-names>X.</given-names>
</string-name>, 
<string-name>
<surname>Esterman</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Koger</surname>, <given-names>D.</given-names>
</string-name>, 
<string-name>
<surname>Hanson</surname>, <given-names>J.</given-names>
</string-name>, 
<string-name>
<surname>Higgs</surname>, <given-names>R.</given-names>
</string-name>, 
<string-name>
<surname>Liu</surname>, <given-names>F.</given-names>
</string-name>, 
<string-name>
<surname>Malkani</surname>, <given-names>S.</given-names>
</string-name>, 
<string-name>
<surname>Bales</surname>, <given-names>K. R.</given-names>
</string-name>, et al. (<year>2004</year>). <article-title>Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid‐beta peptides</article-title>. <source/>Nature Medicine, <volume>10</volume>, <fpage>719</fpage>–<lpage>726</lpage>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0140">
<mixed-citation id="glia23136-cit-0141" publication-type="journal">
<string-name>
<surname>Kong</surname>, <given-names>Q.</given-names>
</string-name>, 
<string-name>
<surname>Chang</surname>, <given-names>L. C.</given-names>
</string-name>, 
<string-name>
<surname>Takahashi</surname>, <given-names>K.</given-names>
</string-name>, 
<string-name>
<surname>Liu</surname>, <given-names>Q.</given-names>
</string-name>, 
<string-name>
<surname>Schulte</surname>, <given-names>D. A.</given-names>
</string-name>, 
<string-name>
<surname>Lai</surname>, <given-names>L.</given-names>
</string-name>, 
<string-name>
<surname>Ibabao</surname>, <given-names>B.</given-names>
</string-name>, 
<string-name>
<surname>Lin</surname>, <given-names>Y.</given-names>
</string-name>, 
<string-name>
<surname>Stouffer</surname>, <given-names>N.</given-names>
</string-name>, 
<string-name>
<surname>Das Mukhopadhyay</surname>, <given-names>C.</given-names>
</string-name> et al. (<year>2014</year>). <article-title>Small‐molecule activator of glutamate transporter EAAT2 translation provides neuroprotection</article-title>. <source/>Journal of Clinical Investigation, <volume>124</volume>, <fpage>1255</fpage>–<lpage>1267</lpage>.
<pub-id pub-id-type="pmid">24569372</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0141">
<mixed-citation id="glia23136-cit-0142" publication-type="journal">
<string-name>
<surname>Kong</surname>, <given-names>Q. M.</given-names>
</string-name>, 
<string-name>
<surname>Takahashi</surname>, <given-names>K.</given-names>
</string-name>, 
<string-name>
<surname>Schulte</surname>, <given-names>D.</given-names>
</string-name>, 
<string-name>
<surname>Stouffer</surname>, <given-names>N.</given-names>
</string-name>, 
<string-name>
<surname>Lin</surname>, <given-names>Y. C.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Lin</surname>, <given-names>C. L. G.</given-names>
</string-name> (<year>2012</year>). <article-title>Increased glial glutamate transporter EAAT2 expression reduces epileptogenic processes following pilocarpine‐induced status epilepticus</article-title>. <source/>Neurobiology of Disease, <volume>47</volume>, <fpage>145</fpage>–<lpage>154</lpage>.
<pub-id pub-id-type="pmid">22513140</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0142">
<mixed-citation id="glia23136-cit-0143" publication-type="journal">
<string-name>
<surname>Kraft</surname>, <given-names>A. D.</given-names>
</string-name>, 
<string-name>
<surname>Johnson</surname>, <given-names>D. A.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Johnson</surname>, <given-names>J. A.</given-names>
</string-name> (<year>2004</year>). <article-title>Nuclear factor E2‐related factor 2‐dependent antioxidant response element activation by tert‐butylhydroquinone and sulforaphane occurring preferentially in astrocytes conditions neurons against oxidative insult</article-title>. <source/>Journal of Neuroscience, <volume>24</volume>, <fpage>1101</fpage>–<lpage>1112</lpage>.
<pub-id pub-id-type="pmid">14762128</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0143">
<mixed-citation id="glia23136-cit-0144" publication-type="journal">
<string-name>
<surname>Kuchibhotla</surname>, <given-names>K. V.</given-names>
</string-name>, 
<string-name>
<surname>Lattarulo</surname>, <given-names>C. R.</given-names>
</string-name>, 
<string-name>
<surname>Hyman</surname>, <given-names>B. T.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Bacskai</surname>, <given-names>B. J.</given-names>
</string-name> (<year>2009</year>). <article-title>Synchronous hyperactivity and intercellular calcium waves in astrocytes in Alzheimer mice</article-title>. <source/>Science, <volume>323</volume>, <fpage>1211</fpage>–<lpage>1215</lpage>.
<pub-id pub-id-type="pmid">19251629</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0144">
<mixed-citation id="glia23136-cit-0145" publication-type="journal">
<string-name>
<surname>Kurt</surname>, <given-names>M. A.</given-names>
</string-name>, 
<string-name>
<surname>Davies</surname>, <given-names>D. C.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Kidd</surname>, <given-names>M.</given-names>
</string-name> (<year>1999</year>). <article-title>Beta‐amyloid immunoreactivity in astrocytes in Alzheimer's disease brain biopsies: An electron microscope study</article-title>. <source/>Experimental Neurology, <volume>158</volume>, <fpage>221</fpage>–<lpage>228</lpage>.
<pub-id pub-id-type="pmid">10448435</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0145">
<mixed-citation id="glia23136-cit-0146" publication-type="journal">
<string-name>
<surname>Lai</surname>, <given-names>T. W.</given-names>
</string-name>, 
<string-name>
<surname>Zhang</surname>, <given-names>S.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Wang</surname>, <given-names>Y. T.</given-names>
</string-name> (<year>2014</year>). <article-title>Excitotoxicity and stroke: Identifying novel targets for neuroprotection</article-title>. <source/>Progress in Neurobiology, <volume>115</volume>, <fpage>157</fpage>–<lpage>188</lpage>.
<pub-id pub-id-type="pmid">24361499</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0146">
<mixed-citation id="glia23136-cit-0147" publication-type="journal">
<string-name>
<surname>Lauriat</surname>, <given-names>T. L.</given-names>
</string-name> &amp; 
<string-name>
<surname>McInnes</surname>, <given-names>L. A.</given-names>
</string-name> (<year>2007</year>). <article-title>EAAT2 regulation and splicing: Relevance to psychiatric and neurological disorders</article-title>. <source/>Molecular Psychiatry, <volume>12</volume>, <fpage>1065</fpage>–<lpage>1078</lpage>.
<pub-id pub-id-type="pmid">17684493</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0147">
<mixed-citation id="glia23136-cit-0148" publication-type="journal">
<string-name>
<surname>Lee</surname>, <given-names>C. J.</given-names>
</string-name>, 
<string-name>
<surname>Mannaioni</surname>, <given-names>G.</given-names>
</string-name>, 
<string-name>
<surname>Yuan</surname>, <given-names>H.</given-names>
</string-name>, 
<string-name>
<surname>Woo</surname>, <given-names>D. H.</given-names>
</string-name>, 
<string-name>
<surname>Gingrich</surname>, <given-names>M. B.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Traynelis</surname>, <given-names>S. F.</given-names>
</string-name> (<year>2007</year>). <article-title>Astrocytic control of synaptic NMDA receptors</article-title>. <source/>Journal of Physiology, <volume>581</volume>, <fpage>1057</fpage>–<lpage>1081</lpage>.
<pub-id pub-id-type="pmid">17412766</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0148">
<mixed-citation id="glia23136-cit-0149" publication-type="journal">
<string-name>
<surname>Lee</surname>, <given-names>H. S.</given-names>
</string-name>, 
<string-name>
<surname>Han</surname>, <given-names>J.</given-names>
</string-name>, 
<string-name>
<surname>Lee</surname>, <given-names>S. H.</given-names>
</string-name>, 
<string-name>
<surname>Park</surname>, <given-names>J. A.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Kim</surname>, <given-names>K. W.</given-names>
</string-name> (<year>2010</year>). <article-title>Meteorin promotes the formation of GFAP‐positive glia via activation of the Jak‐STAT3 pathway</article-title>. <source/>Journal of Cell Science, <volume>123</volume>, <fpage>1959</fpage>–<lpage>1968</lpage>.
<pub-id pub-id-type="pmid">20460434</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0149">
<mixed-citation id="glia23136-cit-0150" publication-type="journal">
<string-name>
<surname>Lee</surname>, <given-names>H. S.</given-names>
</string-name>, 
<string-name>
<surname>Lee</surname>, <given-names>S. H.</given-names>
</string-name>, 
<string-name>
<surname>Cha</surname>, <given-names>J. H.</given-names>
</string-name>, 
<string-name>
<surname>Seo</surname>, <given-names>J. H.</given-names>
</string-name>, 
<string-name>
<surname>Ahn</surname>, <given-names>B. J.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Kim</surname>, <given-names>K. W.</given-names>
</string-name> (<year>2015</year>). <article-title>Meteorin is upregulated in reactive astrocytes and functions as a negative feedback effector in reactive gliosis</article-title>. <source/>Molecular Medicine Reports, <volume>12</volume>, <fpage>1817</fpage>–<lpage>1823</lpage>.
<pub-id pub-id-type="pmid">25873382</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0150">
<mixed-citation id="glia23136-cit-0151" publication-type="journal">
<string-name>
<surname>Lee</surname>, <given-names>J. M.</given-names>
</string-name>, 
<string-name>
<surname>Calkins</surname>, <given-names>M. J.</given-names>
</string-name>, 
<string-name>
<surname>Chan</surname>, <given-names>K. M.</given-names>
</string-name>, 
<string-name>
<surname>Kan</surname>, <given-names>Y. W.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Johnson</surname>, <given-names>J. A.</given-names>
</string-name> (<year>2003</year>). <article-title>Identification of the NF‐E2‐related factor‐2‐dependent genes conferring protection against oxidative stress in primary cortical astrocytes using oligonucleotide microarray analysis</article-title>. <source/>Journal of Biological Chemistry, <volume>278</volume>, <fpage>12029</fpage>–<lpage>12038</lpage>.
<pub-id pub-id-type="pmid">12556532</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0151">
<mixed-citation id="glia23136-cit-0152" publication-type="journal">
<string-name>
<surname>Lee</surname>, <given-names>Y.</given-names>
</string-name>, 
<string-name>
<surname>Morrison</surname>, <given-names>B. M.</given-names>
</string-name>, 
<string-name>
<surname>Li</surname>, <given-names>Y.</given-names>
</string-name>, 
<string-name>
<surname>Lengacher</surname>, <given-names>S.</given-names>
</string-name>, 
<string-name>
<surname>Farah</surname>, <given-names>M. H.</given-names>
</string-name>, 
<string-name>
<surname>Hoffman</surname>, <given-names>P. N.</given-names>
</string-name>, 
<string-name>
<surname>Liu</surname>, <given-names>Y.</given-names>
</string-name>, 
<string-name>
<surname>Tsingalia</surname>, <given-names>A.</given-names>
</string-name>, 
<string-name>
<surname>Jin</surname>, <given-names>L.</given-names>
</string-name>, 
<string-name>
<surname>Zhang</surname>, <given-names>P. W.</given-names>
</string-name>, et al. (<year>2012</year>). <article-title>Oligodendroglia metabolically support axons and contribute to neurodegeneration</article-title>. <source/>Nature, <volume>487</volume>, <fpage>443</fpage>–<lpage>448</lpage>.
<pub-id pub-id-type="pmid">22801498</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0152">
<mixed-citation id="glia23136-cit-0153" publication-type="journal">
<string-name>
<surname>Leng</surname>, <given-names>N.</given-names>
</string-name>, 
<string-name>
<surname>Gu</surname>, <given-names>G. B.</given-names>
</string-name>, 
<string-name>
<surname>Simerly</surname>, <given-names>R. B.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Spindel</surname>, <given-names>E. R.</given-names>
</string-name> (<year>1999</year>). <article-title>Molecular cloning and characterization of two putative G protein‐coupled receptors which are highly expressed in the central nervous system. <italic>Molecular</italic>
</article-title>
<source/>Brain Research, <volume>69</volume>, <fpage>73</fpage>–<lpage>83</lpage>.
<pub-id pub-id-type="pmid">10350639</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0153">
<mixed-citation id="glia23136-cit-0154" publication-type="journal">
<string-name>
<surname>Leybaert</surname>, <given-names>L.</given-names>
</string-name>, 
<string-name>
<surname>Braet</surname>, <given-names>K.</given-names>
</string-name>, 
<string-name>
<surname>Vandamme</surname>, <given-names>W.</given-names>
</string-name>, 
<string-name>
<surname>Cabooter</surname>, <given-names>L.</given-names>
</string-name>, 
<string-name>
<surname>Martin</surname>, <given-names>P. E.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Evans</surname>, <given-names>W. H.</given-names>
</string-name> (<year>2003</year>). <article-title>Connexin channels, connexin mimetic peptides and ATP release</article-title>. <source/>Cell Communication &amp; Adhesion, <volume>10</volume>, <fpage>251</fpage>–<lpage>257</lpage>.
<pub-id pub-id-type="pmid">14681025</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0154">
<mixed-citation id="glia23136-cit-0155" publication-type="journal">
<string-name>
<surname>Li</surname>, <given-names>C.</given-names>
</string-name>, 
<string-name>
<surname>Zhao</surname>, <given-names>R.</given-names>
</string-name>, 
<string-name>
<surname>Gao</surname>, <given-names>K.</given-names>
</string-name>, 
<string-name>
<surname>Wei</surname>, <given-names>Z.</given-names>
</string-name>, 
<string-name>
<surname>Yin</surname>, <given-names>M. Y.</given-names>
</string-name>, 
<string-name>
<surname>Lau</surname>, <given-names>L. T.</given-names>
</string-name>, 
<string-name>
<surname>Chui</surname>, <given-names>D.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Yu</surname>, <given-names>A. C.</given-names>
</string-name> (<year>2011</year>). <article-title>Astrocytes: Implications for neuroinflammatory pathogenesis of Alzheimer's disease</article-title>. <source/>Current Alzheimer Research, <volume>8</volume>, <fpage>67</fpage>–<lpage>80</lpage>.
<pub-id pub-id-type="pmid">21143158</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0155">
<mixed-citation id="glia23136-cit-0156" publication-type="journal">
<string-name>
<surname>Liu</surname>, <given-names>A. Y. C.</given-names>
</string-name>, 
<string-name>
<surname>Mathur</surname>, <given-names>R.</given-names>
</string-name>, 
<string-name>
<surname>Mei</surname>, <given-names>N.</given-names>
</string-name>, 
<string-name>
<surname>Langhammer</surname>, <given-names>C. G.</given-names>
</string-name>, 
<string-name>
<surname>Babiarz</surname>, <given-names>B.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Firestein</surname>, <given-names>B. L.</given-names>
</string-name> (<year>2011</year>). <article-title>Neuroprotective drug riluzole amplifies the heat shock factor 1 (HSF1)‐ and glutamate transporter 1 (GLT1)‐dependent cytoprotective mechanisms for neuronal survival</article-title>. <source/>Journal of Biological Chemistry, <volume>286</volume>, <fpage>2785</fpage>–<lpage>2794</lpage>.
<pub-id pub-id-type="pmid">21098017</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0156">
<mixed-citation id="glia23136-cit-0157" publication-type="journal">
<string-name>
<surname>Liu</surname>, <given-names>Z.</given-names>
</string-name> &amp; 
<string-name>
<surname>Chopp</surname>, <given-names>M.</given-names>
</string-name> (<year>2015</year>). <article-title>Astrocytes, therapeutic targets for neuroprotection and neurorestoration in ischemic stroke</article-title>. <source/>Progress in Neurobiology, <volume>144</volume>, <fpage>103</fpage>–<lpage>120</lpage>.
<pub-id pub-id-type="pmid">26455456</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0157">
<mixed-citation id="glia23136-cit-0158" publication-type="journal">
<string-name>
<surname>Loewenstein</surname>, <given-names>W. R.</given-names>
</string-name> (<year>1981</year>). <article-title>Junctional intercellular communication: The cell‐to‐cell membrane channel</article-title>. <source/>Physiological Reviews, <volume>61</volume>, <fpage>829</fpage>–<lpage>913</lpage>.
<pub-id pub-id-type="pmid">6270711</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0158">
<mixed-citation id="glia23136-cit-0159" publication-type="journal">
<string-name>
<surname>Lovatt</surname>, <given-names>D.</given-names>
</string-name>, 
<string-name>
<surname>Sonnewald</surname>, <given-names>U.</given-names>
</string-name>, 
<string-name>
<surname>Waagepetersen</surname>, <given-names>H. S.</given-names>
</string-name>, 
<string-name>
<surname>Schousboe</surname>, <given-names>A.</given-names>
</string-name>, 
<string-name>
<surname>He</surname>, <given-names>W.</given-names>
</string-name>, 
<string-name>
<surname>Lin</surname>, <given-names>J. H.</given-names>
</string-name>, 
<string-name>
<surname>Han</surname>, <given-names>X.</given-names>
</string-name>, 
<string-name>
<surname>Takano</surname>, <given-names>T.</given-names>
</string-name>, 
<string-name>
<surname>Wang</surname>, <given-names>S.</given-names>
</string-name>, 
<string-name>
<surname>Sim</surname>, <given-names>F. J.</given-names>
</string-name>, et al. (<year>2007</year>). <article-title>The transcriptome and metabolic gene signature of protoplasmic astrocytes in the adult murine cortex</article-title>. <source/>Journal of Neuroscience, <volume>27</volume>, <fpage>12255</fpage>–<lpage>12266</lpage>.
<pub-id pub-id-type="pmid">17989291</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0159">
<mixed-citation id="glia23136-cit-0160" publication-type="journal">
<string-name>
<surname>Low</surname>, <given-names>K.</given-names>
</string-name> &amp; 
<string-name>
<surname>Aebischer</surname>, <given-names>P.</given-names>
</string-name> (<year>2012</year>). <article-title>Use of viral vectors to create animal models for Parkinson's disease</article-title>. <source/>Neurobiology Disease, <volume>48</volume>, <fpage>189</fpage>–<lpage>201</lpage>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0160">
<mixed-citation id="glia23136-cit-0161" publication-type="journal">
<string-name>
<surname>Luo</surname>, <given-names>W.</given-names>
</string-name>, 
<string-name>
<surname>Wang</surname>, <given-names>Y.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Reiser</surname>, <given-names>G.</given-names>
</string-name> (<year>2007</year>). <article-title>Protease‐activated receptors in the brain: Receptor expression, activation, and functions in neurodegeneration and neuroprotection</article-title>. <source/>Brain Research Reviews, <volume>56</volume>, <fpage>331</fpage>–<lpage>345</lpage>.
<pub-id pub-id-type="pmid">17915333</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0161">
<mixed-citation id="glia23136-cit-0162" publication-type="journal">
<string-name>
<surname>Malagon</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Vaudry</surname>, <given-names>H.</given-names>
</string-name>, 
<string-name>
<surname>Van Strien</surname>, <given-names>F.</given-names>
</string-name>, 
<string-name>
<surname>Pelletier</surname>, <given-names>G.</given-names>
</string-name>, 
<string-name>
<surname>Gracia‐Navarro</surname>, <given-names>F.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Tonon</surname>, <given-names>M. C.</given-names>
</string-name> (<year>1993</year>). <article-title>Ontogeny of diazepam‐binding inhibitor‐related peptides (endozepines) in the rat brain</article-title>. <source/>Neuroscience, <volume>57</volume>, <fpage>777</fpage>–<lpage>786</lpage>.
<pub-id pub-id-type="pmid">8309536</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0162">
<mixed-citation id="glia23136-cit-0163" publication-type="journal">
<string-name>
<surname>Mangiarini</surname>, <given-names>L.</given-names>
</string-name>, 
<string-name>
<surname>Sathasivam</surname>, <given-names>K.</given-names>
</string-name>, 
<string-name>
<surname>Seller</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Cozens</surname>, <given-names>B.</given-names>
</string-name>, 
<string-name>
<surname>Harper</surname>, <given-names>A.</given-names>
</string-name>, 
<string-name>
<surname>Hetherington</surname>, <given-names>C.</given-names>
</string-name>, 
<string-name>
<surname>Lawton</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Trottier</surname>, <given-names>Y.</given-names>
</string-name>, 
<string-name>
<surname>Lehrach</surname>, <given-names>H.</given-names>
</string-name>, 
<string-name>
<surname>Davies</surname>, <given-names>S. W.</given-names>
</string-name>, et al. (<year>1996</year>). <article-title>Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice</article-title>. <source/>Cell, <volume>87</volume>, <fpage>493</fpage>–<lpage>506</lpage>.
<pub-id pub-id-type="pmid">8898202</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0163">
<mixed-citation id="glia23136-cit-0164" publication-type="journal">
<string-name>
<surname>Manley</surname>, <given-names>G. T.</given-names>
</string-name>, 
<string-name>
<surname>Fujimura</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Ma</surname>, <given-names>T.</given-names>
</string-name>, 
<string-name>
<surname>Noshita</surname>, <given-names>N.</given-names>
</string-name>, 
<string-name>
<surname>Filiz</surname>, <given-names>F.</given-names>
</string-name>, 
<string-name>
<surname>Bollen</surname>, <given-names>A. W.</given-names>
</string-name>, … 
<string-name>
<surname>Verkman</surname>, <given-names>A. S.</given-names>
</string-name> (<year>2000</year>). <article-title>Aquaporin‐4 deletion in mice reduces brain edema after acute water intoxication and ischemic stroke</article-title>. <source/>Nature Medicine, <volume>6</volume>,<fpage>159</fpage>–<lpage>163</lpage>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0164">
<mixed-citation id="glia23136-cit-0165" publication-type="journal">
<string-name>
<surname>Maragakis</surname>, <given-names>N. J.</given-names>
</string-name> &amp; 
<string-name>
<surname>Rothstein</surname>, <given-names>J. D.</given-names>
</string-name> (<year>2001</year>). <article-title>Glutamate transporters in neurologic disease</article-title>. <source/>Archives of Neurology, <volume>58</volume>, <fpage>365</fpage>–<lpage>370</lpage>.
<pub-id pub-id-type="pmid">11255439</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0165">
<mixed-citation id="glia23136-cit-0166" publication-type="journal">
<string-name>
<surname>Marazziti</surname>, <given-names>D.</given-names>
</string-name>, 
<string-name>
<surname>Di Pietro</surname>, <given-names>C.</given-names>
</string-name>, 
<string-name>
<surname>Golini</surname>, <given-names>E.</given-names>
</string-name>, 
<string-name>
<surname>Mandillo</surname>, <given-names>S.</given-names>
</string-name>, 
<string-name>
<surname>La Sala</surname>, <given-names>G.</given-names>
</string-name>, 
<string-name>
<surname>Matteoni</surname>, <given-names>R.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Tocchini‐Valentini</surname>, <given-names>G. P.</given-names>
</string-name> (<year>2013</year>). <article-title>Precocious cerebellum development and improved motor functions in mice lacking the astrocyte cilium‐, patched 1‐associated Gpr37l1 receptor</article-title>. <source/>Proceedings of the National Academy of Science of United States of America, <volume>110</volume>, <fpage>16486</fpage>–<lpage>16491</lpage>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0166">
<mixed-citation id="glia23136-cit-0167" publication-type="journal">
<string-name>
<surname>Marazziti</surname>, <given-names>D.</given-names>
</string-name>, 
<string-name>
<surname>Di Pietro</surname>, <given-names>C.</given-names>
</string-name>, 
<string-name>
<surname>Mandillo</surname>, <given-names>S.</given-names>
</string-name>, 
<string-name>
<surname>Golini</surname>, <given-names>E.</given-names>
</string-name>, 
<string-name>
<surname>Matteoni</surname>, <given-names>R.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Tocchini‐Valentini</surname>, <given-names>G. P.</given-names>
</string-name> (<year>2011</year>). <article-title>Absence of the GPR37/PAEL receptor impairs striatal Akt and ERK2 phosphorylation, DeltaFosB expression, and conditioned place preference to amphetamine and cocaine</article-title>. <source/>FASEB Journal, <volume>25</volume>, <fpage>2071</fpage>–<lpage>2081</lpage>.
<pub-id pub-id-type="pmid">21372109</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0167">
<mixed-citation id="glia23136-cit-0168" publication-type="journal">
<string-name>
<surname>Marazziti</surname>, <given-names>D.</given-names>
</string-name>, 
<string-name>
<surname>Golini</surname>, <given-names>E.</given-names>
</string-name>, 
<string-name>
<surname>Mandillo</surname>, <given-names>S.</given-names>
</string-name>, 
<string-name>
<surname>Magrelli</surname>, <given-names>A.</given-names>
</string-name>, 
<string-name>
<surname>Witke</surname>, <given-names>W.</given-names>
</string-name>, 
<string-name>
<surname>Matteoni</surname>, <given-names>R.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Tocchini‐Valentini</surname>, <given-names>G. P.</given-names>
</string-name> (<year>2004</year>). <article-title>Altered dopamine signaling and MPTP resistance in mice lacking the Parkinson's disease‐associated GPR37/parkin‐associated endothelin‐like receptor</article-title>. <source/>Proceedings of the National Academy of Science of United States of America, <volume>101</volume>, <fpage>10189</fpage>–<lpage>10194</lpage>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0168">
<mixed-citation id="glia23136-cit-0169" publication-type="journal">
<string-name>
<surname>Marazziti</surname>, <given-names>D.</given-names>
</string-name>, 
<string-name>
<surname>Mandillo</surname>, <given-names>S.</given-names>
</string-name>, 
<string-name>
<surname>Di Pietro</surname>, <given-names>C.</given-names>
</string-name>, 
<string-name>
<surname>Golini</surname>, <given-names>E.</given-names>
</string-name>, 
<string-name>
<surname>Matteoni</surname>, <given-names>R.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Tocchini‐Valentini</surname>, <given-names>G. P.</given-names>
</string-name> (<year>2007</year>). <article-title>GPR37 associates with the dopamine transporter to modulate dopamine uptake and behavioral responses to dopaminergic drugs</article-title>. <source/>Proceedings of the National Academy of Science of United States of America, <volume>104</volume>, <fpage>9846</fpage>–<lpage>9851</lpage>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0169">
<mixed-citation id="glia23136-cit-0170" publication-type="journal">
<string-name>
<surname>Masaki</surname>, <given-names>H.</given-names>
</string-name>, 
<string-name>
<surname>Wakayama</surname>, <given-names>Y.</given-names>
</string-name>, 
<string-name>
<surname>Hara</surname>, <given-names>H.</given-names>
</string-name>, 
<string-name>
<surname>Jimi</surname>, <given-names>T.</given-names>
</string-name>, 
<string-name>
<surname>Unaki</surname>, <given-names>A.</given-names>
</string-name>, 
<string-name>
<surname>Iijima</surname>, <given-names>S.</given-names>
</string-name>, … 
<string-name>
<surname>Hirayama</surname>, <given-names>Y.</given-names>
</string-name> (<year>2010</year>). <article-title>Immunocytochemical studies of aquaporin 4, Kir4.1, and alpha1‐syntrophin in the astrocyte endfeet of mouse brain capillaries</article-title>. <source/>Acta Histochemistry &amp; Cytochemistry, <volume>43</volume>, <fpage>99</fpage>–<lpage>105</lpage>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0170">
<mixed-citation id="glia23136-cit-0171" publication-type="journal">
<string-name>
<surname>Masliah</surname>, <given-names>E.</given-names>
</string-name>, 
<string-name>
<surname>Alford</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>DeTeresa</surname>, <given-names>R.</given-names>
</string-name>, 
<string-name>
<surname>Mallory</surname>, <given-names>M.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Hansen</surname>, <given-names>L.</given-names>
</string-name> (<year>1996</year>). <article-title>Deficient glutamate transport is associated with neurodegeneration in Alzheimer's disease</article-title>. <source/>Annals of Neurology, <volume>40</volume>, <fpage>759</fpage>–<lpage>766</lpage>.
<pub-id pub-id-type="pmid">8957017</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0171">
<mixed-citation id="glia23136-cit-0172" publication-type="journal">
<string-name>
<surname>Matos</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Augusto</surname>, <given-names>E.</given-names>
</string-name>, 
<string-name>
<surname>Agostinho</surname>, <given-names>P.</given-names>
</string-name>, 
<string-name>
<surname>Cunha</surname>, <given-names>R. A.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Chen</surname>, <given-names>J. F.</given-names>
</string-name> (<year>2013</year>). <article-title>Antagonistic interaction between adenosine A2A receptors and Na+/K+‐ATPase‐alpha2 controlling glutamate uptake in astrocytes</article-title>. <source/>Journal of Neuroscience, <volume>33</volume>, <fpage>18492</fpage>–<lpage>18502</lpage>.
<pub-id pub-id-type="pmid">24259572</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0172">
<mixed-citation id="glia23136-cit-0173" publication-type="journal">
<string-name>
<surname>Matos</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Augusto</surname>, <given-names>E.</given-names>
</string-name>, 
<string-name>
<surname>Machado</surname>, <given-names>N. J.</given-names>
</string-name>, 
<string-name>
<surname>dos Santos‐Rodrigues</surname>, <given-names>A.</given-names>
</string-name>, 
<string-name>
<surname>Cunha</surname>, <given-names>R. A.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Agostinho</surname>, <given-names>P.</given-names>
</string-name> (<year>2012</year>). <article-title>Astrocytic adenosine A2A receptors control the amyloid‐beta peptide‐induced decrease of glutamate uptake</article-title>. <source/>Journal of Alzheimers Disease, <volume>31</volume>, <fpage>555</fpage>–<lpage>567</lpage>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0173">
<mixed-citation id="glia23136-cit-0174" publication-type="journal">
<string-name>
<surname>Matos</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Shen</surname>, <given-names>H. Y.</given-names>
</string-name>, 
<string-name>
<surname>Augusto</surname>, <given-names>E.</given-names>
</string-name>, 
<string-name>
<surname>Wang</surname>, <given-names>Y.</given-names>
</string-name>, 
<string-name>
<surname>Wei</surname>, <given-names>C. J.</given-names>
</string-name>, 
<string-name>
<surname>Wang</surname>, <given-names>Y. T.</given-names>
</string-name>, … 
<string-name>
<surname>Chen</surname>, <given-names>J. F.</given-names>
</string-name> (<year>2015</year>). <article-title>Deletion of adenosine A2A receptors from astrocytes disrupts glutamate homeostasis leading to psychomotor and cognitive impairment: Relevance to schizophrenia</article-title>. <source/>Biological Psychiatry, <volume>78</volume>, <fpage>763</fpage>–<lpage>774</lpage>.
<pub-id pub-id-type="pmid">25869810</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0174">
<mixed-citation id="glia23136-cit-0175" publication-type="journal">
<string-name>
<surname>McKhann</surname>, <given-names>G.</given-names>
</string-name>, 
<string-name>
<surname>Drachman</surname>, <given-names>D.</given-names>
</string-name>, 
<string-name>
<surname>Folstein</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Katzman</surname>, <given-names>R.</given-names>
</string-name>, 
<string-name>
<surname>Price</surname>, <given-names>D.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Stadlan</surname>, <given-names>E. M.</given-names>
</string-name> (<year>1984</year>). <article-title>Clinical diagnosis of Alzheimer's disease: Report of the NINCDS‐ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease</article-title>. <source/>Neurology, <volume>34</volume>, <fpage>939</fpage>–<lpage>944</lpage>.
<pub-id pub-id-type="pmid">6610841</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0175">
<mixed-citation id="glia23136-cit-0176" publication-type="journal">
<string-name>
<surname>McMahon</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Itoh</surname>, <given-names>K.</given-names>
</string-name>, 
<string-name>
<surname>Yamamoto</surname>, <given-names>M.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Hayes</surname>, <given-names>J. D.</given-names>
</string-name> (<year>2003</year>). <article-title>Keap1‐dependent proteasomal degradation of transcription factor Nrf2 contributes to the negative regulation of antioxidant response element‐driven gene expression</article-title>. <source/>Journal of Biological Chemistry, <volume>278</volume>, <fpage>21592</fpage>–<lpage>21600</lpage>.
<pub-id pub-id-type="pmid">12682069</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0176">
<mixed-citation id="glia23136-cit-0177" publication-type="journal">
<string-name>
<surname>Meda</surname>, <given-names>L.</given-names>
</string-name>, 
<string-name>
<surname>Baron</surname>, <given-names>P.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Scarlato</surname>, <given-names>G.</given-names>
</string-name> (<year>2001</year>). <article-title>Glial activation in Alzheimer's disease: The role of Abeta and its associated proteins</article-title>. <source/>Neurobiology of Aging, <volume>22</volume>, <fpage>885</fpage>–<lpage>893</lpage>.
<pub-id pub-id-type="pmid">11754995</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0177">
<mixed-citation id="glia23136-cit-0178" publication-type="journal">
<string-name>
<surname>Mehrian‐Shai</surname>, <given-names>R.</given-names>
</string-name>, 
<string-name>
<surname>Yalon</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Simon</surname>, <given-names>A. J.</given-names>
</string-name>, 
<string-name>
<surname>Eyal</surname>, <given-names>E.</given-names>
</string-name>, 
<string-name>
<surname>Pismenyuk</surname>, <given-names>T.</given-names>
</string-name>, 
<string-name>
<surname>Moshe</surname>, <given-names>I.</given-names>
</string-name>, … 
<string-name>
<surname>Toren</surname>, <given-names>A.</given-names>
</string-name> (<year>2015</year>). <article-title>High metallothionein predicts poor survival in glioblastoma multiforme</article-title>. <source/>BMC Medical Genomics, <volume>8</volume>, <fpage>68</fpage>.
<pub-id pub-id-type="pmid">26493598</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0178">
<mixed-citation id="glia23136-cit-0179" publication-type="journal">
<string-name>
<surname>Messing</surname>, <given-names>A.</given-names>
</string-name>, 
<string-name>
<surname>Brenner</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Feany</surname>, <given-names>M. B.</given-names>
</string-name>, 
<string-name>
<surname>Nedergaard</surname>, <given-names>M.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Goldman</surname>, <given-names>J. E.</given-names>
</string-name> (<year>2012</year>). <article-title>Alexander disease</article-title>. <source/>Journal of Neuroscience, <volume>32</volume>, <fpage>5017</fpage>–<lpage>5023</lpage>.
<pub-id pub-id-type="pmid">22496548</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0179">
<mixed-citation id="glia23136-cit-0180" publication-type="journal">
<string-name>
<surname>Meyer</surname>, <given-names>R. C.</given-names>
</string-name>, 
<string-name>
<surname>Giddens</surname>, <given-names>M. M.</given-names>
</string-name>, 
<string-name>
<surname>Schaefer</surname>, <given-names>S. A.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Hall</surname>, <given-names>R. A.</given-names>
</string-name> (<year>2013</year>). <article-title>GPR37 and GPR37L1 are receptors for the neuroprotective and glioprotective factors prosaptide and prosaposin</article-title>. <source/>Proceedings of the National Academy of Science of United States of America, <volume>110</volume>, <fpage>9529</fpage>–<lpage>9534</lpage>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0180">
<mixed-citation id="glia23136-cit-0181" publication-type="journal">
<string-name>
<surname>Miguel‐Hidalgo</surname>, <given-names>J. J.</given-names>
</string-name>, 
<string-name>
<surname>Waltzer</surname>, <given-names>R.</given-names>
</string-name>, 
<string-name>
<surname>Whittom</surname>, <given-names>A. A.</given-names>
</string-name>, 
<string-name>
<surname>Austin</surname>, <given-names>M. C.</given-names>
</string-name>, 
<string-name>
<surname>Rajkowska</surname>, <given-names>G.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Stockmeier</surname>, <given-names>C. A.</given-names>
</string-name> (<year>2010</year>). <article-title>Glial and glutamatergic markers in depression, alcoholism, and their comorbidity</article-title>. <source/>Journal of Affective Disorders, <volume>127</volume>, <fpage>230</fpage>–<lpage>240</lpage>.
<pub-id pub-id-type="pmid">20580095</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0181">
<mixed-citation id="glia23136-cit-0182" publication-type="journal">
<string-name>
<surname>Miller</surname>, <given-names>B. R.</given-names>
</string-name>, 
<string-name>
<surname>Dorner</surname>, <given-names>J. L.</given-names>
</string-name>, 
<string-name>
<surname>Bunner</surname>, <given-names>K. D.</given-names>
</string-name>, 
<string-name>
<surname>Gaither</surname>, <given-names>T. W.</given-names>
</string-name>, 
<string-name>
<surname>Klein</surname>, <given-names>E L.</given-names>
</string-name>, 
<string-name>
<surname>Barton</surname>, <given-names>S. J.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Rebec</surname>, <given-names>G. V.</given-names>
</string-name> (<year>2012a</year>). <article-title>Up‐regulation of GLT1 reverses the deficit in cortically evoked striatal ascorbate efflux in the R6/2 mouse model of Huntington's disease</article-title>. <source/>Journal of Neurochemistry, <volume>121</volume>, <fpage>629</fpage>–<lpage>638</lpage>.
<pub-id pub-id-type="pmid">22332910</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0182">
<mixed-citation id="glia23136-cit-0183" publication-type="journal">
<string-name>
<surname>Miller</surname>, <given-names>B. R.</given-names>
</string-name>, 
<string-name>
<surname>Dorner</surname>, <given-names>J. L.</given-names>
</string-name>, 
<string-name>
<surname>Shou</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Sari</surname>, <given-names>Y.</given-names>
</string-name>, 
<string-name>
<surname>Barton</surname>, <given-names>S. J.</given-names>
</string-name>, 
<string-name>
<surname>Sengelaub</surname>, <given-names>D. R.</given-names>
</string-name>, … 
<string-name>
<surname>Rebec</surname>, <given-names>G. V.</given-names>
</string-name> (<year>2008</year>). <article-title>Up‐regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2 mouse</article-title>. <source/>Neuroscience, <volume>153</volume>, <fpage>329</fpage>–<lpage>337</lpage>.
<pub-id pub-id-type="pmid">18353560</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0183">
<mixed-citation id="glia23136-cit-0184" publication-type="journal">
<string-name>
<surname>Miller</surname>, <given-names>R. G.</given-names>
</string-name>, 
<string-name>
<surname>Mitchell</surname>, <given-names>J. D.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Moore</surname>, <given-names>D. H.</given-names>
</string-name> (<year>2012b</year>). <article-title>Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)</article-title>. <source/>Cochrane Database of Systematic Reviews, <volume>2</volume>, <fpage>CD001447</fpage>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0184">
<mixed-citation id="glia23136-cit-0185" publication-type="journal">
<string-name>
<surname>Min</surname>, <given-names>K.D.</given-names>
</string-name>, 
<string-name>
<surname>Asakura</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Liao</surname>, <given-names>Y. L.</given-names>
</string-name>, 
<string-name>
<surname>Nakamaru</surname>, <given-names>K.</given-names>
</string-name>, 
<string-name>
<surname>Okazaki</surname>, <given-names>H.</given-names>
</string-name>, 
<string-name>
<surname>Takahashi</surname>, <given-names>T.</given-names>
</string-name>, 
<string-name>
<surname>Fujimoto</surname>, <given-names>K.</given-names>
</string-name>, 
<string-name>
<surname>Ito</surname>, <given-names>S.</given-names>
</string-name>, 
<string-name>
<surname>Takahashi</surname>, <given-names>A.</given-names>
</string-name>, 
<string-name>
<surname>Asanuma</surname>, <given-names>H.</given-names>
</string-name>, et al. (<year>2010</year>). <article-title>Identification of genes related to heart failure using global gene expression profiling of human failing myocardium</article-title>. <source/>Biochemical &amp; Biophysical Research Communication, <volume>393</volume>, <fpage>55</fpage>–<lpage>60</lpage>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0185">
<mixed-citation id="glia23136-cit-0186" publication-type="journal">
<string-name>
<surname>Miyazaki</surname>, <given-names>I.</given-names>
</string-name> &amp; 
<string-name>
<surname>Asanuma</surname>, <given-names>M.</given-names>
</string-name> (<year>2016</year>). <article-title>Serotonin 1A receptors on astrocytes as a potential target for the treatment of Parkinson's disease</article-title>. <source/>Current Medicinal Chemistry, <volume>23</volume>, <fpage>686</fpage>–<lpage>700</lpage>.
<pub-id pub-id-type="pmid">26795196</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0186">
<mixed-citation id="glia23136-cit-0187" publication-type="journal">
<string-name>
<surname>Miyazaki</surname>, <given-names>I.</given-names>
</string-name>, 
<string-name>
<surname>Asanuma</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Kikkawa</surname>, <given-names>Y.</given-names>
</string-name>, 
<string-name>
<surname>Takeshima</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Murakami</surname>, <given-names>S.</given-names>
</string-name>, 
<string-name>
<surname>Miyoshi</surname>, <given-names>K.</given-names>
</string-name>, … 
<string-name>
<surname>Kita</surname>, <given-names>T.</given-names>
</string-name> (<year>2011</year>). <article-title>Astrocyte‐derived metallothionein protects dopaminergic neurons from dopamine quinone toxicity</article-title>. <source/>Glia, <volume>59</volume>, <fpage>435</fpage>–<lpage>451</lpage>.
<pub-id pub-id-type="pmid">21264950</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0187">
<mixed-citation id="glia23136-cit-0188" publication-type="journal">
<string-name>
<surname>Miyazaki</surname>, <given-names>I.</given-names>
</string-name>, 
<string-name>
<surname>Asanuma</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Murakami</surname>, <given-names>S.</given-names>
</string-name>, 
<string-name>
<surname>Takeshima</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Torigoe</surname>, <given-names>N.</given-names>
</string-name>, 
<string-name>
<surname>Kitamura</surname>, <given-names>Y.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Miyoshi</surname>, <given-names>K.</given-names>
</string-name> (<year>2013</year>). <article-title>Targeting 5‐HT(1A) receptors in astrocytes to protect dopaminergic neurons in Parkinsonian models</article-title>. <source/>Neurobiology of Disease, <volume>59</volume>, <fpage>244</fpage>–<lpage>256</lpage>.
<pub-id pub-id-type="pmid">23959140</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0188">
<mixed-citation id="glia23136-cit-0189" publication-type="journal">
<string-name>
<surname>Moller</surname>, <given-names>T.</given-names>
</string-name> &amp; 
<string-name>
<surname>Boddeke</surname>, <given-names>H. W.</given-names>
</string-name> (<year>2016</year>). <article-title>Glial cells as drug targets: What does it take?</article-title>
<source/>Glia, <volume>64</volume>, <fpage>1742</fpage>–<lpage>1754</lpage>.
<pub-id pub-id-type="pmid">27121701</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0189">
<mixed-citation id="glia23136-cit-0190" publication-type="journal">
<string-name>
<surname>Mortensen</surname>, <given-names>O. V.</given-names>
</string-name>, 
<string-name>
<surname>Liberato</surname>, <given-names>J. L.</given-names>
</string-name>, 
<string-name>
<surname>Coutinho‐Netto</surname>, <given-names>J.</given-names>
</string-name>, 
<string-name>
<surname>Dos Santos</surname>, <given-names>W. F.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Fontana</surname>, <given-names>A. C.</given-names>
</string-name> (<year>2015</year>). <article-title>Molecular determinants of transport stimulation of EAAT2 are located at interface between the trimerization and substrate transport domains</article-title>. <source/>Journal of Neurochemistry, <volume>133</volume>, <fpage>199</fpage>–<lpage>210</lpage>.
<pub-id pub-id-type="pmid">25626691</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0190">
<mixed-citation id="glia23136-cit-0191" publication-type="journal">
<string-name>
<surname>Mosienko</surname>, <given-names>V.</given-names>
</string-name>, 
<string-name>
<surname>Teschemacher</surname>, <given-names>A. G.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Kasparov</surname>, <given-names>S.</given-names>
</string-name> (<year>2015</year>). <article-title>Is l‐lactate a novel signaling molecule in the brain?</article-title>. <source/>Journal of Cerebral Blood Flow Metabolism, <volume>35</volume>, <fpage>1069</fpage>–<lpage>1075</lpage>.
<pub-id pub-id-type="pmid">25920953</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0191">
<mixed-citation id="glia23136-cit-0192" publication-type="journal">
<string-name>
<surname>Nagy</surname>, <given-names>J. I.</given-names>
</string-name>, 
<string-name>
<surname>Li</surname>, <given-names>W.</given-names>
</string-name>, 
<string-name>
<surname>Hertzberg</surname>, <given-names>E. L.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Marotta</surname>, <given-names>C. A.</given-names>
</string-name> (<year>1996</year>). <article-title>Elevated connexin43 immunoreactivity at sites of amyloid plaques in Alzheimer's disease</article-title>. <source/>Brain Research, <volume>717</volume>, <fpage>173</fpage>–<lpage>178</lpage>.
<pub-id pub-id-type="pmid">8738268</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0192">
<mixed-citation id="glia23136-cit-0193" publication-type="journal">
<string-name>
<surname>Naidu</surname>, <given-names>A.</given-names>
</string-name>, 
<string-name>
<surname>Xu</surname>, <given-names>Q.</given-names>
</string-name>, 
<string-name>
<surname>Catalano</surname>, <given-names>R.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Cordell</surname>, <given-names>B.</given-names>
</string-name> (<year>2002</year>). <article-title>Secretion of apolipoprotein E by brain glia requires protein prenylation and is suppressed by statins</article-title>. <source/>Brain Research, <volume>958</volume>, <fpage>100</fpage>–<lpage>111</lpage>.
<pub-id pub-id-type="pmid">12468034</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0193">
<mixed-citation id="glia23136-cit-0194" publication-type="journal">
<string-name>
<surname>Neusch</surname>, <given-names>C.</given-names>
</string-name>, 
<string-name>
<surname>Rozengurt</surname>, <given-names>N.</given-names>
</string-name>, 
<string-name>
<surname>Jacobs</surname>, <given-names>R. E.</given-names>
</string-name>, 
<string-name>
<surname>Lester</surname>, <given-names>H. A.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Kofuji</surname>, <given-names>P.</given-names>
</string-name> (<year>2001</year>). <article-title>Kir4.1 potassium channel subunit is crucial for oligodendrocyte development and in vivo myelination</article-title>. <source/>Journal of Neuroscience, <volume>21</volume>, <fpage>5429</fpage>–<lpage>5438</lpage>.
<pub-id pub-id-type="pmid">11466414</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0194">
<mixed-citation id="glia23136-cit-0195" publication-type="journal">
<string-name>
<surname>Niclou</surname>, <given-names>S.</given-names>
</string-name>, 
<string-name>
<surname>Suidan</surname>, <given-names>H. S.</given-names>
</string-name>, 
<string-name>
<surname>Brown‐Luedi</surname>, <given-names>M.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Monard</surname>, <given-names>D.</given-names>
</string-name> (<year>1994</year>). <article-title>Expression of the thrombin receptor mRNA in rat brain</article-title>. <source/>Cellular &amp; Molecular Biology (Noisy‐Le‐Grand), <volume>40</volume>, <fpage>421</fpage>–<lpage>428</lpage>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0195">
<mixed-citation id="glia23136-cit-0196" publication-type="journal">
<string-name>
<surname>Nielsen</surname>, <given-names>S.</given-names>
</string-name>, 
<string-name>
<surname>Nagelhus</surname>, <given-names>E. A.</given-names>
</string-name>, 
<string-name>
<surname>Amiry‐Moghaddam</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Bourque</surname>, <given-names>C.</given-names>
</string-name>, 
<string-name>
<surname>Agre</surname>, <given-names>P.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Ottersen</surname>, <given-names>O. P.</given-names>
</string-name> (<year>1997</year>). <article-title>Specialized membrane domains for water transport in glial cells: High‐resolution immunogold cytochemistry of aquaporin‐4 in rat brain</article-title>. <source/>Journal of Neuroscience, <volume>17</volume>, <fpage>171</fpage>–<lpage>180</lpage>.
<pub-id pub-id-type="pmid">8987746</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0196">
<mixed-citation id="glia23136-cit-0197" publication-type="journal">
<string-name>
<surname>Nishino</surname>, <given-names>J.</given-names>
</string-name>, 
<string-name>
<surname>Yamashita</surname>, <given-names>K.</given-names>
</string-name>, 
<string-name>
<surname>Hashiguchi</surname>, <given-names>H.</given-names>
</string-name>, 
<string-name>
<surname>Fujii</surname>, <given-names>H.</given-names>
</string-name>, 
<string-name>
<surname>Shimazaki</surname>, <given-names>T.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Hamada</surname>, <given-names>H.</given-names>
</string-name> (<year>2004</year>). <article-title>Meteorin: A secreted protein that regulates glial cell differentiation and promotes axonal extension</article-title>. <source/>EMBO Journal
<volume>23</volume>, <fpage>1998</fpage>–<lpage>2008</lpage>.
<pub-id pub-id-type="pmid">15085178</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0197">
<mixed-citation id="glia23136-cit-0198" publication-type="book">
<string-name>
<surname>Noda</surname>, <given-names>M. (</given-names>
</string-name>
<year>2014</year>). <source/>Possible therapeutic targets in microglia. Pathological potential of neuroglia(pp. <fpage>293</fpage>–<lpage>313</lpage>). <publisher-name>Springer</publisher-name>, <publisher-loc>New York</publisher-loc>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0198">
<mixed-citation id="glia23136-cit-0199" publication-type="journal">
<string-name>
<surname>O'Brien</surname>, <given-names>J. S.</given-names>
</string-name>, 
<string-name>
<surname>Carson</surname>, <given-names>G. S.</given-names>
</string-name>, 
<string-name>
<surname>Seo</surname>, <given-names>H. C.</given-names>
</string-name>, 
<string-name>
<surname>Hiraiwa</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Weiler</surname>, <given-names>S.</given-names>
</string-name>, 
<string-name>
<surname>Tomich</surname>, <given-names>J. M.</given-names>
</string-name>, … 
<string-name>
<surname>Kishimoto</surname>, <given-names>Y.</given-names>
</string-name> (<year>1995</year>). <article-title>Identification of the neurotrophic factor sequence of prosaposin</article-title>. <source/>FASEB Journal, <volume>9</volume>, <fpage>681</fpage>–<lpage>685</lpage>.
<pub-id pub-id-type="pmid">7768361</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0199">
<mixed-citation id="glia23136-cit-0200" publication-type="journal">
<string-name>
<surname>Oberheim</surname>, <given-names>N. A.</given-names>
</string-name>, 
<string-name>
<surname>Tian</surname>, <given-names>G. F.</given-names>
</string-name>, 
<string-name>
<surname>Han</surname>, <given-names>X.</given-names>
</string-name>, 
<string-name>
<surname>Peng</surname>, <given-names>W.</given-names>
</string-name>, 
<string-name>
<surname>Takano</surname>, <given-names>T.</given-names>
</string-name>, 
<string-name>
<surname>Ransom</surname>, <given-names>B.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Nedergaard</surname>, <given-names>M.</given-names>
</string-name> (<year>2008</year>). <article-title>Loss of astrocytic domain organization in the epileptic brain</article-title>. <source/>Journal of Neuroscience, <volume>28</volume>, <fpage>3264</fpage>–<lpage>3276</lpage>.
<pub-id pub-id-type="pmid">18367594</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0200">
<mixed-citation id="glia23136-cit-0201" publication-type="journal">
<string-name>
<surname>Obrien</surname>, <given-names>J. S.</given-names>
</string-name>, 
<string-name>
<surname>Carson</surname>, <given-names>G. S.</given-names>
</string-name>, 
<string-name>
<surname>Seo</surname>, <given-names>H. C.</given-names>
</string-name>, 
<string-name>
<surname>Hiraiwa</surname>, <given-names>M.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Kishimoto</surname>, <given-names>Y.</given-names>
</string-name> (<year>1994</year>). <article-title>Identification of prosaposin as a neurotrophic factor</article-title>. <source/>Proceedings of the National Academy of Science of United States of America, <volume>91</volume>, <fpage>9593</fpage>–<lpage>9596</lpage>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0201">
<mixed-citation id="glia23136-cit-0202" publication-type="journal">
<string-name>
<surname>Ohno</surname>, <given-names>Y.</given-names>
</string-name> (<year>2011</year>). <article-title>Therapeutic role of 5‐HT1A receptors in the treatment of schizophrenia and Parkinson's disease</article-title>. <source/>CNS Neuroscience &amp; Therapeutics, <volume>17</volume>, <fpage>58</fpage>–<lpage>65</lpage>.
<pub-id pub-id-type="pmid">21091640</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0202">
<mixed-citation id="glia23136-cit-0203" publication-type="journal">
<string-name>
<surname>Olabarria</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Noristani</surname>, <given-names>H. N.</given-names>
</string-name>, 
<string-name>
<surname>Verkhratsky</surname>, <given-names>A.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Rodriguez</surname>, <given-names>J. J.</given-names>
</string-name> (<year>2010</year>). <article-title>Concomitant astroglial atrophy and astrogliosis in a triple transgenic animal model of Alzheimer's disease</article-title>. <source/>Glia, <volume>58</volume>, <fpage>831</fpage>–<lpage>838</lpage>.
<pub-id pub-id-type="pmid">20140958</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0203">
<mixed-citation id="glia23136-cit-0204" publication-type="journal">
<string-name>
<surname>Orellana</surname>, <given-names>J. A.</given-names>
</string-name>, 
<string-name>
<surname>Froger</surname>, <given-names>N.</given-names>
</string-name>, 
<string-name>
<surname>Ezan</surname>, <given-names>P.</given-names>
</string-name>, 
<string-name>
<surname>Jiang</surname>, <given-names>J. X.</given-names>
</string-name>, 
<string-name>
<surname>Bennett</surname>, <given-names>M. V.</given-names>
</string-name>, 
<string-name>
<surname>Naus</surname>, <given-names>C. C.</given-names>
</string-name>, … 
<string-name>
<surname>Saez</surname>, <given-names>J. C.</given-names>
</string-name> (<year>2011</year>). <article-title>ATP and glutamate released via astroglial connexin 43 hemichannels mediate neuronal death through activation of pannexin 1 hemichannels</article-title>. <source/>Journal of Neurochemistry, <volume>118</volume>, <fpage>826</fpage>–<lpage>840</lpage>.
<pub-id pub-id-type="pmid">21294731</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0204">
<mixed-citation id="glia23136-cit-0205" publication-type="journal">
<string-name>
<surname>Orr</surname>, <given-names>A. G.</given-names>
</string-name>, 
<string-name>
<surname>Hsiao</surname>, <given-names>E. C.</given-names>
</string-name>, 
<string-name>
<surname>Wang</surname>, <given-names>M. M.</given-names>
</string-name>, 
<string-name>
<surname>Ho</surname>, <given-names>K.</given-names>
</string-name>, 
<string-name>
<surname>Kim</surname>, <given-names>D. H.</given-names>
</string-name>, 
<string-name>
<surname>Wang</surname>, <given-names>X.</given-names>
</string-name>, 
<string-name>
<surname>Guo</surname>, <given-names>W.</given-names>
</string-name>, 
<string-name>
<surname>Kang</surname>, <given-names>J.</given-names>
</string-name>, 
<string-name>
<surname>Yu</surname>, <given-names>G. Q.</given-names>
</string-name>, 
<string-name>
<surname>Adame</surname>, <given-names>A.</given-names>
</string-name>, et al. (<year>2015</year>). <article-title>Astrocytic adenosine receptor A2A and Gs‐coupled signaling regulate memory</article-title>. <source/>Nature Neuroscience, <volume>18</volume>, <fpage>423</fpage>–<lpage>434</lpage>.
<pub-id pub-id-type="pmid">25622143</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0205">
<mixed-citation id="glia23136-cit-0206" publication-type="journal">
<string-name>
<surname>Orre</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Kamphuis</surname>, <given-names>W.</given-names>
</string-name>, 
<string-name>
<surname>Osborn</surname>, <given-names>L. M.</given-names>
</string-name>, 
<string-name>
<surname>Jansen</surname>, <given-names>A. H.</given-names>
</string-name>, 
<string-name>
<surname>Kooijman</surname>, <given-names>L.</given-names>
</string-name>, 
<string-name>
<surname>Bossers</surname>, <given-names>K.</given-names>
</string-name>, 
<string-name>
<surname>Hol</surname>, <given-names>E. M.</given-names>
</string-name> (<year>2014</year>). <article-title>Isolation of glia from Alzheimer's mice reveals inflammation and dysfunction</article-title>. <source/>Neurobiology of Aging, <volume>35</volume>, <fpage>2746</fpage>–<lpage>2760</lpage>.
<pub-id pub-id-type="pmid">25002035</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0206">
<mixed-citation id="glia23136-cit-0207" publication-type="journal">
<string-name>
<surname>Palygin</surname>, <given-names>O.</given-names>
</string-name>, 
<string-name>
<surname>Lalo</surname>, <given-names>U.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Pankratov</surname>, <given-names>Y.</given-names>
</string-name> (<year>2011</year>). <article-title>Distinct pharmacological and functional properties of NMDA receptors in mouse cortical astrocytes</article-title>. <source/>British Journal of Pharmacology, <volume>163</volume>, <fpage>1755</fpage>–<lpage>1766</lpage>.
<pub-id pub-id-type="pmid">21449975</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0207">
<mixed-citation id="glia23136-cit-0208" publication-type="journal">
<string-name>
<surname>Pannasch</surname>, <given-names>U.</given-names>
</string-name>, 
<string-name>
<surname>Vargova</surname>, <given-names>L.</given-names>
</string-name>, 
<string-name>
<surname>Reingruber</surname>, <given-names>J.</given-names>
</string-name>, 
<string-name>
<surname>Ezan</surname>, <given-names>P.</given-names>
</string-name>, 
<string-name>
<surname>Holcman</surname>, <given-names>D.</given-names>
</string-name>, 
<string-name>
<surname>Giaume</surname>, <given-names>C.</given-names>
</string-name>, … 
<string-name>
<surname>Rouach</surname>, <given-names>N.</given-names>
</string-name> (<year>2011</year>). <article-title>Astroglial networks scale synaptic activity and plasticity</article-title>. <source/>Proceedings of the National Academy of Science of United States of America, <volume>108</volume>, <fpage>8467</fpage>–<lpage>8472</lpage>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0208">
<mixed-citation id="glia23136-cit-0209" publication-type="journal">
<string-name>
<surname>Papadopoulos</surname>, <given-names>M. C.</given-names>
</string-name> &amp; 
<string-name>
<surname>Verkman</surname>, <given-names>A. S.</given-names>
</string-name> (<year>2013</year>). <article-title>Aquaporin water channels in the nervous system</article-title>. <source/>Nature Reviews Neuroscience, <volume>14</volume>, <fpage>265</fpage>–<lpage>277</lpage>.
<pub-id pub-id-type="pmid">23481483</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0209">
<mixed-citation id="glia23136-cit-0210" publication-type="journal">
<string-name>
<surname>Park</surname>, <given-names>J. A.</given-names>
</string-name>, 
<string-name>
<surname>Lee</surname>, <given-names>H. S.</given-names>
</string-name>, 
<string-name>
<surname>Ko</surname>, <given-names>K. J.</given-names>
</string-name>, 
<string-name>
<surname>Park</surname>, <given-names>S. Y.</given-names>
</string-name>, 
<string-name>
<surname>Kim</surname>, <given-names>J. H.</given-names>
</string-name>, 
<string-name>
<surname>Choe</surname>, <given-names>G.</given-names>
</string-name>, 
<string-name>
<surname>Kweon</surname>, <given-names>H. S.</given-names>
</string-name>, 
<string-name>
<surname>Song</surname>, <given-names>H. S.</given-names>
</string-name>, 
<string-name>
<surname>Ahn</surname>, <given-names>J. C.</given-names>
</string-name>, 
<string-name>
<surname>Yu</surname>, <given-names>Y. S.</given-names>
</string-name>, et al. (<year>2008</year>). <article-title>Meteorin regulates angiogenesis at the gliovascular interface</article-title>. <source/>Glia, <volume>56</volume>, <fpage>247</fpage>–<lpage>258</lpage>.
<pub-id pub-id-type="pmid">18059000</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0210">
<mixed-citation id="glia23136-cit-0211" publication-type="journal">
<string-name>
<surname>Parpura</surname>, <given-names>V.</given-names>
</string-name>, 
<string-name>
<surname>Heneka</surname>, <given-names>M. T.</given-names>
</string-name>, 
<string-name>
<surname>Montana</surname>, <given-names>V.</given-names>
</string-name>, 
<string-name>
<surname>Oliet</surname>, <given-names>S. H.</given-names>
</string-name>, 
<string-name>
<surname>Schousboe</surname>, <given-names>A.</given-names>
</string-name>, 
<string-name>
<surname>Haydon</surname>, <given-names>P. G.</given-names>
</string-name>, 
<string-name>
<surname>Stout</surname>, <given-names>R. F.</given-names>, <suffix>Jr.</suffix>
</string-name>, 
<string-name>
<surname>Spray</surname>, <given-names>D. C.</given-names>
</string-name>, 
<string-name>
<surname>Reichenbach</surname>, <given-names>A.</given-names>
</string-name>, 
<string-name>
<surname>Pannicke</surname>, <given-names>T.</given-names>
</string-name>, et al. (<year>2012</year>). <article-title>Glial cells in (patho)physiology</article-title>. <source/>Journal of Neurochemistry, <volume>121</volume>, <fpage>4</fpage>–<lpage>27</lpage>.
<pub-id pub-id-type="pmid">22251135</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0211">
<mixed-citation id="glia23136-cit-0212" publication-type="journal">
<string-name>
<surname>Paxinou</surname>, <given-names>E.</given-names>
</string-name>, 
<string-name>
<surname>Chen</surname>, <given-names>Q.</given-names>
</string-name>, 
<string-name>
<surname>Weisse</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Giasson</surname>, <given-names>B. I.</given-names>
</string-name>, 
<string-name>
<surname>Norris</surname>, <given-names>E. H.</given-names>
</string-name>, 
<string-name>
<surname>Rueter</surname>, <given-names>S. M.</given-names>
</string-name>, … 
<string-name>
<surname>Ischiropoulos</surname>, <given-names>H.</given-names>
</string-name> (<year>2001</year>). <article-title>Induction of alpha‐synuclein aggregation by intracellular nitrative insult</article-title>. <source/>Journal of Neuroscience, <volume>21</volume>, <fpage>8053</fpage>–<lpage>8061</lpage>.
<pub-id pub-id-type="pmid">11588178</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0212">
<mixed-citation id="glia23136-cit-0213" publication-type="journal">
<string-name>
<surname>Pekny</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Pekna</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Messing</surname>, <given-names>A.</given-names>
</string-name>, 
<string-name>
<surname>Steinhauser</surname>, <given-names>C.</given-names>
</string-name>, 
<string-name>
<surname>Lee</surname>, <given-names>J. M.</given-names>
</string-name>, 
<string-name>
<surname>Parpura</surname>, <given-names>V.</given-names>
</string-name>, … 
<string-name>
<surname>Verkhratsky</surname>, <given-names>A.</given-names>
</string-name> (<year>2016</year>). <article-title>Astrocytes: A central element in neurological diseases</article-title>. <source/>Acta Neuropathology, <volume>131</volume>, <fpage>323</fpage>–<lpage>345</lpage>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0213">
<mixed-citation id="glia23136-cit-0214" publication-type="journal">
<string-name>
<surname>Pellerin</surname>, <given-names>L.</given-names>
</string-name> &amp; 
<string-name>
<surname>Magistretti</surname>, <given-names>P. J.</given-names>
</string-name> (<year>1994</year>). <article-title>Glutamate uptake into astrocytes stimulates aerobic glycolysis—A mechanism coupling neuronal‐activity to glucose‐utilization</article-title>. <source/>Proceedings of the National Academy of Science of United States of America, <volume>91</volume>, <fpage>10625</fpage>–<lpage>10629</lpage>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0214">
<mixed-citation id="glia23136-cit-0215" publication-type="journal">
<string-name>
<surname>Pellerin</surname>, <given-names>L.</given-names>
</string-name> &amp; 
<string-name>
<surname>Magistretti</surname>, <given-names>P. J.</given-names>
</string-name> (<year>2003</year>). <article-title>Food for thought: Challenging the dogmas</article-title>. <source/>Journal of Cerebral Blood Flow Metabolism, <volume>23</volume>, <fpage>1282</fpage>–<lpage>1286</lpage>.
<pub-id pub-id-type="pmid">14600434</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0215">
<mixed-citation id="glia23136-cit-0216" publication-type="journal">
<string-name>
<surname>Perez</surname>, <given-names>E. L.</given-names>
</string-name>, 
<string-name>
<surname>Lauritzen</surname>, <given-names>F.</given-names>
</string-name>, 
<string-name>
<surname>Wang</surname>, <given-names>Y.</given-names>
</string-name>, 
<string-name>
<surname>Lee</surname>, <given-names>T. S. W.</given-names>
</string-name>, 
<string-name>
<surname>Kang</surname>, <given-names>D.</given-names>
</string-name>, 
<string-name>
<surname>Zaveri</surname>, <given-names>H. P.</given-names>
</string-name>, … 
<string-name>
<surname>Eid</surname>, <given-names>T.</given-names>
</string-name> (<year>2012</year>). <article-title>Evidence for astrocytes as a potential source of the glutamate excess in temporal lobe epilepsy</article-title>. <source/>Neurobiology of Disease, <volume>47</volume>, <fpage>331</fpage>–<lpage>337</lpage>.
<pub-id pub-id-type="pmid">22659305</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0216">
<mixed-citation id="glia23136-cit-0217" publication-type="journal">
<string-name>
<surname>Plaitakis</surname>, <given-names>A.</given-names>
</string-name> &amp; 
<string-name>
<surname>Shashidharan</surname>, <given-names>P.</given-names>
</string-name> (<year>2000</year>). <article-title>Glutamate transport and metabolism in dopaminergic neurons of substantia nigra: Implications for the pathogenesis of Parkinson's disease</article-title>. <source/>Journal of Neurology, <volume>247 (Suppl 2)</volume>, <fpage>II25</fpage>–II<lpage>35</lpage>.
<pub-id pub-id-type="pmid">10991662</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0217">
<mixed-citation id="glia23136-cit-0218" publication-type="journal">
<string-name>
<surname>Proper</surname>, <given-names>E. A.</given-names>
</string-name>, 
<string-name>
<surname>Hoogland</surname>, <given-names>G.</given-names>
</string-name>, 
<string-name>
<surname>Kappen</surname>, <given-names>S. M.</given-names>
</string-name>, 
<string-name>
<surname>Jansen</surname>, <given-names>G. H.</given-names>
</string-name>, 
<string-name>
<surname>Rensen</surname>, <given-names>M. G.</given-names>
</string-name>, 
<string-name>
<surname>Schrama</surname>, <given-names>L. H.</given-names>
</string-name>, 
<string-name>
<surname>van Veelen</surname>, <given-names>C. W.</given-names>
</string-name>, 
<string-name>
<surname>van Rijen</surname>, <given-names>P. C.</given-names>
</string-name>, 
<string-name>
<surname>van Nieuwenhuizen</surname>, <given-names>O.</given-names>
</string-name>, 
<string-name>
<surname>Gispen</surname>, <given-names>W. H.</given-names>
</string-name>, et al. (<year>2002</year>). <article-title>Distribution of glutamate transporters in the hippocampus of patients with pharmaco‐resistant temporal lobe epilepsy</article-title>. <source/>Brain, <volume>125</volume>, <fpage>32</fpage>–<lpage>43</lpage>.
<pub-id pub-id-type="pmid">11834591</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0218">
<mixed-citation id="glia23136-cit-0219" publication-type="journal">
<string-name>
<surname>Pucadyil</surname>, <given-names>T. J.</given-names>
</string-name>, 
<string-name>
<surname>Kalipatnapu</surname>, <given-names>S.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Chattopadhyay</surname>, <given-names>A.</given-names>
</string-name> (<year>2005</year>). <article-title>The serotonin1A receptor: A representative member of the serotonin receptor family</article-title>. <source/>Cellular &amp; Molecular Neurobiology, <volume>25</volume>, <fpage>553</fpage>–<lpage>580</lpage>.
<pub-id pub-id-type="pmid">16075379</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0219">
<mixed-citation id="glia23136-cit-0220" publication-type="journal">
<string-name>
<surname>Radi</surname>, <given-names>E.</given-names>
</string-name>, 
<string-name>
<surname>Formichi</surname>, <given-names>P.</given-names>
</string-name>, 
<string-name>
<surname>Battisti</surname>, <given-names>C.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Federico</surname>, <given-names>A.</given-names>
</string-name> (<year>2014</year>). <article-title>Apoptosis and oxidative stress in neurodegenerative diseases</article-title>. <source/>Journal of Alzheimers Disease, <volume>42 (Suppl 3)</volume>, <fpage>S125</fpage>–S<lpage>152</lpage>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0220">
<mixed-citation id="glia23136-cit-0221" publication-type="journal">
<string-name>
<surname>Ramachandran</surname>, <given-names>R.</given-names>
</string-name>, 
<string-name>
<surname>Noorbakhsh</surname>, <given-names>F.</given-names>
</string-name>, 
<string-name>
<surname>Defea</surname>, <given-names>K.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Hollenberg</surname>, <given-names>M. D.</given-names>
</string-name> (<year>2012</year>). <article-title>Targeting proteinase‐activated receptors: Therapeutic potential and challenges</article-title>. <source/>Nature Reviews Drug Discovery, <volume>11</volume>, <fpage>69</fpage>–<lpage>86</lpage>.
<pub-id pub-id-type="pmid">22212680</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0221">
<mixed-citation id="glia23136-cit-0222" publication-type="journal">
<string-name>
<surname>Riederer</surname>, <given-names>P.</given-names>
</string-name>, 
<string-name>
<surname>Konradi</surname>, <given-names>C.</given-names>
</string-name>, 
<string-name>
<surname>Schay</surname>, <given-names>V.</given-names>
</string-name>, 
<string-name>
<surname>Kienzl</surname>, <given-names>E.</given-names>
</string-name>, 
<string-name>
<surname>Birkmayer</surname>, <given-names>G.</given-names>
</string-name>, 
<string-name>
<surname>Danielczyk</surname>, <given-names>W.</given-names>
</string-name>, … 
<string-name>
<surname>Youdim</surname>, <given-names>M. B.</given-names>
</string-name> (<year>1987</year>). <article-title>Localization of MAO‐A and MAO‐B in human brain: A step in understanding the therapeutic action of l‐deprenyl</article-title>. <source/>Advances in Neurology, <volume>45</volume>, <fpage>111</fpage>–<lpage>118</lpage>.
<pub-id pub-id-type="pmid">3030067</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0222">
<mixed-citation id="glia23136-cit-0223" publication-type="journal">
<string-name>
<surname>Robel</surname>, <given-names>S.</given-names>
</string-name> (<year>2016</year>). <article-title>Astroglial scarring and seizures: A cell biological perspective on epilepsy</article-title>. <source/>Neuroscientist
<fpage>1073858416645498</fpage>.
<pub-id pub-id-type="pmid">27118807</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0223">
<mixed-citation id="glia23136-cit-0224" publication-type="journal">
<string-name>
<surname>Robel</surname>, <given-names>S.</given-names>
</string-name>, 
<string-name>
<surname>Buckingham</surname>, <given-names>S. C.</given-names>
</string-name>, 
<string-name>
<surname>Boni</surname>, <given-names>J. L.</given-names>
</string-name>, 
<string-name>
<surname>Campbell</surname>, <given-names>S. L.</given-names>
</string-name>, 
<string-name>
<surname>Danbolt</surname>, <given-names>N. C.</given-names>
</string-name>, 
<string-name>
<surname>Riedemann</surname>, <given-names>T.</given-names>
</string-name>, … 
<string-name>
<surname>Sontheimer</surname>, <given-names>H.</given-names>
</string-name> (<year>2015</year>). <article-title>Reactive astrogliosis causes the development of spontaneous seizures</article-title>. <source/>Journal of Neuroscience, <volume>35</volume>, <fpage>3330</fpage>–<lpage>3345</lpage>.
<pub-id pub-id-type="pmid">25716834</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0224">
<mixed-citation id="glia23136-cit-0225" publication-type="journal">
<string-name>
<surname>Robel</surname>, <given-names>S.</given-names>
</string-name> &amp; 
<string-name>
<surname>Sontheimer</surname>, <given-names>H.</given-names>
</string-name> (<year>2016</year>). <article-title>Glia as drivers of abnormal neuronal activity</article-title>. <source/>Nature Neuroscience, <volume>19</volume>, <fpage>28</fpage>–<lpage>33</lpage>.
<pub-id pub-id-type="pmid">26713746</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0225">
<mixed-citation id="glia23136-cit-0226" publication-type="journal">
<string-name>
<surname>Rossi</surname>, <given-names>D.</given-names>
</string-name> &amp; 
<string-name>
<surname>Volterra</surname>, <given-names>A.</given-names>
</string-name> (<year>2009</year>). <article-title>Astrocytic dysfunction: Insights on the role in neurodegeneration</article-title>. <source/>Brain Research Bulletin, <volume>80</volume>, <fpage>224</fpage>–<lpage>232</lpage>.
<pub-id pub-id-type="pmid">19631259</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0226">
<mixed-citation id="glia23136-cit-0227" publication-type="journal">
<string-name>
<surname>Rothstein</surname>, <given-names>J. D.</given-names>
</string-name> (<year>2009</year>). <article-title>Current hypotheses for the underlying biology of amyotrophic lateral sclerosis</article-title>. <source/>Annals of Neurology, <volume>65 (Suppl 1)</volume>, <fpage>S3</fpage>–S<lpage>9</lpage>.
<pub-id pub-id-type="pmid">19191304</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0227">
<mixed-citation id="glia23136-cit-0228" publication-type="journal">
<string-name>
<surname>Rothstein</surname>, <given-names>J. D.</given-names>
</string-name>, 
<string-name>
<surname>Patel</surname>, <given-names>S.</given-names>
</string-name>, 
<string-name>
<surname>Regan</surname>, <given-names>M. R.</given-names>
</string-name>, 
<string-name>
<surname>Haenggeli</surname>, <given-names>C.</given-names>
</string-name>, 
<string-name>
<surname>Huang</surname>, <given-names>Y. H.</given-names>
</string-name>, 
<string-name>
<surname>Bergles</surname>, <given-names>D. E.</given-names>
</string-name>, 
<string-name>
<surname>Jin</surname>, <given-names>L.</given-names>
</string-name>, 
<string-name>
<surname>Dykes Hoberg</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Vidensky</surname>, <given-names>S.</given-names>
</string-name>, 
<string-name>
<surname>Chung</surname>, <given-names>D. S.</given-names>
</string-name>, et al. (<year>2005</year>). <article-title>Beta‐lactam antibiotics offer neuroprotection by increasing glutamate transporter expression</article-title>. <source/>Nature, <volume>433</volume>, <fpage>73</fpage>–<lpage>77</lpage>.
<pub-id pub-id-type="pmid">15635412</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0228">
<mixed-citation id="glia23136-cit-0229" publication-type="journal">
<string-name>
<surname>Rouach</surname>, <given-names>N.</given-names>
</string-name>, 
<string-name>
<surname>Avignone</surname>, <given-names>E.</given-names>
</string-name>, 
<string-name>
<surname>Meme</surname>, <given-names>W.</given-names>
</string-name>, 
<string-name>
<surname>Koulakoff</surname>, <given-names>A.</given-names>
</string-name>, 
<string-name>
<surname>Venance</surname>, <given-names>L.</given-names>
</string-name>, 
<string-name>
<surname>Blomstrand</surname>, <given-names>F.</given-names>
</string-name>, 
<string-name>
<surname>Giaume</surname>, <given-names>C.</given-names>
</string-name> (<year>2002</year>). <article-title>Gap junctions and connexin expression in the normal and pathological central nervous system</article-title>. <source/>Biology of the Cell, <volume>94</volume>, <fpage>457</fpage>–<lpage>475</lpage>.
<pub-id pub-id-type="pmid">12566220</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0229">
<mixed-citation id="glia23136-cit-0230" publication-type="journal">
<string-name>
<surname>Rouach</surname>, <given-names>N.</given-names>
</string-name>, 
<string-name>
<surname>Glowinski</surname>, <given-names>J.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Giaume</surname>, <given-names>C.</given-names>
</string-name> (<year>2000</year>). <article-title>Activity‐dependent neuronal control of gap‐junctional communication in astrocytes</article-title>. <source/>Journal of Cell Biology, <volume>149</volume>, <fpage>1513</fpage>–<lpage>1526</lpage>.
<pub-id pub-id-type="pmid">10871289</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0230">
<mixed-citation id="glia23136-cit-0231" publication-type="journal">
<string-name>
<surname>Rushmore</surname>, <given-names>T. H.</given-names>
</string-name>, 
<string-name>
<surname>Morton</surname>, <given-names>M. R.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Pickett</surname>, <given-names>C. B.</given-names>
</string-name> (<year>1991</year>). <article-title>The antioxidant responsive element. Activation by oxidative stress and identification of the DNA consensus sequence required for functional activity</article-title>. <source/>Journal of Biological Chemistry, <volume>266</volume>, <fpage>11632</fpage>–<lpage>11639</lpage>.
<pub-id pub-id-type="pmid">1646813</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0231">
<mixed-citation id="glia23136-cit-0232" publication-type="journal">
<string-name>
<surname>Rushmore</surname>, <given-names>T. H.</given-names>
</string-name> &amp; 
<string-name>
<surname>Pickett</surname>, <given-names>C. B.</given-names>
</string-name> (<year>1990</year>). <article-title>Transcriptional regulation of the rat glutathione <italic>S</italic>‐transferase‐Ya subunit gene—Characterization of a xenobiotic‐responsive element controlling inducible expression by phenolic antioxidants</article-title>. <source/>Journal of Biological Chemistry, <volume>265</volume>, <fpage>14648</fpage>–<lpage>14653</lpage>.
<pub-id pub-id-type="pmid">2387873</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0232">
<mixed-citation id="glia23136-cit-0233" publication-type="journal">
<string-name>
<surname>Sada</surname>, <given-names>N.</given-names>
</string-name>, 
<string-name>
<surname>Lee</surname>, <given-names>S.</given-names>
</string-name>, 
<string-name>
<surname>Katsu</surname>, <given-names>T.</given-names>
</string-name>, 
<string-name>
<surname>Otsuki</surname>, <given-names>T.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Inoue</surname>, <given-names>T.</given-names>
</string-name> (<year>2015</year>). <article-title>Epilepsy treatment. Targeting LDH enzymes with a stiripentol analog to treat epilepsy</article-title>. <source/>Science, <volume>347</volume>, <fpage>1362</fpage>–<lpage>1367</lpage>.
<pub-id pub-id-type="pmid">25792327</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0233">
<mixed-citation id="glia23136-cit-0234" publication-type="journal">
<string-name>
<surname>Saijo</surname>, <given-names>K.</given-names>
</string-name>, 
<string-name>
<surname>Winner</surname>, <given-names>B.</given-names>
</string-name>, 
<string-name>
<surname>Carson</surname>, <given-names>C. T.</given-names>
</string-name>, 
<string-name>
<surname>Collier</surname>, <given-names>J. G.</given-names>
</string-name>, 
<string-name>
<surname>Boyer</surname>, <given-names>L.</given-names>
</string-name>, 
<string-name>
<surname>Rosenfeld</surname>, <given-names>M. G.</given-names>
</string-name>, … 
<string-name>
<surname>Glass</surname>, <given-names>C. K.</given-names>
</string-name> (<year>2009</year>). <article-title>A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation‐induced death</article-title>. <source/>Cell, <volume>137</volume>, <fpage>47</fpage>–<lpage>59</lpage>.
<pub-id pub-id-type="pmid">19345186</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0234">
<mixed-citation id="glia23136-cit-0235" publication-type="journal">
<string-name>
<surname>Sayre</surname>, <given-names>L. M.</given-names>
</string-name>, 
<string-name>
<surname>Smith</surname>, <given-names>M. A.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Perry</surname>, <given-names>G.</given-names>
</string-name> (<year>2001</year>). <article-title>Chemistry and biochemistry of oxidative stress in neurodegenerative disease</article-title>. <source/>Current Medicinal Chemistry, <volume>8</volume>, <fpage>721</fpage>–<lpage>738</lpage>.
<pub-id pub-id-type="pmid">11375746</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0235">
<mixed-citation id="glia23136-cit-0236" publication-type="journal">
<string-name>
<surname>Schaap</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Hancock</surname>, <given-names>R.</given-names>
</string-name>, 
<string-name>
<surname>Wilderspin</surname>, <given-names>A.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Wells</surname>, <given-names>G.</given-names>
</string-name> (<year>2013</year>). <article-title>Development of a steady‐state FRET‐based assay to identify inhibitors of the Keap1‐Nrf2 protein–protein interaction</article-title>. <source/>Protein Science, <volume>22</volume>, <fpage>1812</fpage>–<lpage>1819</lpage>.
<pub-id pub-id-type="pmid">24130096</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0236">
<mixed-citation id="glia23136-cit-0237" publication-type="journal">
<string-name>
<surname>Seifert</surname>, <given-names>G.</given-names>
</string-name>, 
<string-name>
<surname>Schilling</surname>, <given-names>K.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Steinhauser</surname>, <given-names>C.</given-names>
</string-name> (<year>2006</year>). <article-title>Astrocyte dysfunction in neurological disorders: A molecular perspective</article-title>. <source/>Nature Review Neuroscience, <volume>7</volume>, <fpage>194</fpage>–<lpage>206</lpage>.
<pub-id pub-id-type="pmid">16495941</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0237">
<mixed-citation id="glia23136-cit-0238" publication-type="journal">
<string-name>
<surname>Seifert</surname>, <given-names>G.</given-names>
</string-name> &amp; 
<string-name>
<surname>Steinhauser</surname>, <given-names>C.</given-names>
</string-name> (<year>2013</year>). <article-title>Neuron‐astrocyte signaling and epilepsy</article-title>. <source/>Experimental Neurology, <volume>244</volume>, <fpage>4</fpage>–<lpage>10</lpage>.
<pub-id pub-id-type="pmid">21925173</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0238">
<mixed-citation id="glia23136-cit-0239" publication-type="journal">
<string-name>
<surname>Selinfreund</surname>, <given-names>R. H.</given-names>
</string-name>, 
<string-name>
<surname>Barger</surname>, <given-names>S. W.</given-names>
</string-name>, 
<string-name>
<surname>Pledger</surname>, <given-names>W. J.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Vaneldik</surname>, <given-names>L. J.</given-names>
</string-name> (<year>1991</year>). <article-title>Neurotrophic protein S100‐beta stimulates glial–cell proliferation</article-title>. <source/>Proceedings of the National Academy of Science of United States of America, <volume>88</volume>, <fpage>3554</fpage>–<lpage>3558</lpage>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0239">
<mixed-citation id="glia23136-cit-0240" publication-type="journal">
<string-name>
<surname>Sharma</surname>, <given-names>S.</given-names>
</string-name> &amp; 
<string-name>
<surname>Ebadi</surname>, <given-names>M.</given-names>
</string-name> (<year>2014</year>). <article-title>Significance of metallothioneins in aging brain</article-title>. <source/>Neurochemical International, <volume>65</volume>, <fpage>40</fpage>–<lpage>48</lpage>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0240">
<mixed-citation id="glia23136-cit-0241" publication-type="journal">
<string-name>
<surname>Sharma</surname>, <given-names>S.</given-names>
</string-name>, 
<string-name>
<surname>Rais</surname>, <given-names>A.</given-names>
</string-name>, 
<string-name>
<surname>Sandhu</surname>, <given-names>R.</given-names>
</string-name>, 
<string-name>
<surname>Nel</surname>, <given-names>W.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Ebadi</surname>, <given-names>M.</given-names>
</string-name> (<year>2013</year>). <article-title>Clinical significance of metallothioneins in cell therapy and nanomedicine</article-title>. <source/>International Journal of Nanomedicine, <volume>8</volume>, <fpage>1477</fpage>–<lpage>1488</lpage>.
<pub-id pub-id-type="pmid">23620664</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0241">
<mixed-citation id="glia23136-cit-0242" publication-type="journal">
<string-name>
<surname>Sharpe</surname>, <given-names>M. A.</given-names>
</string-name> &amp; 
<string-name>
<surname>Baskin</surname>, <given-names>D. S.</given-names>
</string-name> (<year>2016</year>). <article-title>Monoamine oxidase B levels are highly expressed in human gliomas and are correlated with the expression of HiF‐1alpha and with transcription factors Sp1 and Sp3</article-title>. <source/>Oncotarget, <volume>7</volume>, <fpage>3379</fpage>–<lpage>3393</lpage>.
<pub-id pub-id-type="pmid">26689994</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0242">
<mixed-citation id="glia23136-cit-0243" publication-type="journal">
<string-name>
<surname>Shih</surname>, <given-names>A. Y.</given-names>
</string-name>, 
<string-name>
<surname>Johnson</surname>, <given-names>D. A.</given-names>
</string-name>, 
<string-name>
<surname>Wong</surname>, <given-names>G.</given-names>
</string-name>, 
<string-name>
<surname>Kraft</surname>, <given-names>A. D.</given-names>
</string-name>, 
<string-name>
<surname>Jiang</surname>, <given-names>L.</given-names>
</string-name>, 
<string-name>
<surname>Erb</surname>, <given-names>H.</given-names>
</string-name>, … 
<string-name>
<surname>Murphy</surname>, <given-names>T. H.</given-names>
</string-name> (<year>2003</year>). <article-title>Coordinate regulation of glutathione biosynthesis and release by Nrf2‐expressing glia potently protects neurons from oxidative stress</article-title>. <source/>Journal of Neuroscience, <volume>23</volume>, <fpage>3394</fpage>–<lpage>3406</lpage>.
<pub-id pub-id-type="pmid">12716947</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0243">
<mixed-citation id="glia23136-cit-0244" publication-type="journal">
<string-name>
<surname>Shimada</surname>, <given-names>F.</given-names>
</string-name>, 
<string-name>
<surname>Shiga</surname>, <given-names>Y.</given-names>
</string-name>, 
<string-name>
<surname>Morikawa</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Kawazura</surname>, <given-names>H.</given-names>
</string-name>, 
<string-name>
<surname>Morikawa</surname>, <given-names>O.</given-names>
</string-name>, 
<string-name>
<surname>Matsuoka</surname>, <given-names>T.</given-names>
</string-name>, … 
<string-name>
<surname>Saito</surname>, <given-names>N.</given-names>
</string-name> (<year>1999</year>). <article-title>The neuroprotective agent MS‐153 stimulates glutamate uptake</article-title>. <source/>European Journal of Pharmacology, <volume>386</volume>, <fpage>263</fpage>–<lpage>270</lpage>.
<pub-id pub-id-type="pmid">10618478</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0244">
<mixed-citation id="glia23136-cit-0245" publication-type="journal">
<string-name>
<surname>Shin</surname>, <given-names>J. Y.</given-names>
</string-name>, 
<string-name>
<surname>Fang</surname>, <given-names>Z. H.</given-names>
</string-name>, 
<string-name>
<surname>Yu</surname>, <given-names>Z. X.</given-names>
</string-name>, 
<string-name>
<surname>Wang</surname>, <given-names>C. E.</given-names>
</string-name>, 
<string-name>
<surname>Li</surname>, <given-names>S. H.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Li</surname>, <given-names>X. J.</given-names>
</string-name> (<year>2005</year>). <article-title>Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity</article-title>. <source/>Journal of Cell Biology, <volume>171</volume>, <fpage>1001</fpage>–<lpage>1012</lpage>.
<pub-id pub-id-type="pmid">16365166</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0245">
<mixed-citation id="glia23136-cit-0246" publication-type="journal">
<string-name>
<surname>Sidoryk‐Wegrzynowicz</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Wegrzynowicz</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Lee</surname>, <given-names>E.</given-names>
</string-name>, 
<string-name>
<surname>Bowman</surname>, <given-names>A. B.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Aschner</surname>, <given-names>M.</given-names>
</string-name> (<year>2011</year>). <article-title>Role of astrocytes in brain function and disease</article-title>. <source/>Toxicologic Pathology, <volume>39</volume>, <fpage>115</fpage>–<lpage>123</lpage>.
<pub-id pub-id-type="pmid">21075920</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0246">
<mixed-citation id="glia23136-cit-0247" publication-type="journal">
<string-name>
<surname>Sikora</surname>, <given-names>J.</given-names>
</string-name>, 
<string-name>
<surname>Harzer</surname>, <given-names>K.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Elleder</surname>, <given-names>M.</given-names>
</string-name> (<year>2007</year>). <article-title>Neurolysosomal pathology in human prosaposin deficiency suggests essential neurotrophic function of prosaposin</article-title>. <source/>Acta Neuropathology, <volume>113</volume>, <fpage>163</fpage>–<lpage>175</lpage>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0247">
<mixed-citation id="glia23136-cit-0248" publication-type="journal">
<string-name>
<surname>Silver</surname>, <given-names>J.</given-names>
</string-name> &amp; 
<string-name>
<surname>Miller</surname>, <given-names>J. H.</given-names>
</string-name> (<year>2004</year>). <article-title>Regeneration beyond the glial scar</article-title>. <source/>Nature Review Neuroscience, <volume>5</volume>, <fpage>146</fpage>–<lpage>156</lpage>.
<pub-id pub-id-type="pmid">14735117</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0248">
<mixed-citation id="glia23136-cit-0249" publication-type="journal">
<string-name>
<surname>Simard</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Arcuino</surname>, <given-names>G.</given-names>
</string-name>, 
<string-name>
<surname>Takano</surname>, <given-names>T.</given-names>
</string-name>, 
<string-name>
<surname>Liu</surname>, <given-names>Q. S.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Nedergaard</surname>, <given-names>M.</given-names>
</string-name> (<year>2003</year>). <article-title>Signaling at the gliovascular interface</article-title>. <source/>Journal of Neuroscience, <volume>23</volume>, <fpage>9254</fpage>–<lpage>9262</lpage>.
<pub-id pub-id-type="pmid">14534260</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0249">
<mixed-citation id="glia23136-cit-0250" publication-type="journal">
<string-name>
<surname>Simpson</surname>, <given-names>J. E.</given-names>
</string-name>, 
<string-name>
<surname>Ince</surname>, <given-names>P. G</given-names>
</string-name>, 
<string-name>
<surname>Lace</surname>, <given-names>G.</given-names>
</string-name>, 
<string-name>
<surname>Forster</surname>, <given-names>G.</given-names>
</string-name>, 
<string-name>
<surname>Shaw</surname>, <given-names>P. J.</given-names>
</string-name>, 
<string-name>
<surname>Matthews</surname>, <given-names>F.</given-names>
</string-name>, … 
<string-name>
<surname>Ne</surname>, <given-names>M. C. F. A.</given-names>
</string-name> (<year>2010</year>). <article-title>Astrocyte phenotype in relation to Alzheimer‐type pathology in the ageing brain</article-title>. <source/>Neurobiology of Aging, <volume>31</volume>, <fpage>578</fpage>–<lpage>590</lpage>.
<pub-id pub-id-type="pmid">18586353</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0250">
<mixed-citation id="glia23136-cit-0251" publication-type="journal">
<string-name>
<surname>Sofic</surname>, <given-names>E.</given-names>
</string-name>, 
<string-name>
<surname>Paulus</surname>, <given-names>W.</given-names>
</string-name>, 
<string-name>
<surname>Jellinger</surname>, <given-names>K.</given-names>
</string-name>, 
<string-name>
<surname>Riederer</surname>, <given-names>P.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Youdim</surname>, <given-names>M. B.</given-names>
</string-name> (<year>1991</year>). <article-title>Selective increase of iron in substantia nigra zona compacta of parkinsonian brains</article-title>. <source/>Journal of Neurochemistry, <volume>56</volume>, <fpage>978</fpage>–<lpage>982</lpage>.
<pub-id pub-id-type="pmid">1704426</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0251">
<mixed-citation id="glia23136-cit-0252" publication-type="journal">
<string-name>
<surname>Sofroniew</surname>, <given-names>M. V.</given-names>
</string-name> &amp; 
<string-name>
<surname>Vinters</surname>, <given-names>H. V.</given-names>
</string-name> (<year>2010</year>). <article-title>Astrocytes: Biology and pathology</article-title>. <source/>Acta Neuropathology, <volume>119</volume>, <fpage>7</fpage>–<lpage>35</lpage>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0252">
<mixed-citation id="glia23136-cit-0253" publication-type="journal">
<string-name>
<surname>Spillantini</surname>, <given-names>M. G.</given-names>
</string-name>, 
<string-name>
<surname>Schmidt</surname>, <given-names>M. L.</given-names>
</string-name>, 
<string-name>
<surname>Lee</surname>, <given-names>V. M.</given-names>
</string-name>, 
<string-name>
<surname>Trojanowski</surname>, <given-names>J. Q.</given-names>
</string-name>, 
<string-name>
<surname>Jakes</surname>, <given-names>R.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Goedert</surname>, <given-names>M.</given-names>
</string-name> (<year>1997</year>). <article-title>Alpha‐synuclein in Lewy bodies</article-title>. <source/>Nature, <volume>388</volume>, <fpage>839</fpage>–<lpage>840</lpage>.
<pub-id pub-id-type="pmid">9278044</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0253">
<mixed-citation id="glia23136-cit-0254" publication-type="journal">
<string-name>
<surname>Staats</surname>, <given-names>K A.</given-names>
</string-name> &amp; 
<string-name>
<surname>Van Den Bosch</surname>, <given-names>L.</given-names>
</string-name> (<year>2009</year>). <article-title>Astrocytes in amyotrophic lateral sclerosis: Direct effects on motor neuron survival</article-title>. <source/>Journal of Biological Physics, <volume>35</volume>, <fpage>337</fpage>–<lpage>346</lpage>.
<pub-id pub-id-type="pmid">19669429</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0254">
<mixed-citation id="glia23136-cit-0255" publication-type="journal">
<string-name>
<surname>Stefanis</surname>, <given-names>L.</given-names>
</string-name> (<year>2012</year>). <article-title>alpha‐Synuclein in Parkinson's disease</article-title>. <source/>Cold Spring Harbor Perspectives in Medicines, <volume>2</volume>, <fpage>a009399</fpage>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0255">
<mixed-citation id="glia23136-cit-0256" publication-type="journal">
<string-name>
<surname>Subramaniam</surname>, <given-names>S.</given-names>
</string-name> &amp; 
<string-name>
<surname>Unsicker</surname>, <given-names>K.</given-names>
</string-name> (<year>2010</year>). <article-title>ERK and cell death: ERK1/2 in neuronal death</article-title>. <source/>FEBS J, <volume>277</volume>, <fpage>22</fpage>–<lpage>29</lpage>.
<pub-id pub-id-type="pmid">19843173</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0256">
<mixed-citation id="glia23136-cit-0257" publication-type="journal">
<string-name>
<surname>Swanson</surname>, <given-names>R. A.</given-names>
</string-name>, 
<string-name>
<surname>Farrell</surname>, <given-names>K.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Stein</surname>, <given-names>B. A.</given-names>
</string-name> (<year>1997</year>). <article-title>Astrocyte energetics, function, and death under conditions of incomplete ischemia: A mechanism of glial death in the penumbra</article-title>. <source/>Glia, <volume>21</volume>, <fpage>142</fpage>–<lpage>153</lpage>.
<pub-id pub-id-type="pmid">9298857</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0257">
<mixed-citation id="glia23136-cit-0258" publication-type="journal">
<string-name>
<surname>Sykiotis</surname>, <given-names>G. P.</given-names>
</string-name> &amp; 
<string-name>
<surname>Bohmann</surname>, <given-names>D.</given-names>
</string-name> (<year>2010</year>). <article-title>Stress‐activated cap'n'collar transcription factors in aging and human disease</article-title>. <source/>Science Signaling, <volume>3</volume>, <fpage>re3</fpage>.
<pub-id pub-id-type="pmid">20215646</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0258">
<mixed-citation id="glia23136-cit-0259" publication-type="journal">
<string-name>
<surname>Takahahshi</surname>, <given-names>R.</given-names>
</string-name> (<year>2006</year>). <article-title>The pathological role of Pael‐receptor/GPR37 in AR‐JP</article-title>. <source/>Parkinsonism Related Disorder, <volume>12</volume>, <fpage>S110</fpage>–<lpage>S113</lpage>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0259">
<mixed-citation id="glia23136-cit-0260" publication-type="journal">
<string-name>
<surname>Takahashi</surname>, <given-names>K.</given-names>
</string-name>, 
<string-name>
<surname>Foster</surname>, <given-names>J. B.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Lin</surname>, <given-names>C. G.</given-names>
</string-name> (<year>2015a</year>). <article-title>Glutamate transporter EAAT2: Regulation, function, and potential as a therapeutic target for neurological and psychiatric disease</article-title>. <source/>Cellular &amp; Molecular Life Sciences, <volume>72</volume>, <fpage>3489</fpage>–<lpage>3506</lpage>.
<pub-id pub-id-type="pmid">26033496</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0260">
<mixed-citation id="glia23136-cit-0261" publication-type="journal">
<string-name>
<surname>Takahashi</surname>, <given-names>K.</given-names>
</string-name>, 
<string-name>
<surname>Kong</surname>, <given-names>Q.</given-names>
</string-name>, 
<string-name>
<surname>Lin</surname>, <given-names>Y.</given-names>
</string-name>, 
<string-name>
<surname>Stouffer</surname>, <given-names>N.</given-names>
</string-name>, 
<string-name>
<surname>Schulte</surname>, <given-names>D. A.</given-names>
</string-name>, 
<string-name>
<surname>Lai</surname>, <given-names>L.</given-names>
</string-name>, 
<string-name>
<surname>Liu</surname>, <given-names>Q.</given-names>
</string-name>, 
<string-name>
<surname>Chang</surname>, <given-names>L. C.</given-names>
</string-name>, 
<string-name>
<surname>Dominguez</surname>, <given-names>S.</given-names>
</string-name>, 
<string-name>
<surname>Xing</surname>, <given-names>X.</given-names>
</string-name>, et al. (<year>2015b</year>). <article-title>Restored glial glutamate transporter EAAT2 function as a potential therapeutic approach for Alzheimer's disease</article-title>. <source/>Journal of Experimental Medicine, <volume>212</volume>, <fpage>319</fpage>–<lpage>332</lpage>.
<pub-id pub-id-type="pmid">25711212</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0261">
<mixed-citation id="glia23136-cit-0262" publication-type="journal">
<string-name>
<surname>Takano</surname>, <given-names>T.</given-names>
</string-name>, 
<string-name>
<surname>Oberheim</surname>, <given-names>N.</given-names>
</string-name>, 
<string-name>
<surname>Cotrina</surname>, <given-names>M. L.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Nedergaard</surname>, <given-names>M.</given-names>
</string-name> (<year>2009</year>). <article-title>Astrocytes and ischemic injury</article-title>. <source/>Stroke, <volume>40</volume>, <fpage>S8</fpage>–<lpage>12</lpage>.
<pub-id pub-id-type="pmid">19064795</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0262">
<mixed-citation id="glia23136-cit-0263" publication-type="journal">
<string-name>
<surname>Takeuchi</surname>, <given-names>H.</given-names>
</string-name> &amp; 
<string-name>
<surname>Suzumuram</surname>, <given-names>A.</given-names>
</string-name> (<year>2014</year>). <article-title>Gap junctions and hemichannels composed of connexins: Potential therapeutic targets for neurodegenerative diseases</article-title>. <source/>Frontiers in Cellular Neuroscience, <volume>8</volume>, <fpage>189</fpage>.
<pub-id pub-id-type="pmid">25228858</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0263">
<mixed-citation id="glia23136-cit-0264" publication-type="journal">
<string-name>
<surname>Tanaka</surname>, <given-names>J.</given-names>
</string-name>, 
<string-name>
<surname>Toku</surname>, <given-names>K.</given-names>
</string-name>, 
<string-name>
<surname>Zhang</surname>, <given-names>B.</given-names>
</string-name>, 
<string-name>
<surname>Ishihara</surname>, <given-names>K.</given-names>
</string-name>, 
<string-name>
<surname>Sakanaka</surname>, <given-names>M.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Maeda</surname>, <given-names>N.</given-names>
</string-name> (<year>1999</year>). <article-title>Astrocytes prevent neuronal death induced by reactive oxygen and nitrogen species</article-title>. <source/>Glia, <volume>28</volume>, <fpage>85</fpage>–<lpage>96</lpage>.
<pub-id pub-id-type="pmid">10533053</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0264">
<mixed-citation id="glia23136-cit-0265" publication-type="journal">
<string-name>
<surname>Tanaka</surname>, <given-names>K.</given-names>
</string-name>, 
<string-name>
<surname>Watase</surname>, <given-names>K.</given-names>
</string-name>, 
<string-name>
<surname>Manabe</surname>, <given-names>T.</given-names>
</string-name>, 
<string-name>
<surname>Yamada</surname>, <given-names>K.</given-names>
</string-name>, 
<string-name>
<surname>Watanabe</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Takahashi</surname>, <given-names>K.</given-names>
</string-name>, 
<string-name>
<surname>Iwama</surname>, <given-names>H.</given-names>
</string-name>, 
<string-name>
<surname>Nishikawa</surname>, <given-names>T.</given-names>
</string-name>, 
<string-name>
<surname>Ichihara</surname>, <given-names>N.</given-names>
</string-name>, 
<string-name>
<surname>Kikuchi</surname>, <given-names>T.</given-names>
</string-name>, et al. (<year>1997</year>). <article-title>Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT‐1</article-title>. <source/>Science, <volume>276</volume>, <fpage>1699</fpage>–<lpage>1702</lpage>.
<pub-id pub-id-type="pmid">9180080</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0265">
<mixed-citation id="glia23136-cit-0266" publication-type="journal">
<string-name>
<surname>Tang</surname>, <given-names>F.</given-names>
</string-name>, 
<string-name>
<surname>Lane</surname>, <given-names>S.</given-names>
</string-name>, 
<string-name>
<surname>Korsak</surname>, <given-names>A.</given-names>
</string-name>, 
<string-name>
<surname>Paton</surname>, <given-names>J. F.</given-names>
</string-name>, 
<string-name>
<surname>Gourine</surname>, <given-names>A. V.</given-names>
</string-name>, 
<string-name>
<surname>Kasparov</surname>, <given-names>S.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Teschemacher</surname>, <given-names>A. G.</given-names>
</string-name> (<year>2014</year>). <article-title>Lactate‐mediated glia‐neuronal signalling in the mammalian brain</article-title>. <source/>Nature Communication, <volume>5</volume>, <fpage>3284</fpage>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0266">
<mixed-citation id="glia23136-cit-0267" publication-type="journal">
<string-name>
<surname>Thone‐Reineke</surname>, <given-names>C.</given-names>
</string-name>, 
<string-name>
<surname>Neumann</surname>, <given-names>C.</given-names>
</string-name>, 
<string-name>
<surname>Namsolleck</surname>. <given-names>P.</given-names>
</string-name>, 
<string-name>
<surname>Schmerbach</surname>, <given-names>K.</given-names>
</string-name>, 
<string-name>
<surname>Krikov</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Schefe</surname>, <given-names>J. H.</given-names>
</string-name>, 
<string-name>
<surname>Lucht</surname>, <given-names>K.</given-names>
</string-name>, 
<string-name>
<surname>Hortnagl</surname>, <given-names>H.</given-names>
</string-name>, 
<string-name>
<surname>Godes</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Muller</surname>, <given-names>S.</given-names>
</string-name>, et al. (<year>2008</year>). <article-title>The beta‐lactam antibiotic, ceftriaxone, dramatically improves survival, increases glutamate uptake and induces neurotrophins in stroke</article-title>. <source/>Journal of Hypertens, <volume>26</volume>, <fpage>2426</fpage>–<lpage>2435</lpage>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0267">
<mixed-citation id="glia23136-cit-0268" publication-type="journal">
<string-name>
<surname>Thrane</surname>, <given-names>A. S.</given-names>
</string-name>, 
<string-name>
<surname>Rangroo Thrane</surname>, <given-names>V.</given-names>
</string-name>, 
<string-name>
<surname>Plog</surname>, <given-names>B. A.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Nedergaard</surname>, <given-names>M.</given-names>
</string-name> (<year>2015</year>). <article-title>Filtering the muddied waters of brain edema</article-title>. <source/>Trends in Neuroscience, <volume>38</volume>, <fpage>333</fpage>–<lpage>335</lpage>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0268">
<mixed-citation id="glia23136-cit-0269" publication-type="journal">
<string-name>
<surname>Tian</surname>, <given-names>G. L.</given-names>
</string-name>, 
<string-name>
<surname>Kong</surname>, <given-names>Q. M.</given-names>
</string-name>, 
<string-name>
<surname>Lai</surname>, <given-names>L. C.</given-names>
</string-name>, 
<string-name>
<surname>Ray‐Chaudhury</surname>, <given-names>A.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Lin</surname>, <given-names>C. L. G.</given-names>
</string-name> (<year>2010a</year>). <article-title>Increased expression of cholesterol 24S‐hydroxylase results in disruption of glial glutamate transporter EAAT2 association with lipid rafts: A potential role in Alzheimer's disease</article-title>. <source/>Journal of Neurochemistry, <volume>113</volume>, <fpage>978</fpage>–<lpage>989</lpage>.
<pub-id pub-id-type="pmid">20193040</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0269">
<mixed-citation id="glia23136-cit-0270" publication-type="journal">
<string-name>
<surname>Tian</surname>, <given-names>R.</given-names>
</string-name>, 
<string-name>
<surname>Wu</surname>, <given-names>X.</given-names>
</string-name>, 
<string-name>
<surname>Hagemann</surname>, <given-names>T. L.</given-names>
</string-name>, 
<string-name>
<surname>Sosunov</surname>, <given-names>A. A.</given-names>
</string-name>, 
<string-name>
<surname>Messing</surname>, <given-names>A.</given-names>
</string-name>, 
<string-name>
<surname>McKhann</surname>, <given-names>G. M.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Goldman</surname>, <given-names>J. E.</given-names>
</string-name> (<year>2010b</year>). <article-title>Alexander disease mutant glial fibrillary acidic protein compromises glutamate transport in astrocytes</article-title>. <source/>Journal of Neuropathology &amp; Experimental Neurology, <volume>69</volume>, <fpage>335</fpage>–<lpage>345</lpage>.
<pub-id pub-id-type="pmid">20448479</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0270">
<mixed-citation id="glia23136-cit-0271" publication-type="journal">
<string-name>
<surname>Tokuda</surname>, <given-names>E.</given-names>
</string-name>, 
<string-name>
<surname>Okawa</surname>, <given-names>E.</given-names>
</string-name>, 
<string-name>
<surname>Watanabe</surname>, <given-names>S.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Ono</surname>, <given-names>S.</given-names>
</string-name> (<year>2014</year>). <article-title>Overexpression of metallothionein‐I, a copper‐regulating protein, attenuates intracellular copper dyshomeostasis and extends lifespan in a mouse model of amyotrophic lateral sclerosis caused by mutant superoxide dismutase‐1</article-title>. <source/>Human Molecular Genetics, <volume>23</volume>, <fpage>1271</fpage>–<lpage>1285</lpage>.
<pub-id pub-id-type="pmid">24163136</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0271">
<mixed-citation id="glia23136-cit-0272" publication-type="journal">
<string-name>
<surname>Tomita</surname>, <given-names>H.</given-names>
</string-name>, 
<string-name>
<surname>Ziegler</surname>, <given-names>M. E.</given-names>
</string-name>, 
<string-name>
<surname>Kim</surname>, <given-names>H. B.</given-names>
</string-name>, 
<string-name>
<surname>Evans</surname>, <given-names>S. J.</given-names>
</string-name>, 
<string-name>
<surname>Choudary</surname>, <given-names>P. V.</given-names>
</string-name>, 
<string-name>
<surname>Li</surname>, <given-names>J. Z.</given-names>
</string-name>, 
<string-name>
<surname>Meng</surname>, <given-names>F.</given-names>
</string-name>, 
<string-name>
<surname>Dai</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Myers</surname>, <given-names>R. M.</given-names>
</string-name>, 
<string-name>
<surname>Neal</surname>, <given-names>C. R.</given-names>
</string-name>, et al. (<year>2013</year>). <article-title>G protein‐linked signaling pathways in bipolar and major depressive disorders</article-title>. <source/>Frontiers in Genetics, <volume>4</volume>, <fpage>297</fpage>.
<pub-id pub-id-type="pmid">24391664</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0272">
<mixed-citation id="glia23136-cit-0273" publication-type="journal">
<string-name>
<surname>Tong</surname>, <given-names>X.</given-names>
</string-name>, 
<string-name>
<surname>Ao</surname>, <given-names>Y.</given-names>
</string-name>, 
<string-name>
<surname>Faas</surname>, <given-names>G. C.</given-names>
</string-name>, 
<string-name>
<surname>Nwaobi</surname>, <given-names>S. E.</given-names>
</string-name>, 
<string-name>
<surname>Xu</surname>, <given-names>J.</given-names>
</string-name>, 
<string-name>
<surname>Haustein</surname>, <given-names>M. D.</given-names>
</string-name>, 
<string-name>
<surname>Anderson</surname>, <given-names>M. A.</given-names>
</string-name>, 
<string-name>
<surname>Mody</surname>, <given-names>I.</given-names>
</string-name>, 
<string-name>
<surname>Olsen</surname>, <given-names>M. L.</given-names>
</string-name>, 
<string-name>
<surname>Sofroniew</surname>, <given-names>M. V.</given-names>
</string-name>, et al. (<year>2014</year>). <article-title>Astrocyte Kir4.1 ion channel deficits contribute to neuronal dysfunction in Huntington's disease model mice</article-title>. <source/>Nature Neuroscience, <volume>17</volume>, <fpage>694</fpage>–<lpage>703</lpage>.
<pub-id pub-id-type="pmid">24686787</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0273">
<mixed-citation id="glia23136-cit-0274" publication-type="journal">
<string-name>
<surname>Traynelis</surname>, <given-names>S. F.</given-names>
</string-name> &amp; 
<string-name>
<surname>Trejo</surname>, <given-names>J.</given-names>
</string-name> (<year>2007</year>). <article-title>Protease‐activated receptor signaling: New roles and regulatory mechanisms</article-title>. <source/>Current Opinion in Hematology, <volume>14</volume>, <fpage>230</fpage>–<lpage>235</lpage>.
<pub-id pub-id-type="pmid">17414212</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0274">
<mixed-citation id="glia23136-cit-0275" publication-type="journal">
<string-name>
<surname>Trotti</surname>, <given-names>D.</given-names>
</string-name>, 
<string-name>
<surname>Rolfs</surname>, <given-names>A.</given-names>
</string-name>, 
<string-name>
<surname>Danbolt</surname>, <given-names>N. C.</given-names>
</string-name>, 
<string-name>
<surname>Brown</surname>, <given-names>R. H.</given-names>, <suffix>Jr</suffix>
</string-name>, &amp; 
<string-name>
<surname>Hediger</surname>, <given-names>M. A.</given-names>
</string-name> (<year>1999</year>). <article-title>SOD1 mutants linked to amyotrophic lateral sclerosis selectively inactivate a glial glutamate transporter</article-title>. <source/>Nature Neuroscience, <volume>2</volume>, <fpage>848</fpage>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0275">
<mixed-citation id="glia23136-cit-0276" publication-type="journal">
<string-name>
<surname>Turner</surname>, <given-names>B. J.</given-names>
</string-name> &amp; 
<string-name>
<surname>Talbot</surname>, <given-names>K.</given-names>
</string-name> (<year>2008</year>). <article-title>Transgenics, toxicity and therapeutics in rodent models of mutant SOD1‐mediated familial ALS</article-title>. <source/>Progress in Neurobiology, <volume>85</volume>, <fpage>94</fpage>–<lpage>134</lpage>.
<pub-id pub-id-type="pmid">18282652</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0276">
<mixed-citation id="glia23136-cit-0277" publication-type="journal">
<string-name>
<surname>Turner</surname>, <given-names>M. R.</given-names>
</string-name>, 
<string-name>
<surname>Cagnin</surname>, <given-names>A.</given-names>
</string-name>, 
<string-name>
<surname>Turkheimer</surname>, <given-names>F. E.</given-names>
</string-name>, 
<string-name>
<surname>Miller</surname>, <given-names>C. C.</given-names>
</string-name>, 
<string-name>
<surname>Shaw</surname>, <given-names>C. E.</given-names>
</string-name>, 
<string-name>
<surname>Brooks</surname>, <given-names>D. J.</given-names>
</string-name>, … 
<string-name>
<surname>Banati</surname>, <given-names>R. B.</given-names>
</string-name> (<year>2004</year>). <article-title>Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: An [11C](R)‐PK11195 positron emission tomography study</article-title>. <source/>Neurobiology of Disease, <volume>15</volume>, <fpage>601</fpage>–<lpage>609</lpage>.
<pub-id pub-id-type="pmid">15056468</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0277">
<mixed-citation id="glia23136-cit-0278" publication-type="journal">
<string-name>
<surname>Unwin</surname>, <given-names>P. N.</given-names>
</string-name> &amp; 
<string-name>
<surname>Zampighi</surname>, <given-names>G.</given-names>
</string-name> (<year>1980</year>). <article-title>Structure of the junction between communicating cells</article-title>. <source/>Nature
<volume>283</volume>, <fpage>545</fpage>–<lpage>549</lpage>.
<pub-id pub-id-type="pmid">7354837</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0278">
<mixed-citation id="glia23136-cit-0279" publication-type="journal">
<string-name>
<surname>Uttara</surname>, <given-names>B.</given-names>
</string-name>, 
<string-name>
<surname>Singh</surname>, <given-names>A. V.</given-names>
</string-name>, 
<string-name>
<surname>Zamboni</surname>, <given-names>P.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Mahajan</surname>, <given-names>R. T.</given-names>
</string-name> (<year>2009</year>). <article-title>Oxidative stress and neurodegenerative diseases: A review of upstream and downstream antioxidant therapeutic options</article-title>. <source/>Current Neuropharmacology, <volume>7</volume>, <fpage>65</fpage>–<lpage>74</lpage>.
<pub-id pub-id-type="pmid">19721819</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0279">
<mixed-citation id="glia23136-cit-0280" publication-type="journal">
<string-name>
<surname>Valdenaire</surname>, <given-names>O.</given-names>
</string-name>, 
<string-name>
<surname>Giller</surname>, <given-names>T.</given-names>
</string-name>, 
<string-name>
<surname>Breu</surname>, <given-names>V.</given-names>
</string-name>, 
<string-name>
<surname>Ardati</surname>, <given-names>A.</given-names>
</string-name>, 
<string-name>
<surname>Schweizer</surname>, <given-names>A.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Richards</surname>, <given-names>J. G.</given-names>
</string-name> (<year>1998</year>). <article-title>A new family of orphan G protein‐coupled receptors predominantly expressed in the brain</article-title>. <source/>FEBS Letters, <volume>424</volume>, <fpage>193</fpage>–<lpage>196</lpage>.
<pub-id pub-id-type="pmid">9539149</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0280">
<mixed-citation id="glia23136-cit-0281" publication-type="journal">
<string-name>
<surname>Valori</surname>, <given-names>C. F.</given-names>
</string-name>, 
<string-name>
<surname>Brambilla</surname>, <given-names>L.</given-names>
</string-name>, 
<string-name>
<surname>Martorana</surname>, <given-names>F.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Rossi</surname>, <given-names>D.</given-names>
</string-name> (<year>2014</year>). <article-title>The multifaceted role of glial cells in amyotrophic lateral sclerosis</article-title>. <source/>Cellular &amp; Molecular Life Sciences, <volume>71</volume>, <fpage>287</fpage>–<lpage>297</lpage>.
<pub-id pub-id-type="pmid">23912896</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0281">
<mixed-citation id="glia23136-cit-0282" publication-type="journal">
<string-name>
<surname>van Muiswinkel</surname>, <given-names>F. L.</given-names>
</string-name> &amp; 
<string-name>
<surname>Kuiperij</surname>, <given-names>H. B.</given-names>
</string-name> (<year>2005</year>). <article-title>The Nrf2‐ARE signalling pathway: Promising drug target to combat oxidative stress in neurodegenerative disorders</article-title>. <source/>Current Drug Targets—CNS &amp; Neurological Disorders, <volume>4</volume>, <fpage>267</fpage>–<lpage>281</lpage>.
<pub-id pub-id-type="pmid">15975029</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0282">
<mixed-citation id="glia23136-cit-0283" publication-type="journal">
<string-name>
<surname>Vance</surname>, <given-names>K. M.</given-names>
</string-name>, 
<string-name>
<surname>Rogers</surname>, <given-names>R. C.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Hermann</surname>, <given-names>G. E.</given-names>
</string-name> (<year>2015</year>). <article-title>PAR1‐activated astrocytes in the nucleus of the solitary tract stimulate adjacent neurons via NMDA receptors</article-title>. <source/>Journal of Neuroscience, <volume>35</volume>, <fpage>776</fpage>–<lpage>785</lpage>.
<pub-id pub-id-type="pmid">25589770</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0283">
<mixed-citation id="glia23136-cit-0284" publication-type="journal">
<string-name>
<surname>Vangeison</surname>, <given-names>G.</given-names>
</string-name>, 
<string-name>
<surname>Carr</surname>, <given-names>D.</given-names>
</string-name>, 
<string-name>
<surname>Federoff</surname>, <given-names>H. J.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Rempe</surname>, <given-names>D. A.</given-names>
</string-name> (<year>2008</year>). <article-title>The good, the bad, and the cell type‐specific roles of hypoxia inducible factor‐1 alpha in neurons and astrocytes</article-title>. <source/>Journal of Neuroscience, <volume>28</volume>,<fpage>1988</fpage>–<lpage>1993</lpage>.
<pub-id pub-id-type="pmid">18287515</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0284">
<mixed-citation id="glia23136-cit-0285" publication-type="journal">
<string-name>
<surname>Vargas</surname>, <given-names>M. R.</given-names>
</string-name>, 
<string-name>
<surname>Johnson</surname>, <given-names>D. A.</given-names>
</string-name>, 
<string-name>
<surname>Sirkis</surname>, <given-names>D. W.</given-names>
</string-name>, 
<string-name>
<surname>Messing</surname>, <given-names>A.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Johnson</surname>, <given-names>J. A.</given-names>
</string-name> (<year>2008</year>). <article-title>Nrf2 activation in astrocytes protects against neurodegeneration in mouse models of familial amyotrophic lateral sclerosis</article-title>. <source/>Journal of Neuroscience, <volume>28</volume>,<fpage>13574</fpage>–<lpage>13581</lpage>.
<pub-id pub-id-type="pmid">19074031</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0285">
<mixed-citation id="glia23136-cit-0286" publication-type="journal">
<string-name>
<surname>Vargas</surname>, <given-names>M. R.</given-names>
</string-name> &amp; 
<string-name>
<surname>Johnson</surname>, <given-names>J. A.</given-names>
</string-name> (<year>2009</year>). <article-title>The Nrf2‐ARE cytoprotective pathway in astrocytes</article-title>. <source/>Expert Reviews in Molecular Medicine, <volume>11</volume>, <fpage>e17</fpage>.
<pub-id pub-id-type="pmid">19490732</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0286">
<mixed-citation id="glia23136-cit-0287" publication-type="journal">
<string-name>
<surname>Vasak</surname>, <given-names>M.</given-names>
</string-name> (<year>2005</year>). <article-title>Advances in metallothionein structure and functions</article-title>. <source/>Journal of Trace Elements in Medicine and Biology, <volume>19</volume>,<fpage>13</fpage>–<lpage>17</lpage>.
<pub-id pub-id-type="pmid">16240666</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0287">
<mixed-citation id="glia23136-cit-0288" publication-type="journal">
<string-name>
<surname>Vaughan</surname>, <given-names>P. J.</given-names>
</string-name>, 
<string-name>
<surname>Pike</surname>, <given-names>C. J.</given-names>
</string-name>, 
<string-name>
<surname>Cotman</surname>, <given-names>C. W.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Cunningham</surname>, <given-names>D. D.</given-names>
</string-name> (<year>1995</year>). <article-title>Thrombin receptor activation protects neurons and astrocytes from cell death produced by environmental insults</article-title>. <source/>Journal of Neuroscience, <volume>15</volume>, <fpage>5389</fpage>–<lpage>5401</lpage>.
<pub-id pub-id-type="pmid">7623161</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0288">
<mixed-citation id="glia23136-cit-0289" publication-type="journal">
<string-name>
<surname>Verellen</surname>, <given-names>R. M.</given-names>
</string-name> &amp; 
<string-name>
<surname>Cavazos</surname>, <given-names>J. E.</given-names>
</string-name> (<year>2010</year>). <article-title>Post‐traumatic epilepsy: An overview</article-title>. <source/>Therapy, <volume>7</volume>, <fpage>527</fpage>–<lpage>531</lpage>.
<pub-id pub-id-type="pmid">24761136</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0289">
<mixed-citation id="glia23136-cit-0290" publication-type="journal">
<string-name>
<surname>Verkhratsky</surname>, <given-names>A.</given-names>
</string-name> &amp; 
<string-name>
<surname>Parpura</surname>, <given-names>V.</given-names>
</string-name> (<year>2016</year>). <article-title>Astrogliopathology in neurological, neurodevelopmental and psychiatric disorders</article-title>. <source/>Neurobiology of Disorders, <volume>85</volume>, <fpage>254</fpage>–<lpage>261</lpage>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0290">
<mixed-citation id="glia23136-cit-0291" publication-type="journal">
<string-name>
<surname>Verkhratsky</surname>, <given-names>A.</given-names>
</string-name>, 
<string-name>
<surname>Parpura</surname>, <given-names>V.</given-names>
</string-name>, 
<string-name>
<surname>Pekna</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Pekny</surname>, <given-names>M.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Sofroniew</surname>, <given-names>M.</given-names>
</string-name> (<year>2014</year>). <article-title>Glia in the pathogenesis of neurodegenerative diseases</article-title>. <source/>Biochemical Society Transactions, <volume>42</volume>, <fpage>1291</fpage>–<lpage>1301</lpage>.
<pub-id pub-id-type="pmid">25233406</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0291">
<mixed-citation id="glia23136-cit-0292" publication-type="journal">
<string-name>
<surname>Verkman</surname>, <given-names>A. S.</given-names>
</string-name>, 
<string-name>
<surname>Anderson</surname>, <given-names>M. O.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Papadopoulos</surname>, <given-names>M. C.</given-names>
</string-name> (<year>2014</year>). <article-title>Aquaporins: Important but elusive drug targets</article-title>. <source/>Nature Review Drug Discovery, <volume>13</volume>, <fpage>259</fpage>–<lpage>277</lpage>.
<pub-id pub-id-type="pmid">24625825</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0292">
<mixed-citation id="glia23136-cit-0293" publication-type="journal">
<string-name>
<surname>Vonsattel</surname>, <given-names>J. P.</given-names>
</string-name>, 
<string-name>
<surname>Myers</surname>, <given-names>R. H.</given-names>
</string-name>, 
<string-name>
<surname>Stevens</surname>, <given-names>T. J.</given-names>
</string-name>, 
<string-name>
<surname>Ferrante</surname>, <given-names>R. J.</given-names>
</string-name>, 
<string-name>
<surname>Bird</surname>, <given-names>E. D.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Richardson</surname>, <given-names>E. P.</given-names>, <suffix>Jr.</suffix>
</string-name> (<year>1985</year>). <article-title>Neuropathological classification of Huntington's disease</article-title>. <source/>Journal of Neuropathology &amp; Experimental Neurology, <volume>44</volume>, <fpage>559</fpage>–<lpage>577</lpage>.
<pub-id pub-id-type="pmid">2932539</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0293">
<mixed-citation id="glia23136-cit-0294" publication-type="journal">
<string-name>
<surname>Wallraff</surname>, <given-names>A.</given-names>
</string-name>, 
<string-name>
<surname>Kohling</surname>, <given-names>R.</given-names>
</string-name>, 
<string-name>
<surname>Heinemann</surname>, <given-names>U.</given-names>
</string-name>, 
<string-name>
<surname>Theis</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Willecke</surname>, <given-names>K.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Steinhauser</surname>, <given-names>C.</given-names>
</string-name> (<year>2006</year>). <article-title>The impact of astrocytic gap junctional coupling on potassium buffering in the hippocampus</article-title>. <source/>Journal of Neuroscience, <volume>26</volume>, <fpage>5438</fpage>–<lpage>5447</lpage>.
<pub-id pub-id-type="pmid">16707796</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0294">
<mixed-citation id="glia23136-cit-0295" publication-type="journal">
<string-name>
<surname>Wang</surname>, <given-names>H.</given-names>
</string-name>, 
<string-name>
<surname>Ubl</surname>, <given-names>J. J.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Reiser</surname>, <given-names>G.</given-names>
</string-name> (<year>2002</year>). <article-title>Four subtypes of protease‐activated receptors, co‐expressed in rat astrocytes, evoke different physiological signaling</article-title>. <source/>Glia, <volume>37</volume>, <fpage>53</fpage>–<lpage>63</lpage>.
<pub-id pub-id-type="pmid">11746783</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0295">
<mixed-citation id="glia23136-cit-0296" publication-type="journal">
<string-name>
<surname>Wang</surname>, <given-names>L.</given-names>
</string-name>, 
<string-name>
<surname>Lin</surname>, <given-names>F.</given-names>
</string-name>, 
<string-name>
<surname>Wang</surname>, <given-names>J.</given-names>
</string-name>, 
<string-name>
<surname>Wu</surname>, <given-names>J.</given-names>
</string-name>, 
<string-name>
<surname>Han</surname>, <given-names>R.</given-names>
</string-name>, 
<string-name>
<surname>Zhu</surname>, <given-names>L.</given-names>
</string-name>, … 
<string-name>
<surname>Qin</surname>, <given-names>Z.</given-names>
</string-name> (<year>2012</year>). <article-title>Expression of mutant N‐terminal huntingtin fragment (htt552‐100Q) in astrocytes suppresses the secretion of BDNF</article-title>. <source/>Brain Research, <volume>1449</volume>, <fpage>69</fpage>–<lpage>82</lpage>.
<pub-id pub-id-type="pmid">22410294</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0296">
<mixed-citation id="glia23136-cit-0297" publication-type="journal">
<string-name>
<surname>Wang</surname>, <given-names>Q. Q.</given-names>
</string-name>, 
<string-name>
<surname>Liu</surname>, <given-names>Y. J.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Zhou</surname>, <given-names>J. W.</given-names>
</string-name> (<year>2015</year>). <article-title>Neuroinflammation in Parkinson's disease and its potential as therapeutic target</article-title>. <source/>Translational Neurodegeneration, <volume>4</volume>, <fpage>18</fpage>.
<pub-id pub-id-type="pmid">26448863</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0297">
<mixed-citation id="glia23136-cit-0298" publication-type="journal">
<string-name>
<surname>Wang</surname>, <given-names>R.</given-names>
</string-name>, 
<string-name>
<surname>Mason</surname>, <given-names>D. E.</given-names>
</string-name>, 
<string-name>
<surname>Choe</surname>, <given-names>K. P.</given-names>
</string-name>, 
<string-name>
<surname>Lewin</surname>, <given-names>A. S.</given-names>
</string-name>, 
<string-name>
<surname>Peters</surname>, <given-names>E. C.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Luesch</surname>, <given-names>H.</given-names>
</string-name> (<year>2013</year>). <article-title>In vitro and in vivo characterization of a tunable dual‐reactivity probe of the Nrf2‐ARE pathway</article-title>. <source/>ACS Chemical Biology, <volume>8</volume>, <fpage>1764</fpage>–<lpage>1774</lpage>.
<pub-id pub-id-type="pmid">23773140</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0298">
<mixed-citation id="glia23136-cit-0299" publication-type="journal">
<string-name>
<surname>Wang</surname>, <given-names>Y.</given-names>
</string-name>, 
<string-name>
<surname>Luo</surname>, <given-names>W.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Reiser</surname>, <given-names>G.</given-names>
</string-name> (<year>2007</year>). <article-title>Activation of protease‐activated receptors in astrocytes evokes a novel neuroprotective pathway through release of chemokines of the growth‐regulated oncogene/cytokine‐induced neutrophil chemoattractant family</article-title>. <source/>European Journal of Neuroscience, <volume>26</volume>, <fpage>3159</fpage>–<lpage>3168</lpage>.
<pub-id pub-id-type="pmid">18005059</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0299">
<mixed-citation id="glia23136-cit-0300" publication-type="journal">
<string-name>
<surname>Wang</surname>, <given-names>Y.</given-names>
</string-name>, 
<string-name>
<surname>Luo</surname>, <given-names>W.</given-names>
</string-name>, 
<string-name>
<surname>Stricker</surname>, <given-names>R.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Reiser</surname>, <given-names>G.</given-names>
</string-name> (<year>2006</year>). <article-title>Protease‐activated receptor‐1 protects rat astrocytes from apoptotic cell death via JNK‐mediated release of the chemokine GRO/CINC‐1</article-title>. <source/>Journal of Neurochemistry, <volume>98</volume>, <fpage>1046</fpage>–<lpage>1060</lpage>.
<pub-id pub-id-type="pmid">16749907</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0300">
<mixed-citation id="glia23136-cit-0301" publication-type="journal">
<string-name>
<surname>Wetherington</surname>, <given-names>J.</given-names>
</string-name>, 
<string-name>
<surname>Serrano</surname>, <given-names>G.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Dingledine</surname>, <given-names>R.</given-names>
</string-name> (<year>2008</year>). <article-title>Astrocytes in the epileptic brain</article-title>. <source/>Neuron, <volume>58</volume>, <fpage>168</fpage>–<lpage>178</lpage>.
<pub-id pub-id-type="pmid">18439402</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0301">
<mixed-citation id="glia23136-cit-0302" publication-type="journal">
<string-name>
<surname>Williamson</surname>, <given-names>T. P.</given-names>
</string-name>, 
<string-name>
<surname>Amirahmadi</surname>, <given-names>S.</given-names>
</string-name>, 
<string-name>
<surname>Joshi</surname>, <given-names>G.</given-names>
</string-name>, 
<string-name>
<surname>Kaludov</surname>, <given-names>N. K.</given-names>
</string-name>, 
<string-name>
<surname>Martinov</surname>, <given-names>M. N.</given-names>
</string-name>, 
<string-name>
<surname>Johnson</surname>, <given-names>D. A.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Johnson</surname>, <given-names>J. A.</given-names>
</string-name> (<year>2012</year>). <article-title>Discovery of potent, novel Nrf2 inducers via quantum modeling, virtual screening, and in vitro experimental validation</article-title>. <source/>Chemical Biology &amp; Drug Design, <volume>80</volume>, <fpage>810</fpage>–<lpage>820</lpage>.
<pub-id pub-id-type="pmid">22925725</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0302">
<mixed-citation id="glia23136-cit-0303" publication-type="journal">
<string-name>
<surname>Wojtowicz</surname>, <given-names>A. M.</given-names>
</string-name>, 
<string-name>
<surname>Dvorzhak</surname>, <given-names>A.</given-names>
</string-name>, 
<string-name>
<surname>Semtner</surname>, <given-names>M.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Grantyn</surname>, <given-names>R.</given-names>
</string-name> (<year>2013</year>). <article-title>Reduced tonic inhibition in striatal output neurons from Huntington mice due to loss of astrocytic GABA release through GAT‐3</article-title>. <source/>Frontiers in Neural Circuits, <volume>7</volume>, <fpage>188</fpage>.
<pub-id pub-id-type="pmid">24324407</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0303">
<mixed-citation id="glia23136-cit-0304" publication-type="journal">
<string-name>
<surname>Wong</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Ess</surname>, <given-names>K. C.</given-names>
</string-name>, 
<string-name>
<surname>Uhlmann</surname>, <given-names>E. J.</given-names>
</string-name>, 
<string-name>
<surname>Jansen</surname>, <given-names>L. A.</given-names>
</string-name>, 
<string-name>
<surname>Li</surname>, <given-names>W.</given-names>
</string-name>, 
<string-name>
<surname>Crino</surname>, <given-names>P. B.</given-names>
</string-name>, … 
<string-name>
<surname>Gutmann</surname>, <given-names>D. H.</given-names>
</string-name> (<year>2003</year>). <article-title>Impaired glial glutamate transport in a mouse tuberous sclerosis epilepsy model</article-title>. <source/>Annals of Neurology, <volume>54</volume>, <fpage>251</fpage>–<lpage>256</lpage>.
<pub-id pub-id-type="pmid">12891680</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0304">
<mixed-citation id="glia23136-cit-0305" publication-type="journal">
<string-name>
<surname>Wu</surname>, <given-names>K. C.</given-names>
</string-name>, 
<string-name>
<surname>McDonald</surname>, <given-names>P. R.</given-names>
</string-name>, 
<string-name>
<surname>Liu</surname>, <given-names>J. J.</given-names>
</string-name>, 
<string-name>
<surname>Chaguturu</surname>, <given-names>R.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Klaassen</surname>, <given-names>C. D.</given-names>
</string-name> (<year>2012</year>). <article-title>Implementation of a high‐throughput screen for identifying small molecules to activate the Keap1‐Nrf2‐ARE pathway</article-title>. <source/>PLoS One, <volume>7</volume>, <fpage>e44686</fpage>.
<pub-id pub-id-type="pmid">23056183</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0305">
<mixed-citation id="glia23136-cit-0306" publication-type="journal">
<string-name>
<surname>Xiao</surname>, <given-names>M.</given-names>
</string-name> &amp; 
<string-name>
<surname>Hu</surname>, <given-names>G.</given-names>
</string-name> (<year>2014</year>). <article-title>Involvement of aquaporin 4 in astrocyte function and neuropsychiatric disorders</article-title>. <source/>CNS Neuroscience &amp; Therapeutics, <volume>20</volume>, <fpage>385</fpage>–<lpage>390</lpage>.
<pub-id pub-id-type="pmid">24712483</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0320">
<mixed-citation id="glia23136-cit-0321" publication-type="journal">
<string-name>
<surname>Xie</surname>, <given-names>L.</given-names>
</string-name>, 
<string-name>
<surname>Kang</surname>, <given-names>H.</given-names>
</string-name>, 
<string-name>
<surname>Xu</surname>, <given-names>Q.</given-names>
</string-name>, 
<string-name>
<surname>Chen</surname>, <given-names>M.J.</given-names>
</string-name>, 
<string-name>
<surname>Liao</surname>, <given-names>Y.</given-names>
</string-name>, 
<string-name>
<surname>Thiyagarajan</surname>, <given-names>M.</given-names>
</string-name>, … 
<string-name>
<surname>Nedergaard</surname>, <given-names>M.</given-names>
</string-name> (<year>2013</year>). <article-title>Sleep drives metabolite clearance from the adult brain</article-title>. <source/>Science, <volume>342</volume>, <fpage>373</fpage>–<lpage>377</lpage>.
<pub-id pub-id-type="pmid">24136970</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0306">
<mixed-citation id="glia23136-cit-0307" publication-type="journal">
<string-name>
<surname>Xing</surname>, <given-names>X.</given-names>
</string-name>, 
<string-name>
<surname>Chang</surname>, <given-names>L. C.</given-names>
</string-name>, 
<string-name>
<surname>Kong</surname>, <given-names>Q.</given-names>
</string-name>, 
<string-name>
<surname>Colton</surname>, <given-names>C. K.</given-names>
</string-name>, 
<string-name>
<surname>Lai</surname>, <given-names>L.</given-names>
</string-name>, 
<string-name>
<surname>Glicksman</surname>, <given-names>M. A.</given-names>
</string-name>, … 
<string-name>
<surname>Cuny</surname>, <given-names>G. D.</given-names>
</string-name> (<year>2011</year>). <article-title>Structure‐activity relationship study of pyridazine derivatives as glutamate transporter EAAT2 activators</article-title>. <source/>Bioorganic &amp; Medicinal Chemistry Letters, <volume>21</volume>, <fpage>5774</fpage>–<lpage>5777</lpage>.
<pub-id pub-id-type="pmid">21875806</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0307">
<mixed-citation id="glia23136-cit-0308" publication-type="journal">
<string-name>
<surname>Xue</surname>, <given-names>M.</given-names>
</string-name>, 
<string-name>
<surname>Hollenberg</surname>, <given-names>M. D.</given-names>
</string-name>, 
<string-name>
<surname>Demchuk</surname>, <given-names>A.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Yong</surname>, <given-names>V. W.</given-names>
</string-name> (<year>2009</year>). <article-title>Relative importance of proteinase‐activated receptor‐1 versus matrix metalloproteinases in intracerebral hemorrhage‐mediated neurotoxicity in mice</article-title>. <source/>Stroke, <volume>40</volume>, <fpage>2199</fpage>–<lpage>2204</lpage>.
<pub-id pub-id-type="pmid">19359644</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0308">
<mixed-citation id="glia23136-cit-0309" publication-type="journal">
<string-name>
<surname>Yamanaka</surname>, <given-names>K.</given-names>
</string-name>, 
<string-name>
<surname>Chun</surname>, <given-names>S. J.</given-names>
</string-name>, 
<string-name>
<surname>Boillee</surname>, <given-names>S.</given-names>
</string-name>, 
<string-name>
<surname>Fujimori‐Tonou</surname>, <given-names>N.</given-names>
</string-name>, 
<string-name>
<surname>Yamashita</surname>, <given-names>H.</given-names>
</string-name>, 
<string-name>
<surname>Gutmann</surname>, <given-names>D. H.</given-names>
</string-name>, … 
<string-name>
<surname>Cleveland</surname>, <given-names>D. W.</given-names>
</string-name> (<year>2008</year>). <article-title>Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis</article-title>. <source/>Nature Neuroscience, <volume>11</volume>, <fpage>251</fpage>–<lpage>253</lpage>.
<pub-id pub-id-type="pmid">18246065</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0309">
<mixed-citation id="glia23136-cit-0310" publication-type="journal">
<string-name>
<surname>Yan</surname>, <given-names>L.</given-names>
</string-name>, 
<string-name>
<surname>Otero</surname>, <given-names>D. A.</given-names>
</string-name>, 
<string-name>
<surname>Hiraiwa</surname>, <given-names>M.</given-names>
</string-name>, &amp; 
<string-name>
<surname>O'Brien</surname>, <given-names>J. S.</given-names>
</string-name> (<year>2000</year>). <article-title>Prosaptide D5 reverses hyperalgesia: Inhibition of calcium channels through a pertussis toxin‐sensitive G‐protein mechanism in the rat</article-title>. <source/>Neuroscience Letters, <volume>278</volume>, <fpage>120</fpage>–<lpage>122</lpage>.
<pub-id pub-id-type="pmid">10643816</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0310">
<mixed-citation id="glia23136-cit-0311" publication-type="journal">
<string-name>
<surname>Yang</surname>, <given-names>X.</given-names>
</string-name>, 
<string-name>
<surname>Doser</surname>, <given-names>T. A.</given-names>
</string-name>, 
<string-name>
<surname>Fang</surname>, <given-names>C. X.</given-names>
</string-name>, 
<string-name>
<surname>Nunn</surname>, <given-names>J. M.</given-names>
</string-name>, 
<string-name>
<surname>Janardhanan</surname>, <given-names>R.</given-names>
</string-name>, 
<string-name>
<surname>Zhu</surname>, <given-names>M.</given-names>
</string-name>, … 
<string-name>
<surname>Ren</surname>. <given-names>J.</given-names>
</string-name> (<year>2006</year>). <article-title>Metallothionein prolongs survival and antagonizes senescence‐associated cardiomyocyte diastolic dysfunction: Role of oxidative stress</article-title>. <source/>FASEB Journal, <volume>20</volume>,<fpage>1024</fpage>–<lpage>1026</lpage>.
<pub-id pub-id-type="pmid">16585059</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0311">
<mixed-citation id="glia23136-cit-0312" publication-type="journal">
<string-name>
<surname>Yogev</surname>, <given-names>R.</given-names>
</string-name>, 
<string-name>
<surname>Shulman</surname>, <given-names>S. T.</given-names>
</string-name>, 
<string-name>
<surname>Chadwick</surname>, <given-names>E. G.</given-names>
</string-name>, 
<string-name>
<surname>Davis</surname>, <given-names>A. T.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Glogowski</surname>, <given-names>W.</given-names>
</string-name> (<year>1986</year>). <article-title>Once daily ceftriaxone for central nervous system infections and other serious pediatric infections</article-title>. <italic>The</italic>
<source/>Pediatric Infectious Disease Journal, <volume>5</volume>, <fpage>298</fpage>–<lpage>303</lpage>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0312">
<mixed-citation id="glia23136-cit-0313" publication-type="journal">
<string-name>
<surname>Yoneshige</surname>, <given-names>A.</given-names>
</string-name>, 
<string-name>
<surname>Suzuki</surname>, <given-names>K.</given-names>
</string-name>, 
<string-name>
<surname>Suzuki</surname>, <given-names>K.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Matsuda</surname>, <given-names>J.</given-names>
</string-name> (<year>2010</year>). <article-title>A mutation in the saposin C domain of the sphingolipid activator protein (Prosaposin) gene causes neurodegenerative disease in mice</article-title>. <source/>Journal of Neuroscience Research, <volume>88</volume>, <fpage>2118</fpage>–<lpage>2134</lpage>.
<pub-id pub-id-type="pmid">20175216</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0313">
<mixed-citation id="glia23136-cit-0314" publication-type="journal">
<string-name>
<surname>Zeng</surname>, <given-names>Z. Z.</given-names>
</string-name>, 
<string-name>
<surname>Su</surname>, <given-names>K.</given-names>
</string-name>, 
<string-name>
<surname>Kyaw</surname>, <given-names>H.</given-names>
</string-name>, &amp; 
<string-name>
<surname>Li</surname>, <given-names>Y.</given-names>
</string-name> (<year>1997</year>). <article-title>A novel endothelin receptor type‐B‐like gene enriched in the brain</article-title>. <source/>Biochemical &amp; Biophysical Research Communication, <volume>233</volume>, <fpage>559</fpage>–<lpage>567</lpage>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0314">
<mixed-citation id="glia23136-cit-0315" publication-type="journal">
<string-name>
<surname>Zhang</surname>, <given-names>Y.</given-names>
</string-name>, 
<string-name>
<surname>Chen</surname>, <given-names>K.</given-names>
</string-name>, 
<string-name>
<surname>Sloan</surname>, <given-names>S. A.</given-names>
</string-name>, 
<string-name>
<surname>Bennett</surname>, <given-names>M. L.</given-names>
</string-name>, 
<string-name>
<surname>Scholze</surname>, <given-names>A. R.</given-names>
</string-name>, 
<string-name>
<surname>O'Keeffe</surname>, <given-names>S.</given-names>
</string-name>, 
<string-name>
<surname>Phatnani</surname>, <given-names>H. P.</given-names>
</string-name>, 
<string-name>
<surname>Guarnieri</surname>, <given-names>P.</given-names>
</string-name>, 
<string-name>
<surname>Caneda</surname>, <given-names>C.</given-names>
</string-name>, 
<string-name>
<surname>Ruderisch</surname>, <given-names>N.</given-names>
</string-name>, et al. (<year>2014</year>). <article-title>An RNA‐sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex</article-title>. <source/>Journal of Neuroscience, <volume>34</volume>, <fpage>11929</fpage>–<lpage>11947</lpage>.
<pub-id pub-id-type="pmid">25186741</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0315">
<mixed-citation id="glia23136-cit-0316" publication-type="journal">
<string-name>
<surname>Zhao</surname>, <given-names>Y.</given-names>
</string-name> &amp; 
<string-name>
<surname>Rempe</surname>, <given-names>D. A.</given-names>
</string-name> (<year>2010</year>). <article-title>Targeting astrocytes for stroke therapy</article-title>. <source/>Neurotherapeutics, <volume>7</volume>, <fpage>439</fpage>–<lpage>451</lpage>.
<pub-id pub-id-type="pmid">20880507</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0316">
<mixed-citation id="glia23136-cit-0317" publication-type="journal">
<string-name>
<surname>Zhao</surname>, <given-names>Y.</given-names>
</string-name> &amp; 
<string-name>
<surname>Zhao</surname>, <given-names>B.</given-names>
</string-name> (<year>2013</year>). <article-title>Oxidative stress and the pathogenesis of Alzheimer's disease</article-title>. <source/>Oxidative Medicine &amp; Cellular Longevity, <volume>2013</volume>, <fpage>316523</fpage>.
<pub-id pub-id-type="pmid">23983897</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0317">
<mixed-citation id="glia23136-cit-0318" publication-type="journal">
<string-name>
<surname>Zhu</surname>, <given-names>Y.</given-names>
</string-name>, 
<string-name>
<surname>Fotinos</surname>, <given-names>A.</given-names>
</string-name>, 
<string-name>
<surname>Mao</surname>, <given-names>L. L.</given-names>
</string-name>, 
<string-name>
<surname>Atassi</surname>, <given-names>N.</given-names>
</string-name>, 
<string-name>
<surname>Zhou</surname>, <given-names>E. W.</given-names>
</string-name>, 
<string-name>
<surname>Ahmad</surname>, <given-names>S.</given-names>
</string-name>, … 
<string-name>
<surname>Wang</surname>, <given-names>X.</given-names>
</string-name> (<year>2015</year>). <article-title>Neuroprotective agents target molecular mechanisms of disease in ALS</article-title>. <source/>Drug Discovery Today, <volume>20</volume>, <fpage>65</fpage>–<lpage>75</lpage>.
<pub-id pub-id-type="pmid">25205348</pub-id></mixed-citation>
</ref>
<ref id="glia23136-bib-0318">
<mixed-citation id="glia23136-cit-0319" publication-type="journal">
<string-name>
<surname>Zhu</surname>, <given-names>Z.</given-names>
</string-name> &amp; 
<string-name>
<surname>Reiser</surname>, <given-names>G.</given-names>
</string-name> (<year>2014</year>). <article-title>PAR‐1 activation rescues astrocytes through the PI3K/Akt signaling pathway from chemically induced apoptosis that is exacerbated by gene silencing of beta‐arrestin 1</article-title>. <source/>Neurochemical International, <volume>67</volume>, <fpage>46</fpage>–<lpage>56</lpage>.
</mixed-citation>
</ref>
<ref id="glia23136-bib-0319">
<mixed-citation id="glia23136-cit-0320" publication-type="journal">
<string-name>
<surname>Zipper</surname>, <given-names>L. M.</given-names>
</string-name> &amp; 
<string-name>
<surname>Mulcahy</surname>, <given-names>R. T.</given-names>
</string-name> (<year>2002</year>). <article-title>The Keap1 BTB/POZ dimerization function is required to sequester Nrf2 in cytoplasm</article-title>. <source/>Journal of Biological Chemistry, <volume>277</volume>, <fpage>36544</fpage>–<lpage>36552</lpage>.
<pub-id pub-id-type="pmid">12145307</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>